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SUMMARY 
 
The Natural Killer (NK) cell activating receptor DNAM-1 (CD226) is stimulated through 
recognition of CD112 (nectin-2) and CD155 (nectin-like molecule 5; PVR) on target cells. 
HCMV UL141 elicits protection from NK-cells by down-regulating CD155 from the cell 
surface and sequestering it in the ER (Tomasec, 2005). Here, HCMV UL141 was shown to 
be involved in the down-regulation of CD112. Interestingly, UL141 appeared necessary 
but not sufficient to modulate CD112 expression. This thesis therefore focused on a 
hypothesis whereby UL141 was acting with one or more additional HCMV genes to target 
CD112 for degradation.  
This project was the first to utilise an entire recombinant adenovirus (RAd) library 
expressing individual HCMV ORFs (RAd-HCMV-ORF library) to screen for function. 
The RAd-HCMV-ORF library clearly provided an extremely powerful tool for the 
screening of HCMV gene function as results were highly repeatable and robust. The co-
infection of RAd-UL141 and RAd-US2 resulted in a single, clear, positive hit in the final 
screening process. This hit was further verified by immunoblot where CD112 appeared to 
be down-regulated in cells infected with both RAd-UL141 and RAd-US2, compared to 
controls. While a Hela-US2 cell line which stably expressed US2 also down-regulated 
CD112 when infected with RAd-UL141. A RCMVΔUS1-11 virus was constructed, which 
failed to down-regulate CD112 from the cell surface of RCMVΔSU1-11 infected cells. 
The addition of proteasome inhibitors was able to partially restore CD112 expression in 
HCMV infected cells (Prod'homme et al., 2010). It therefore appeared that US2 and 
UL141 act to degrade CD112 via the proteasome during HCMV infection. CD112 
downregulation may have the potential to prevent DNAM-1:CD112 interaction between 
HCMV infected targets and effector cells of the immune system, providing another facet to 
HCMV’s ability to avoid the human immune response.   
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1.0. INTRODUCTION  
1.1 HERPESVIRIDAE 
Viruses can be defined as infectious particles that are incapable of reproduction in the 
absence of a living host cell. Viruses likely infect all living organisms and, like their hosts, 
show a wide diversity of structures, complexities and life cycles.  
Herpesviruses represent a large family of enveloped double stranded DNA viruses that 
result in lifelong infection of the host. Herpesviruses fall into the order herpesvirales, 
which consists of three families (Herpesviridae, Alloherpesviridae and 
Malacoherpesviridae), three subfamilies and 17 genera (Davison, 2010). To date, 
approximately 150 members of the herpesvirales have been identified from a wide range of 
species including mammals, birds and fish which include 90 species and 58 tentative 
species and unassigned viruses (Roizman and Sears, 2001, Davison, 2010).  
The specific architectural and biological properties of the herpesviridae distinguish 
members from other viruses and families of the double stranded DNA (dsDNA) group. 
Herpesviridae virions contain a linear dsDNA genome packaged in an icosahedral (T=16) 
capsid. The capsid is surrounded by an amorphous protein rich layer termed the tegument. 
The tegument, in turn, is enclosed in a glycoprotein containing lipid bilayer, referred to as 
the envelope. Herpesviridae capsids range from approximately 115 to 130nm in diameter, 
with the complete virion diameter ranging from 150-200nm, Figure 1.1 
Based on biological criteria, the herpesviridae family has been classified into 3 
subfamilies, alphaherpesvirinae, betaherpesvirinae and gammaherpesvirinae (Roizman and 
Sears, 2001). These biological classifications pre-date genome sequencing and were 
traditionally based on specific properties such as host species specificity, tissue tropism, 
serology and growth kinetics (Roizman et al., 1981, Roizman et al., 1973, Roizman and 
Sears, 2001). However, the increasing volume of sequence data has lead to the use of 
sequence homology in assigning herepsviruses to the relevant taxa. Lineages are defined 
by two criteria: (a) comparison of nucleotide or predicted amino acid sequences to 
conserved herpesvirus genes, and (b) identification of genes unique to a virus subset 
(Fauquet, 2005). 
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Figure 1.1. The HCMV virion. 
A cartoon depicting the HMCV virion (not to scale). The double stranded DNA genome is 
surrounded by a capsid, which in turn is surrounded by an amorphous protein rich tegument. 
The tegument is  in turn surrounded by a host derived envelope that contains various 
glycoproteins thought to be important in virus entry and immune evasion.  
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1.1.1. Human Herpesviruses 
All human herpesviruses fall into the family Herpesviridae (Davison, 2010). To date, 9 
human herpesviruses have been indentified, with representatives from all three 
subfamilies, Table1.1. The herpesviridae comprise some of the largest characterised 
human virus genomes, with Human cytomegalovirus (HCMV) being the largest 
characterised human virus to date, with a genome size of approximately 236kb, Figure 1.2 
(Dolan, 2004). All herpesviruses result in lifelong infection and are associated with high 
seroprevalence within populations, although seroprevalence varies with important 
cofounders including geographical location and socio-economic status (Kangro et al., 
1994, Cannon et al., 2010). 
The alphaherpesvirinae are neurotrophic, have a relatively short reproduction cycle 
compared to other herpesviruses (~18hours) and spread rapidly in culture causing efficient 
destruction of infected cells (Roizman et al., 1981). A key attribute of the 
alphaherpesvirinae is their ability to establish lifelong latent infection in the peripheral 
nervous system of the host and are primarily, but not exclusively, found in sensory ganglia 
(Baringer and Swoveland, 1973). Members of this group include Herpes simplex type I 
(HSV-1, HHV-1) the causative agent of oral coldsores, Herpes simplex type II (HSV-2, 
HHV-2) the causative agent of genital herpes and Varicella Zoster virus (VZV, HHV-3) 
the causative agent of chicken pox and shingles. 
The betaherpesvirinae contain the roseolviruses (HHV-6A, HHV-6B and HHV-7) and 
cytomegalovirus (HCMV, HHV-5). All betaherpesvirinae grow less efficiently compared 
to other herpesviruses with long reproductive cycles and slow spread of infection from cell 
to cell in culture (Roizman et al., 1981). Members are lymphotrophic, establishing latency 
in cells of the immune system. Roseolavirus latency is established in macrophages and T-
lymphocytes, while HCMV latency is associated with CD34
+
 progenitors (Kempf et al., 
1997, Sinclair, 2008). In the immunocompetent population there is little clinical relevance 
of betaherpesvirinae infection. However, HCMV is able to cause severe morbidity in those 
with a weakened or compromised immune system.  
The gammaherpesvirinae are also lymphotrophic and tend to be specific for either T or B 
lymphocytes, with some able to establish lytic infection in epithelial and fibroblast cells. 
The subfamily consists of Epstein Barr virus (EBV, HHV-4), and Kaposi’s sarcoma 
associated herpesvirus (KSHV) (HHV-8). Both viruses are associated with malignant 
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Subfamily   Genus  Species  Common name  Acronym   
Alphaherpesvirinae  Simplexvirus  Human herpesvirus 1 (HHV1)  Herpes simplex virus 
1  
HSV-1  
  Human herpesvirus 2 (HHV-2)  Herpes simplex virus 
2  
HSV-2  
 Varicellovirus  Human herpesvirus 3 (HHV-3)  Varicella-Zoster 
virus   
VZV  
     
Betaherpesvirinae  Cytomegalovirus  Human herpesvirus 5 (HHV-5)  Cytomegalovirus  HCMV  
 Roseolovirus  Human herpesvirus 6 (HHV-6A)  -  -  
  Human herpesvirus 6B (HHV-6B)  -  -  
  Human herpesvirus 7 (HHV-7)  -  -  
     
Gammaherpesvirinae  Lymphocryptovirus  Human herpesvirus 4 (HHV-4)  Epstein Barr virus   EBV  
 Rhadinovirus  Human herpesvirus 8 (HHV-8)  Karpsoi’s sarcoma 
associated 
Herpesvirus  
KSHV  
 
Table 1.1. Members of the Human Herpesviridae family, which consist of the alphaherpesevirinae, betaherpesvirinae and gammaherpesvirinae 
subfamilies 
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Figure 1.2. Comparison of the human herpesviridae family genome size.  
Genome sizes were obtained from NCBI database. Alphaherpesviruses are designated 
Red and consist of HHV-1 (accession X14112), HHV-2 (accession Z86099), HHV-3 
(accession X04370), Betaherpesviruses are found in yellow and consist of HHV-6A 
(accession X83413), HHV-6B (accession AF157706), HHV-7 (AF037218) and HHV-5 
(AY446894). Gammaherpesviruses are designated blue and consist of HHV-4 
(accession AJ507799) and HHV-8 (Accession AF148805). 
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transformation. EBV can lead to the development of lymphomas, such as Burkitt’s 
lymphoma (BL), Hodgkin’s lymphoma (HL) or post transplant lymphoma. KSHV is 
present in all clinical variants of Karposi’s sarcoma and the lymphoproliferative diseases: 
primary effusion lymphoma (PEL) and multicentric Calstlemans disease (MCD) (Dupin et 
al., 1999). In-vivo EBV latency is associated with resting B lymphocytes (Miyashita et al., 
1997) In KSHV infection, productively infected lymphocytes transmit KSHV to other 
circulating cell types that are then recruited to tissues, and to resident endothelial cells that 
became latently infected (Blasig et al., 1997, Dupin et al., 1999, Sirianni et al., 1998, 
Sirianni et al., 1997, Ensoli et al., 2001). 
 
1.2. HUMAN CYTOMEGALOVIRUS 
A member of the betaherpesvirinae, HCMV is a ubiquitous pathogen with a worldwide 
distribution infecting up to 100% of the population in developing countries. HCMV 
seroprevalence in developed countries varies between 50-80%, which is generally 
attributed to a cleaner, more aseptic environment (Griffiths et al., 2000, Cannon et al., 
2010).  
The first observation of HCMV was by Ribbert (1904), who described an 1881 case where 
he noticed ‘protozoan like cells’ in kidney sections of a still born infant. The large cells 
had eccentric nuclei surrounded by a clear halo with clear cytoplasmic and nuclear 
inclusions. At the time this was not attributed to altered cell morphology as a result of viral 
infection but instead as a result of protozoa infection (Ribbert, 1904). Subsequently, the 
protozoan origin theory was dismissed when Goodpasture and Talbot suggested a viral 
aetiology (Goodpasture and Talbot, 1921). Shortly after, Cole and Kuttner (1926) showed 
that the causative agent of altered cell morphology in the submaxillary glands of guinea 
pigs was able to pass through filters that prevented the passage of protozoa. This 
confirmed that the causative agent of the altered cell morphology  was viral and could not 
be due to protozoa (Cole and Kuttner, 1926).  
The murine relative of the virus, murine cytomegalovirus (MCMV), was isolated and 
cultured in-vitro using primary murine fibroblasts in 1954 (Smith, 1954). Shortly after 
HCMV was isolated by three groups independently (Craig et al., 1957, Smith, 1956, Rowe 
et al., 1956). Smith (1956) isolated the virus from the submaxillary salivary gland of a 
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seven month old infant with adrenal cortical carcinoma and from the kidney of a one 
month old infant dying of generalised salivary gland virus (SGV) disease. Rowe et al 
(1956) isolated the virus from the adenoid tissues of three children; ages 6, 7 and 11, with 
the virus isolated from the 7 year old child to become the first laboratory strain of HCMV 
designated AD169. Craig et al (1957) isolated the virus from the liver and urine of an 
infected child. All three groups used primary human fibroblasts to isolate the virus and all 
three groups described almost identical cytopathic effects (cpe).   
Initially these viruses were known as Salivary gland viruses (SGV) until the term 
‘cytomegalovirus’ was eventually coined by Weller et al (1957) based on the typical cpe of 
infected cells involving characteristic nuclear and cytoplasmic inclusions and cell 
enlargement ‘cytomegalia’ (Weller et al., 1957). Human cytomegalovirus was later given 
the formal designation human herpesvirus 5 (HHV-5) by the committee on the taxonomy 
of viruses.    
   
1.2.1. HCMV virion structure  
The HCMV virion is comprised of four distinct structural components. The central core 
contains a double stranded DNA genome. The capsid surrounds the central core, which in 
turn is surrounded by an amorphous protein rich area known as the tegument. The 
tegument is itself surrounded with a lipid bilayer known as the envelope which contains 
various glycoproteins, Figure 1.1. The known virion proteins included 5 capsid proteins
 
(UL46, UL48-49, UL80, UL85, and UL86), 14 tegument proteins
 
(UL24, UL25, UL26, 
UL32, UL43, UL47, UL48, UL82, UL83, UL94,
 
UL99, US22, US23, and US24), 11 
glycoproteins (TRL10, UL22A,
 
UL41A, UL55, UL73, UL74, UL75, UL77, UL100, 
UL115, and UL119),
 
12 proteins involved in DNA replication and transcription (IRS1,
 
TRS1, UL44, UL45, UL54, UL57, UL69, UL72, UL84, UL89, UL97,
 
and UL122), and 3 
G-protein-coupled proteins (UL33, US27 and US28) (Varnum et al., 2004). Other virion 
constituents include UL5, UL38,
 
UL50, UL71, UL79, UL93, UL96, UL103, UL132, 
US23, and US24, 9 of which are required for efficient growth in cultured cells (Varnum et 
al., 2004).  
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1.2.1.1. Capsid 
The HCMV capsid displays icosahedral, T=16, symmetry, which consists of five core 
capsid proteins arranged in hexons, pentons and triplexes. The five capsid proteins are 
major capsid protein (MCP, pUL86), minor capsid protein (mCP, pUL85), minor capsid 
binding protein (mCPBp, pUL46), smallest capsid protein (SCP, pUL48A) and portal 
protein PORT (pUL104) (Chee et al., 1989, Baldick Jr and Shenk, 1996, Gibson et al., 
1996a, Dittmer et al., 2005).  
Capsid assembly is co-ordinated by the assembly protein precursor (pUL80.5) and the 
genetically related protease precursor (pUL80A), both of which are ultimately eliminated 
from the maturing particle. The major capsid protein, pUL86, is the most abundant protein 
component of the capsid and forms the pentons and hexons of the icosahedral capsid in the 
cytoplasm. The minor capsid proteins pUL85 and pUL46 interact with each other in the 
cytoplasm to form heterotrimers called triplexes, which are later incorporated between the 
pentons and hexons to form the correct structure. The pentons, hexons and triplexes are 
translocated to the nucleus and coalesce to form the procapsid, incorporating the portal 
protein complex (pUL104). The small capsid protein pUL48A decorates the hexons of the 
capsid and is essential for the assembly of infectious virus (Borst et al., 2001). Activation 
of pUL80A results in cleavage and elimination of both pUL80.5 and pUL80A from the 
procapsid resulting in the mature capsid. Elimination of the internal scaffold proteins, 
pUL80.5 and pUL80A, and incorporation of viral DNA appear to be concomitant, Figure 
1.3. 
There are three different capsid structures, termed A, B and C capsids formed within the 
infected cell. The fully mature capsids are termed C capsids and are the only form where 
DNA is incorporated (Pass, 2001). Type A capsids lack the scaffold protein UL80 and are 
unable to stably package the viral genome and hence just consist of the empty protein shell 
with no DNA (Irmiere and Gibson, 1983). Finally B capsids are an intermediate form 
containing the assembly protein UL80 and are predominately localised in the nucleus as 
precursors of mature capsids. All three forms are capable of acquiring envelopes but only 
C capsids are capable of producing mature infectious virus. Enveloped A and B capsids 
can be isolated from cytoplasmic and cell free preparations and are classified as non-
infectious enveloped particles (NIEP).Therefore, NIEPs are enveloped B-capsids that 
closely resemble virions in structure and composition, but retain the internal scaffolding  
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Figure 1.3. HCMV capsid assembly model.  
A simplified illustration of the interactions between the five structural HCMV proteins during virion 
morphogenesis. The major capsid protein UL86, assembly protein precursor UL80.5 and protease 
precursor UL80.5  form complexes in the cytoplasm. The minor capsid protein UL85 and the minor capsid 
binding protein UL46 also interact with each other in the cytoplasm to form heterotrimers called triplexes. 
These two types of oligomers are translocated to the nucleus where the coalesce to form the procapsid 
(Pro), incorporating the portal protein UL104. Activation of the UL80.5 protease results in cleavage and 
elimination of the internal scaffold proteins UL80 and UL80.5 from the capsid. Brackets around the B-
capsid (B) indicates uncertainty about the nature of putative intermediates between procapsids and DNA 
containing nucleocapsids. Modified from  Shenk and Stinski (2008). 
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proteins. Dense bodies (DBs), which differ from NIEPs and virions by their larger and 
more heterogeneous size and absence of all nucleocapsid constituents, are solid spheroidal 
aggregates of a single predominant tegument species, pUL83, surrounded by an envelope 
so far undistinguished from that of the virion. 
 
1.2.1.2. Tegument 
The tegument is an amorphous proteinaceous layer that lies between the capsid and the 
lipid envelope and is thought to primarily consist of phosphoproteins (Roby and Gibson, 
1986). More than half of the recognised virion proteins are believed to be located within 
the tegument region, ~22 in total (Varnum et al., 2004). Two major components of the 
tegument are the phosphoproteins ppUL32 (pp150) and ppUL83 (pp65) (Jahn et al., 1987). 
ppUL32 constitutes approximately 20% of the virion protein content and binds specifically 
to the nucleocapsid through its amino-terminus (Baxter and Gibson, 2001). ppUL83 is 
another abundant tegument protein, constituting approximately 15% of the HCMV virion, 
but is not essential for virion structure as ppUL83 is dispensable for growth in-vitro 
(Varnum et al., 2004, Schmolke et al., 1995). The amount of ppUL83 produced by low 
passage clinical isolates is much reduced compared to that produced by laboratory adapted 
strains and has been correlated to dense body formations during infection (Klages et al., 
1989).  
Tegument proteins have a tendency to be both phosphorylated and highly immunogenic. 
Antibody responses can be detected against UL55 (gB), UL75 (gH), UL44 (pp50) and 
UL98 (pp28).  HCMV ppUL83 (pp65) also appears to be a major target of HCMV specific 
cytotoxic T-cells (Boppana and Britt, 1996). 
Although the tegument appears amorphous it is known to participate in highly ordered 
structural interactions with both the envelope and the capsid. The tegument protein pUL47 
coprecipitates with two other tegument proteins, pUL48 and pUL69, as well as the major 
capsid protein UL86, and it is proposed that this complex is involved in release of viral 
DNA from the disassembling virion, as deletion of UL47 delays this process (Bechtel and 
Shenk, 2002, Baldick Jr and Shenk, 1996). The tegument protein ppUL99 (pp28) interacts 
with the virion envelope membrane via a myristylated domain (Silva et al., 2003). This 
11 
 
interaction is important for the accumulation of tegument proteins prior to envelopment 
(Sanchez et al., 2000). 
The process of tegumentation occurs in two separate cellular locations during viral 
assembly. Initial components, including pUL83 (pp65) and UL97 kinase initiate 
interactions with the nucleocapsid in the nucleus (Sanchez et al., 1998, Wolf et al., 2001). 
The UL97 kinase is involved in DNA replication and capsid assembly. While ppUL83 
(pp65) is required for the recruitment of other tegument proteins, including pUL25 and 
pUL69 into the virion (Zini et al., 1999, Chevillotte et al., 2009). Following nuclear egress, 
a second round of tegumentation occurs in the cytoplasm where ppUL99 (pp28) is added 
and is required for final envelopment of the virion (Sanchez et al., 2000, Silva et al., 2003).  
In addition to structural roles in viral assembly, the virion tegument proteins also play 
important roles in the initiation of productive infection following successful cell entry, 
suggesting that tegument proteins may have functions unrelated to the structural role of the 
viral tegument. The tegument proteins are released in infected cells prior to immediate 
early (IE) gene expression. The UL82 gene product ppUL82 (pp71, Virus transactivator, 
VTA) plays a critical role in the initiation of infection by relieving hDaxx repression of 
virus replication by promoting hDaxx degradation via the proteasome (Cantrell and 
Bresnahan, 2006). ppUL82 and ppUL35 have been shown to interact and cooperatively 
activate the major immediate-early enhancer, enhancing the infectivity of viral DNA and 
accelerating the infection cycle (Baldick Jr et al., 1997, Schierling et al., 2004). pUL69 is a 
viral transactivator and is expressed as three differentially phosphorylated forms, only one 
of which is incorporated into the tegument (Winkler and Stamminger, 1996).   
Other tegument proteins include the product of the UL26 open reading frame, pUL26, 
which contains a strong transcriptional activation domain (Stamminger et al., 2002). 
While, several proteins encoded by the US22 family members are also components of the 
tegument, including UL23, UL24, IRS1 and TRS1 (Adair et al., 2002, Romanowski et al., 
1997). 
 
1.2.1.3. Envelope glycoproteins 
Once in the cytoplasm and completely tegumented, capsids bud into cytoplasmic vesicles 
or tubules to acquire their final envelope derived from the host cell endoplasmic reticulum 
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(ER)-Golgi intermediate compartment (ERGIC) membrane (Sanchez et al., 2000). This 
process requires pUL99; as in its absence, tegumented capsids accumulate in the 
cytoplasm (Silva et al., 2003).   
The virion envelope is complex and many of the proteins comprising this structure remain 
undefined. Virion glycoproteins have been the most extensively studied virion envelope 
constituents. Studies have suggested the glycoproteins are present in the following order of 
abundance; gM/gN > gB > gH/gL/gO (gpUL100/gpUL73 > gpUL55 > 
gpUL75/gpUL115/gpUL74) (Britt and Boppana, 2004). There were originally believed to 
be three major glycoprotein complexes present on the envelope: gCI (gB), gCII (gM:gN) 
and gCIII (gH;gL) (Gretch et al., 1988).  
gCI consists of disulphide-linked gB (gpUL55) homodimers (Kari et al., 1990). Translated 
as a 160kDa monomer, gB is then processed by host proteases to generate 116kDa and 
55kDa polypeptides. The 55kDa species is found on the outside of the envelope and 
remains in complex with the 116kDa transmembrane component (Britt and Vugler, 1992, 
Britt and Vugler, 1989). Proteolytic cleavage of gB is dispensable for viral growth (Strive 
et al., 2002). However, gB is involved in the initial stages of virion-to-cell attachment. The 
gB glycoprotein is also a major target of human neutralising antibodies, which prevent 
both attachment and fusion of the virus to host cell membrane by interfering with a 
receptor-binding event during initial virus-host cell interaction (Marshall et al., 1992, 
Gicklhorn et al., 2003). Proteins thought to be involved in gB binding are cell surface 
heparin sulphate proteoglycans (HSPGs) as soluble gB binding is reduced by ~40% in 
HSPG-deficient cell lines (Boyle and Compton, 1998). After attachment the glycoprotein 
promotes specific interactions with epidermal growth factor receptor (EGFR) and αVβ3 
integrin (Wang et al., 2005).  
The gCII complex is comprised of gM (gpUL100) and gN (gpUL73) that are covalently 
linked by a disulphide bond, although gCII complex formation can occur in the absence of 
disulphide bonding (Mach et al., 2000, Mach et al., 2005). Only the initial 118aa of gM are 
essential for interaction with gN (Mach et al., 2005). Complex formation occurs within the 
ER, and is required for the transport of gM:gN to the secretory system. Both gM and gN 
have also been reported to interact with HSPGs on entry (Kari and Gehrz, 1992). As with 
gCI, gCII is also a target for neutralising antibodies in human sera. In one study most sera 
13 
 
failed to react to either gM or gN when expressed in isolation. However, 62% of sera were 
positive for the gCII (gM-gN) complex (Mach et al., 2000).  
gCIII, consists of gH (gpUL75), gL (gpUL115) and gO (gpUL74) in virions purified from 
laboratory-adapted HCMV strains (Huber and Compton, 1998). Glycoprotein-H is a fusion 
receptor, while gL is a chaperone required for gH localisation; both are complexed with 
gO, which enhances virus entry. gH is linked to gL by disulphide bonds that are formed in 
the ER (Huber and Compton, 1999). gL is required for the transport of gH to the cell 
surface (Spaete et al 1993). The gH:gL complex binds to a gO precursor forming a 220kDa 
gCIII precursor before gO is post-translationally modified in a post-ER compartment to 
form the fully mature gCIII complex (Theiler and Compton, 2001). It has been reported 
that gH also binds EGFR and αVβ3 integrin (Wang et al., 2005). Both gH and gO have 
been implicated in viral fusion as antibodies against gH or gO inhibit this process 
(Paterson et al., 2002). However, although antibodies to gH block viral fusion they do not 
inhibit attachment (Keay and Baldwin, 1991). 
In addition to gCIII, a second envelope complex involving gH and gL has been described 
(Wang and Shenk, 2005). This complex comprises of gH, gL and the products of UL128, 
UL130 and UL131A, known as the UL128locus. The co-expression of the UL128locus 
increases the transport of gH:gL from the ER and the gH:gL:pUL128-131A complex is 
required for epithelial and endothelial cell tropism (Adler et al., 2006, Ryckman et al., 
2008). HCMV virions lacking this complex can be internalised but do not initiate IE gene 
expression in epithelial cells (Sinzger et al., 2000). In-vitro passage of HCMV in 
fibroblasts rapidly leads to mutation and loss of function of the UL128locus, leading to an 
inability to productively infect epithelial cells (Dolan, 2004). Strains that lack the 
UL128locus, such as AD169 produce virions that only contain the gH-gL-gO gCIII 
complex (Wang and Shenk, 2005). Thus it appears the gCIII complex allowing fibroblast 
tropism consists of gO:gH:gL. While the gCIII complex permitting endothelial/epithelial 
tropism consists of a complex of gH:gL:UL128Locus. 
In addition to the major glycoprotein complexes there are also other virus-encoded 
glycoproteins present in the virion envelope. HCMV encodes four G coupled protein 
receptor homologues UL33, US27, US28 and UL74, three of which, UL33, US27 and 
US28, have been described as components of the virion (Varnum et al., 2004, Fraile-
Ramos et al., 2001). In addition to those glycoproteins discussed above, Varnum and 
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colleagues (Varnum et al., 2004) identified twelve HCMV glycoproteins that are minor 
envelope constituents including UL79, UL33 and UL5.  
 
1.2.1.4. Other virion constituents 
In addition to viral encoded proteins, over 70 host encoded proteins have been identified in 
the HCMV virion including proteins involved in cell structure (α-actin, Vimentin), protein 
transport (clatharin, polyubiquitin B), transcription-translation (elongation factor 2) and 
signalling (α1-casein kinase 2) (Varnum et al., 2004). The presence of many of these host 
proteins within the virion is controversial. Results are dependent on the method used to 
purify virions and it is possible that cellular contamination may occur during the 
purification of infectious particles (Hudecz et al., 1985). However, support of the direct 
incorporation of cellular protein comes from functional studies. For example the host cell 
phospholipase cPLA2α was detected in virions and inhibition of cPLA2α activity in the 
virion correlated with a decrease of IE gene expression (Allal et al., 2004). Over 1000 
annexin II molecules are present per virus particle, and HCMV infectivity could be 
inhibited by treating the virus with annexin-II specific mAb (Wright et al., 1995). 
Although a later report contradicted this finding where they found interference with 
annexin II had no effect on HCMV entry (Pietropaolo and Compton, 1999). 
The core of HCMV virion comprises of viral DNA and 2 polyamines (spermidine and 
spermine). Elimination of the spermidine pool by drug treatment has been shown to 
interfere with HCMV replication, resulting in reduced titres and incomplete capsid 
formation, suggesting the spermidine and spermine are involved in DNA packaging or 
capsid envelopment (Gibson et al., 1984).  
Although HCMV is described as a DNA virus, several viral RNA transcripts have also 
been detected (Bresnahan and Shenk, 2000a, Greijer et al., 2000). The viral RNA of 
UL21A is present in the HCMV virion. The protein product from UL21A RNA, pUL21A, 
has been shown to function by blocking RANTES (regulated upon activation, normal T-
cell expressed and secreted), suggesting that pUL21A can modulate the host antiviral 
response even before the newly infecting viral genome has become transcriptionally active 
(Wang et al., 2004). Two viral RNAs were identified within the HCMV origin of 
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replication, oriLyt. One of these viral RNAs, termed vRNA-2, was shown to form a stable 
RNA-DNA hybrid structure in an oriLyt containing plasmid (Prichard et al., 1998).  
In addition to these viral RNAs, 2 cell RNAs, those for glyceraldehydes-3-phosphate 
dehydrogenase (GAPDH) and U1A, were found in the HCMV virion (Greijer et al., 2000). 
Selective concentration of specific transcripts imply biological function, however this 
viewpoint is controversial as studies have also shown that RNA molecules are 
incorporated into the virion in proportion to cellular concentration (Terhune et al., 2004). 
Incorporation of cellular RNA is most likely via non-specific interactions with RNA-
binding proteins such as ppUL99 (pp28) (Terhune et al., 2004). 
 
1.2.2. HCMV genome organisation 
Human Cytomegalovirus has the largest genome of any characterised human virus; 
consisting of ~236Kb, and is predicted to encode ~167 open reading frames, ~10miRNAs 
and other additional non coding transcripts (Davison, 2003, Grey and Nelson, 2008). The 
virus is described as having a class E isomerising genome that consists of a unique long 
(UL) and a unique short (US) region. Each region is flanked by inverted internal and 
terminal repeats, terminal repeat long (TRL), internal repeat long (IRL), terminal repeat 
short (TRS) and internal repeat short (IRS), Figure 1.4. A directly repeated sequence, 
termed a, is present at both termini and also in the region between the UL and US regions. 
The presence of the terminal and internal a sequences cause genome isomerisation, 
producing four isomers of the genome that are equally packaged into mature virions 
(Landolfo et al., 2003). In addition, the a regions contain the conserved pac1 and pac2 
elements that are conserved between herpesviruses and act as a signal for the packaging of 
the genome into the capsid. 
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Figure 1.4. HCMV strain AD169 and Toledo genome structures 
A) The HCMV genome is split into two main regions UL (unique Long) and US (unique 
short). These regions are flanked by terminal and inverted terminal repeats. These are termed 
terminal repeat long (TRL), internal repeat long (IRL), internal repeat short (IRS) and 
terminal repeat short (TRS). The a sequence is  a directly repeated sequence that contains  
conserved packaging elements required for packaging the genome into capsids. B)  The 
presence of terminal and internal a sequences allows for genome isomeration resulting in four 
genome isomers produced in viral progeny (class E genome).  These include the prototype (p) 
inverted long (IL), inverted short (IS) and inverted long and short (ILS) genome isomers.  
Adapted from Landolfo et al (2003) 
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1.2.2.1. Genome annotation  
The AD169 stock generated by Rowe et al (1956) was passaged another 56-64 times in 
human fibroblasts at St George’s hospital, London, before being used to produce an 
attenuated in-vitro strain for use in vaccination (Elek and Stern, 1974). This strain was 
termed strain AD169varUK and was later cloned (Greenaway et al., 1982) and used to 
generate the first complete sequence of the HCMV genome (Chee, 1990).  HCMV open 
reading frames (ORFs) were classified on their relative order within the genome and on 
which region they were encoded. For example UL1 is the first ORF of the UL region and 
US2 is the second ORF of the US region. Chee et al (1990) correctly identified that as 
technology and understanding of genomic structure developed then so would the 
annotation of the HCMV genome. This prediction was proved correct when the annotation 
of the HCMV genome was revisited by Davison et al (2003). Here the HCMV genome 
was compared to the Chimpanzee cytomegalovirus (CCMV) genome, the closest 
evolutionary relative of HCMV, and was predicted to comprise a total of 164-167 open 
frames. This number was attained by the addition of ORFs in the AD169 genome plus the 
number of ORFs found in the UL’b region of the Toledo strain, a region lost in strain 
AD169.  Uncertainty remained as the existence of UL155, UL156 and UL157 found in 
CCMV genome could not be discounted (Davison, 2003). A later annotation to the HCMV 
genome came after the sequencing of the Merlin genome a clinical isolate now designated 
the prototype HCMV genome, Figure1.5 (Dolan, 2004, Wilkinson, 2008). A more recent 
analysis of the HCMV strain Merlin genome has also identified 5 non coding viral RNA 
transcripts (Gatherer et al., 2011). 
In addition to protein coding ORFs, Grey and Nelson (2008) examined the human AD169 
genome for MicroRNAs (miRNAs), an extensive class of non-coding genes that regulate 
gene expression through post-transcriptional repression. Using a bioinformatics approach 
they identified 406 potential stem-loop structures, of which 110 were conserved between 
chimpanzee cytomegalovirus (Grey and Nelson, 2008). Of these, 13 exhibited a significant 
score using the MiRscan algorithm and 5 of the 13 predicted miRNAs were found 
expressed during infection by examining total RNA from HCMV infected cells.  
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Figure 1.5. Genomic map of HCMV strain Merlin 
Annotation of the wild type HCMV strain Merlin. Protein coding ORFs are indicated by 
arrows and have been colour coded into gene families. Reproduced from Wilkinson et al 
(2008), which was adapted from Dolan et al (2004) 
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1.2.2.2. Gene expression during infection  
During productive HCMV infection, viral gene expression has been divided into three 
categories. These classes are based on temporal kinetics of gene expression and sensitivity 
to inhibition of protein or viral DNA synthesis and have been designated as immediate 
early (IE), early (E) and late (L). Expression of IE genes occurs immediately post viral 
entry and is required for the expression of both E and L genes, Figure 1.6. Transcription of 
the HCMV genome is performed by the host cell polymerase and its basal transcription 
complex.  
 
1.2.2.3. Immediate early gene expression 
Immediate early genes are defined as those that are transcribed in the absence of de novo 
virus-encoded protein synthesis. Four regions of IE gene expression have been mapped on 
the HCMV genome; the major IE (MIE) gene region encodes UL123 (IE1), UL122 (IE2) 
and less abundant proteins include UL36, UL37, TRS1, IRS1 and US3. By definition, IE 
gene expression is required to progress to productive infection. Although IE genes are 
primarily associated with key functions as transcriptional activators, the majority have 
been attributed to evading intrinsic, innate and adaptive host immune responses, immune 
evasion functions of these genes are discussed later in section 1.6.   
The most abundant IE transcripts are those controlled by the MIE promoter-enhancer, one 
of the strongest transcriptional enhancers identified in mammalian biology (Boshart et al., 
1985, Chee, 1990). The MIE promoter is located between -580 and -40 relative to the 
transcriptional start site and contains binding sites for an array of transcription factors, 
which include NF-κB and CREB (Sambucetti et al., 1989).  In addition to host 
transcription factors, the MIE promoter is also activated by viral tegument proteins 
ppUL82 (pp71) and ppUL36 ensuring IE gene expression without relying on de novo viral 
gene expression or host transcription factors (Bresnahan and Shenk, 2000b).  
UL123 (IE1/p72) and UL122 (IE2/p86) are the two major products of the MIE locus and 
are differentially spliced variants. These proteins contain the same 85aa N-terminus (exons 
2 and 3) but following differential splicing, IE1 fuses with exon 4 and IE2 with exon 5. 
Three less abundant proteins are also produced; IE1p38, IE2p55 and IE2p18. With IE2p18 
only produced in human infected monocyte-derived macrophages or cycloheximide- 
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Figure 1.6. Phases of HCMV gene expression. 
A simplified illustration of HCMV’s temporal gene expression and the effect on viral and host 
gene regulation. Adapted and modified from Landolfo et al (2003).  
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treated HFFF cells (Kerry et al., 1995). These proteins play an important role in initiating 
and maintaining gene regulation during infections.  
UL123 (IE1) stimulates expression from its own promoter, but is a weak activator of 
heterologous promoters. However, via interaction with other factors, including IE2, it can 
influence gene expression.  The gene product initially traffics to, and induces the 
disruption of, Promyelocytic Leukaemia (PML) bodies (also known as ND-10 or PODs) 
(Kelly et al., 1995, Wilkinson et al., 1998). PML-bodies are punctuated intranuclear 
domains defined by their association with the tumour suppressor PML and are the site of 
HCMV transcription and DNA replication (Ahn and Hayward, 2000). PML-bodies are 
believed to constitute an intrinsic barrier to DNA-virus infection and their disruption is 
necessary for productive HCMV infection, as demonstrated by RNA interference 
knockdown of PML which significantly enhances the efficiency of infection (Tavalai et 
al., 2008, Tavalai et al., 2006). Post infection, PML disruption occurs within the first 6hrs. 
IE1 induces the dislocation of hDaxx, a PML-associated protein, which is then targeted for 
degradation by ppUL82. The interaction of hDaxx with histones (H2A, H2B, H3 and H4) 
and chromatin-associated proteins are related to its capacity to recruit histone deacetylase 
to sites of transcription (Woodhall et al., 2006). In preventing the recruitment of hDaxx-
dependant histone deacetylase to sites of transcription, ppUL123 and ppUL82 act together 
to counteract an intrinsic barrier to HCMV replication (Saffert and Kalejta, 2006, 
Hollenbach et al., 2002).  
UL122 (IE2p86) does not co-localise with PML-bodies, like UL123, but is instead located 
in discrete adjacent domains (Ahn and Hayward, 1997). IE2 binds a 15 base-pair cis 
repression signal (crs) located immediately upstream of the transcription initiation site, 
thereby negatively regulating expression from the MIE promoter, as well as functioning as 
a transactivator of both viral and host promoters (Cherrington et al., 1991, Lang and 
Stamminger, 1993).  Through IE2’s function as a transcriptional trans-activator, it 
mediates the switch from IE to E phase of gene expression. At early and late times of 
infection two additional proteins are expressed from the IE2 gene, IE2p40 and IE2p60, 
while IE2p40 represses expression from the MIE promoter, the other is required for 
efficient E and L gene expression (White et al., 2007). 
UL36 and UL37 are both IE inhibitors of apoptosis (Al-Barazi and Colberg-Poley, 1996). 
Individually, UL36 and UL37 are dispensable, but deletion of both results in viral progeny 
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unable to inhibit apoptosis, resulting in programmed cell death of the infected cell. 
Therefore the presence of one is essential for productive HCMV infection (Patterson and 
Shenk, 1999, Al-Barazi and Colberg-Poley, 1996). pUL36 (vICA) blocks Fas-mediated 
apoptosis by binding to caspase 8 and pUL37 (vMIA) functions downstream of caspase 8 
to inhibit apoptosis (Skaletskaya et al., 2001, Goldmacher et al., 1999).  
TRS1 and IRS1 gene products have been shown to transactivate E promoters in co-
operation with IE1 and IE2 and block interferon-induced dsRNA activated antiviral 
pathways (Child et al., 2004, Romanowski et al., 1997). While US3 encodes an ER-
resident membrane glycoprotein that inhibits antigen presentation by retaining MHC class 
I heavy chains in complex in the ER (Jones et al., 1996).     
   
1.2.2.4. Early gene expression 
Expression of E genes occurs prior to viral DNA replication and requires the presence of 
functional IE gene products (Fortunato and Spector, 1999).  Experimentally identifying E 
genes can be achieved by infecting and harvesting RNA in the presence of an inhibitor of 
HCMV DNA polymerase UL54. Inhibition of UL54 blocks L gene expression resulting in 
the accumulation of E gene products.  However, understanding of E gene expression and 
regulation is incompletely understood. Many E genes continue to express into the L phase 
of gene expression. However, true L gene expression is dependent on viral DNA 
replication. Early proteins involved in viral DNA replication include the catalytic and 
accessory protein subunits of the viral DNA polymerase UL54 and UL44 respectively 
(Kerry et al., 1994, Ertl and Powell, 1992). As well as UL112-113 that encode four nuclear 
phosphoproteins also involved in the initiation of DNA synthesis (Penfold and Mocarski, 
1997). Other E proteins include the structural proteins UL4 (gp48) and UL55 (gB) and the 
immune evasion proteins gpUS28 and gpUS11.  Early genes are also involved in gene 
regulations with pUL34 repressing the expression of the IE US3 by binding transcriptional 
repressor elements in the promoter, comparable with the crs of the MIE promoter 
(LaPierre and Biegalke, 2001). 
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1.2.2.5. Late gene expression 
True L gene expression is characterised by a dependency on Viral DNA replication and 
true L genes are only observed after onset of HCMV DNA synthesis and require the prior 
expression of IE/E gene products (Stinski, 1978). Late genes are believed to mainly encode 
structural proteins. The regulation of L phase gene expression is poorly understood with 
studies being based on a small number of genes; UL94, UL99 and UL44.  
The UL94 gene product is a tegument protein that associates with ppUL99 (pp28) (Liu et 
al., 2009). UL94 is a true L gene controlled by a promoter with a negative response 
element (NRE) and a positive response element (PRE) (Wing et al., 1996, Wing et al., 
1998). During the E phase of infection, IE2p86 and cellular p53 interact with the NRE to 
prevent expression of UL94, while during L phase the PRE is dominant driving expression 
of UL94 (Wing et al., 1998). Another L gene, ppUL99, also contains repressor elements 
that modulate gene expression (Kerry et al., 1997). 
UL44 encodes a DNA polymerase accessory subunit and has three distinct transcription 
start sites that produce three functionally distinct proteins (Isomura et al., 2007). The 
proximal and distal start sites, under control of TATA elements, produce proteins with E 
phase kinetics and are essential for DNA replication (Iwayama et al., 1994, Isomura et al., 
2008), while expression of the middle start site produces a protein with true L kinetics 
(Isomura et al., 2007). This gene product does not influence DNA synthesis but instead 
increases global viral protein synthesis and is controlled by a non-canonical TATA 
element (Isomura et al., 2008). 
 
1.2.3. Non-coding RNA 
Mitochondria, in addition to their role in bioenergetics, play a central role in response to 
apoptotic signals. Consequently, a number of viruses target mitochondria to control 
apoptosis and also ensure that the large energy demands of viral replication are met. The 
HCMV β2.7 RNA is unique in that it is the only example of a viral non-coding RNA 
(ncRNA) that targets the mitochondrion to maintain high levels of ATP production during 
infection. Transcription of β2.7 accounts for ~80% of total cellular transcription during the 
E stage of infection. Exactly how β2.7 RNA binds mitochondrial complex I and prevents 
relocalisation of essential genes thereby inhibiting proapoptotic signals remains to be 
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elucidated (Reeves et al., 2007). Since the description of β2.7, 4 other ncRNA’s have been 
identified in HCMV although their function remains unknown (Gatherer et al., 2011).    
 
1.2.4. Latency and reactivation 
Classically, latency has been described as the maintenance of the viral genome without the 
production of cell free virus. However, in HCMV lifelong infection is associated with 
chronic viral re-activation and replication. This long-term low-level persistence is likely to 
result from a latent HCMV reservoir that constantly reactivates lytic replication. 
Reactivation results in productive infection, which is controlled by the cellular immune 
response and does not cause clinically-relevant disease in the immuno-competent 
population.  
Studies have identified one site of latency to be CD34
+
 haematopoietic progenitor cells. As 
CD34
+ 
cells undergo differentiation into cell types carrying Dendritic cell markers, viral 
genomes can be reactivated. However, not all lineages arising from CD34
+
 progenitors 
carry viral genomes. CD4
+ 
T-cells, CD19
+
 B-cells as well as polymorphonuclear cells do 
not carry HCMV genomes (Taylor-Wiedeman et al., 1991, Wang et al., 1993). The reason 
for this remains unclear. Sinclair et al (2008) have put forward possible theories such as 
HCMV infection of CD34
+
 progenitors could alter lineage commitment, or latent infection 
results in lack of proliferation of certain lymphoid or myeloid cell types (Sinclair, 2008). 
These theories still need to be addressed .While hematopoietic mononuclear cells have 
received attention as one site of latency, whether other sites exist and exactly how latency 
is maintained and how reactivation occurs is not known (Reeves and Sinclair, 2008).  
 
1.2.5. In-vivo transmission and primary infection. 
Farber and Wolbach (1932) provided the first evidence for HCMV infection of individuals 
when cells typical of HCMV infection were detected in 12% of 183 infants who had died 
from other, unrelated, diseases (Farber and Wolbach, 1932). Although primary infection is 
generally attributed to those early on in life, HCMV is capable of infecting people of all 
ages. The virus can be transmitted via exposure to virus-containing bodily fluids including 
saliva, urine, cervical and vaginal secretions, semen, breast milk, tears, faeces and blood 
and is thought to be transmitted horizontally and vertically via contact with these bodily 
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fluids from infected individuals (Pass, 2001). HCMV is also capable of crossing the 
placenta and is a common cause of viral congenital malformation in humans (Stagno et al., 
1987).  Following primary infection, infectious virus is excreted for prolonged periods of 
time which enhances the spread of the virus throughout the population. 
Following primary infection, HCMV spreads to the lymphoid tissues and then 
systematically through circulating lymphocytes and monocytes to the lymph nodes and 
spleen. The infection can also be localised in the duct and epithelial cells of salivary 
glands, kidney tubules, cervix, testes and epididymis. Pathologic changes in the immuno-
competent population are rare, with the virus usually resulting in an asymptomatic 
infection or a mild flu-like illness and mononucleosis.  
 
1.3. CLINICAL OUTCOMES OF HCMV INFECTION  
One of the more striking observations is that severe CMV disease is found in those with 
weakened or compromised immune systems where infection leads to clinical manifestation 
with potential complications including pneumonia, hepatitis and autoantibody production 
(Seehofer et al., 2002, Bartholomaeus et al., 1988, Enright et al., 1993). In particular 
patients undergoing bone marrow transplantation or who have AIDS, where there is an 
impairment of T-lymphocytes, seem to be particularly susceptible (Hibberd and Snydman, 
1995). 
 
1.3.1. Congenital infection 
Congenital CMV infection is one of the TORCH infections (toxoplasmosis, other 
infections including syphilis, rubella, CMV and herpes simplex virus), which carry a risk 
of significant symptomatic disease and developmental defect in newborns.  
The most common complications reported in neonates associated with HCMV disease are 
jaundice, hepatosplenomegaly and petechiae, and these symptoms may affect up to 70% of 
overtly infected infants (Boppana et al., 1992). Other complications can include CNS 
disorders such as brain inflammation/microcepthaly and damage to the retina and cochlear 
which can result in blindness and deafness (Boppana et al., 1992). Primary infection 
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during pregnancy is thought to be one of the largest viral causes of congenital deafness and 
mental retardation (Stagno et al., 1977).  
Congenital transmission of HCMV resulting in clinically relevant disease is more common 
following primary infection during pregnancy, as compared to viral reactivation. One 
study, by Reynolds et al (1973), reported that up to 40% of mothers who seroconvert 
during gestation transmitted the virus transplacentally to their child. In comparison,  only 
1% of children born to HCMV seropositive women who suffered a recurrent infection 
were born seropositive (Reynolds et al., 1973). 
 
1.3.2. Transplantation 
HCMV infection is one of the largest causes of solid organ and bone marrow transplant 
rejection (Hibberd and Snydman, 1995, Neiman et al., 1977, Lopez et al., 1974). 
Typically, rejection occurs in transplants between seropositive and seronegative patients. 
For HCMV seropositive recipients, the immunosuppressive treatment required prior to 
surgery provides an opportunity for viral reactivation and HCMV can be detected in bodily 
fluids in these patients (Rubin, 2001).  
For seronegative recipients who receive transplanted organs from seropositive donors, 
HCMV present in transplanted organs can result in primary infection and subsequent 
complications including graft rejection (Lopez et al., 1974). The major clinical 
manifestations in infected solid organ recipients are fever, gastroenteritis, mononucleosis, 
retinitis, malaise and macular rash. While life-threatening complications such as 
pneumonia and hepatitis occur in fewer patients (Kotton, 2010).     
In addition to solid organ transplants, patients undergoing allogenic bone marrow 
transplantation can also develop CMV disease. One report by Rubie et al (1993) showed 
the incidence of CMV infection and CMV interstitial pneumonitis (CMV-IP) in patients 
undergoing allogenic bone marrow transplantation were 44% and 13% respectively, with 
CMV-IP being the most clinically significant  and life threatening (Rubie et al., 1993). 
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1.3.3. HIV/AIDS 
In people with advanced HIV infection that have developed acquired immune deficiency 
syndrome (AIDS) HCMV can be reactivated as a result of an impaired immune system and 
consequently CMV disease is an AIDS defining condition. A HIV negative individual has 
a normal CD4
+
 T-cell count varying between 600-1200 cells/mm
3
. The average CD4
+
 cell 
count of a HIV+ individual at the time they develop their first episode of HCMV is below 
30 cells /mm
3
 (Kuppermann et al., 1993). Historically, over 20 % of people with HIV have 
developed CMV disease within 2 years of their CD4
+
 cell count falling below 
100cells/mm
3
 (Gallant et al., 1992).  
In humans, CD4
+
 helper T-lymphocytes respond to multiple structural and non-structural 
CMV proteins and the reduction in CD4
+
 T-cells allows for opportunistic CMV infection 
(Sinclair et al., 2004). The HCMV immediate early proteins IE1 and IE2, have been shown 
to interact with the HIV Tat (transcriptional activator of the long terminal repeat) protein, 
indicating that dual infection with HCMV and HIV could play a role in HIV activation and 
acceleration of the onset of AIDS (Monte et al., 1997). Therefore, co-infection with 
HCMV and HIV has been described as an independent predictor of mortality in AIDS.   
The most common manifestation of infection within this subgroup is HCMV retinitis, a 
progressive disease causing total retinal destruction and blindness affecting up to 5% of 
AIDS patients (Jacobson et al., 1988). Interestingly, CMV retinitis is almost uniquely 
found within this immunocompromised group, demonstrating the importance of CD4
+
 T-
cells in controlling HCMV infection. Other complications include gastro-intestinal lesions, 
HCMV pneumonitis and HCMV central nervous disease. However, with the onset of 
Highly Active Anti-Retroviral Treatment (HAART), HCMV related complications have 
been rapidly reduced within the HIV/AIDS population (Hammer et al., 1997, Clumeck et 
al., 2001, Squires et al., 2000, Eron Jr et al., 2000). 
 
1.3.4. Treatment 
HCMV is an important pathogen which is difficult to treat and currently has a significant 
unmet medical need. Acyclovir, which is commonly used to treat other herpesviruses, is 
generally ineffective (Singh et al., 1994). Two other agents are therefore more generally 
used; Ganciclovir and Foscarnet. These two agents have been shown to have strong in-vivo 
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activity against HCMV. However, resistance to these agents is becomingly increasingly 
common in the population, especially amongst AIDS patients (Jabs et al., 1998a, Jabs et 
al., 1998b). Cidofovir is another agent used in the treatment of CMV but is limited to use 
in AIDS patients due to its high toxicity. HCMV therefore provides an excellent 
pharmaco-economic case for drug development. Nevertheless, years of development has, 
thus far, failed to bring a drug to market that is both potent and safe. 
Ganciclovir is a prodrug that has demonstrated efficacy against a number of the 
herpesviridae. Administered by intravenous (IV) injection in its inactive form, upon 
entering infected cells ganciclovir is phosphorylated to a monophosphate form by the 
enzyme encoded by the UL97 open reading frame (ORF) of HCMV (Littler et al., 1992, 
Sullivan et al., 1992). The monophosphate form of ganciclovir is further phosphorylated 
by host kinases to a triphosphate form. Ganciclovir triphosphate then competes with 
deoxyguanosine triphosphate as a substrate for DNA polymerase. Incorporation in the 
growing DNA chain slows DNA synthesis and consequently inhibits viral replication. 
Despite being the drug of choice for the treatment of HCMV, resistant HCMV isolates 
have emerged that contain mutations in UL97 that prevent the phosphorylation of 
ganciclovir (Chou et al., 1995).   
Ganciclovir is administered by IV injection, which is inconvenient and can be complicated 
by infection. Valganciclovir (VGCV) is a prodrug valyl derivative of ganciclovir, which 
can be administered orally. After absorption through the gut, the valine moiety is rapidly 
cleaved off by the liver yielding ganciclovir, which is inactive until it becomes 
triphosphorylated and its mechanism of action is as above.   
For those patients that are intolerant to ganciclovir, or have failed ganciclovir treatment, 
forscarnet can be used to treat HCMV disease. Forscarnet is an inorganic pyrophosphate 
analogue that selectively inhibits the viral DNA polymerase, encoded for by UL54. 
However, HCMV mutants with resistance to forscarnet have been identified (Baldanti et 
al., 1996).  
Cidofovir (Vistide, HPMPC) is a nucleotide analogue with a prolonged intracellular half 
life and potent activity against a spectrum of Herpesviruses, including CMV. As a 
nucleotide, cidofovir does not require virus-mediated activation by phosphorylation and 
therefore retains activity against many ganciclovir-resistant CMV clinical isolates 
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(Lalezari et al., 1995). Cidofovir is also administered IV but due to its high toxicity is 
predominantly reserved solely for treatment of CMV retinitis.  
Growing antiviral-resistance is a major issue in treating HCMV disease. In one study, Jabs 
et al (1998a), identified Ganciclovir-resistant isolates in 27% of CMV retinitis patients 
treated with ganciclovir for 9 months. Identification of a resistant isolate was associated 
with adverse disease outcomes, such as dissemination to the other eye or rapid progression 
of the retinitis (Jabs et al., 1998a). In a similar study 37% of patients treated with 
forscarnet for 9 months developed a forscarnet-resistant isolate, and 29% of patients 
treated with cidofovir for 3months a cidofovir-resistant isolate (Jabs et al., 1998b). The 
rapid development of resistance is of obvious concern and thus drives the need to develop 
more effective treatments.    
 
1.3.5. Vaccination 
Due to the lifelong persistence of viral infection, its ability to become reactivated at times 
of immuno suppression and the irreversible nature of some of its symptoms HCMV 
remains an important virus to treat.  In 1999, a review of priorities for vaccine 
development by the Institute of Medicine (IOM) of the National Academy of Sciences 
(USA) ranked a vaccine to prevent CMV disease as the highest priority on the basis of life-
time cost to the healthcare system and the impact of the virus on human suffering. 
Subsequently, this priority was also endorsed by the US vaccination programme office, 
which proposed a series of recommendations including support for increased funding by 
government agencies for HCMV vaccine research. Many attempts have been made to 
vaccinate against HCMV, but thus far immunisation has proven ineffective at preventing 
infection.  
One of the earliest developments in the CMV vaccine field involved the use of a live 
attenuated strain of HCMV as a vaccine. The Towne strain was first described in 1975 and 
the Towne-virus vaccine has been used in various studies with, thus far, little success.  
Trials in both CMV-positive and CMV-negative renal-transplant patients showed that 
vaccination with the live attenuated Towne virus was unable to prevent re-infection or re-
activation of HCMV, but could dampen the pathology of infection (Plotkin et al., 1991). 
The vaccine has also been evaluated in healthy immunocompetent individuals and was 
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shown to induce virus-specific cellular immunity that was detectable 10 years post-
immunisation (Plotkin et al., 1991). In a separate study, vaccinated volunteers challenged 
with pathogenic HCMV showed that vaccinated individuals were more resistant to viral 
challenge than seronegative individuals (Plotkin et al., 1990). However, natural 
seropositive individuals were 5-10 times less likely to develop disease than were Towne 
vaccinated individuals. Another trial involved administrating the Towne vaccine to women 
with children in daycare centres. Transmission of CMV from toddlers to their seronegative 
mothers occurred in ~40% of cases, but there was no difference in vaccinated versus 
unvaccinated women (Adler et al., 1995). Progress for the Towne vaccine diminished 
because of regulatory concerns and its moderate efficacy within the seropositive 
population. 
Of those exposed to CMV nearly all appear to have antibodies in their sera raised against a 
variety of proteins including the envelope glycoproteins gB (gpUL55) and gH (gpUL75) . 
Many attempts have been made to vaccinate against HCMV glycoproteins, but until 
recently immunisation has proven ineffective at preventing infection. A recent paper 
described the successful conclusion of a phase II, placebo-controlled, randomised, double-
blind clinical trial for the prevention of maternal CMV infection. The vaccine consisted of 
a recombinant CMV envelope glycoprotein gB (gpUL55) administered with MF59 
adjuvant. Vaccine efficacy was 50% and is now being progressed to phase III clinical trials 
(Pass et al., 2009).  
 
1.4. IMMUNE RESPONSE TO HCMV   
Evidence from both animal experimentation and human investigation have shown that both 
innate and adaptive immunity play a part in the control of CMV disease. The innate 
immune response provides a front line defence against infection. In particular Natural 
Killer (NK) cells are important in controlling viral infections. Murine experiments have 
demonstrated that mice, genetically deficient in functional NK cells, show an increased 
susceptibility to MCMV (Shellam et al., 1981), while depletion of NK cells from mice 
leads to more serious infections after challenge (Bukowski et al., 1984). In humans, 
patients with defects in NK cell function also exhibit extreme sensitivity to HCMV disease 
as their immune systems appear unable to cope with the infection (Biron, 1989). While 
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indirect evidence of the importance of NK cells comes from the observation that highly 
conserved HCMV gene products appear to protect against NK cell cytotoxicity. 
Adaptive immunity also plays an important role in controlling persistent CMV infection. 
CMV specific CD4
+
 and CD8
+
 lymphocytes play an important role in immune protection 
after primary infection or reactivation from latency; as demonstrated by CD4
+ 
and CD8
+
 
responses specific to HCMV antigens. In seropositive individuals CMV-specific T-cells 
are the most abundant subset in the T-cell repertoire comprising on average ~10% of both 
the CD4
+
 and CD8
+
 memory compartments in peripheral blood (Sylwester et al., 2005). 
The importance of CD4
+ 
T-cells is also evident in HIV infections, where the depletion of 
CD4
+
 T-cells renders individuals susceptible to CMV infection.  
B-cell function is also important in controlling infection. During primary infection, CMV 
specific immunoglobulin (Ig) M antibodies are produced first, later followed by IgG 
antibodies. IgM antibodies may be found as early as 4-7weeks and may persist as long as 
16-20 weeks after initial infection, while IgG antibodies are lifelong (Middeldorp et al., 
1984). Antibodies have been identified with specificity for many proteins. The majority of 
neutralising antibodies are directed against envelope glycoprotein B (gB). Studies have 
shown that more than 50% of neutralising activity in serum is directed against gB 
(Boppana and Britt, 1996). However, virion tegument proteins such as ppUL32 (pp150), 
ppUL99 (pp28) and ppUL82 (pp65) evoke strong and potent antibody responses (Britt et 
al., 1990, Landini et al., 1988).  
 
1.5. MODULATION OF HOST RESPONSES BY HCMV. 
As a large and complex DNA virus, HCMV encodes many ORFs that express proteins 
dispensable for productive replication of infectious virus in culture. These so called ‘non-
core’ genes are thought to potentially play a role during initial infection of the host and in 
the modulation of the immune response. A significant number of these non-core genes 
have already been identified as modulators of the human immune system and of cellular 
defence mechanisms, Table 1.2. HCMV has co-evolved with the human immune system 
and this close evolutionary interplay has allowed the virus to develop an array of immuno-
modulatory functions, Figure 1.7. The virus has shown a vast array of functions that  
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Aspect of the immune 
system HCMV gene  
Downregulation of MHC-1 US2, US3, US6, US11 
Downregulation of MHC-II US2, US3 
NK cell evasion 
UL16, UL18, UL40, UL83, UL141, UL142, miR-
UL112,  
Chemokine receptor US28, UL33, UL78 
TNFR homologue UL144 
IL-10 homologue UL111A 
Virokine UL146, UL147 
RANTES-binding UL22A 
Inhibitors of apoptosis UL123 (IE1), UL122 (IE2), UL36, UL37 
Interferon response IRS1, TRS1, UL83 
  
Table 1.2. HCMV gene implicated in immune modulation. 
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  Figure 1.7. Overview of HCMV immunomodulation of infected cells.  
UL18 encodes a MHC-1 homologue that inhibits LIR1+ NK cells, however activates LIR1- NK cells. UL16, 
UL142 and miR-Ul112 all act in concert to suppress cell surface presentation of NKG2D ligands represented 
here by MIICA, MICB, ULBP1 and ULBP2. UL40 upregulates the cell surface expression of HLA-E, a non-
classical MHC-1 molecule. UL141 binds a sequesters CD155 in the ER preventing NK activation through 
DNAM-1 receptor. UL83 prevents NK activation by binding NKp30, although the as UL83 is not expressed 
at the infected cells surface it is unclear how this works in vivo. UL83 has also been shown to target MHC-II 
to the lysosome for degradation. MHC-II cell surface expression is also inhibited through ER sequestration 
of HLA-DR by US3 and US2 mediated degradation. MHC-I cell surface expression is inhibited byUS2 and 
US11 mediated proteasome degradation, US3 ER sequestration and US6 prevents TAP mediated peptide 
loading of MHC-I molecules. HCMV also encodes chemokine receptors US27 US28, UL33 and UL78. 
TNF-receptor homologue UL144, IL-10 homologue UL111A, Virokines UL46 and UL147. RANTES-
binding protein UL22A.  Apoptosis is also inhibited through the action of UL36 and UL37. All mechanisms 
are discussed in more detail in section 1.5.   
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interfere with many aspects of the infected cell from protein mimicry to targeted 
degradation; and it is these mechanisms that allow the long term survival of HCMV. 
 
1.5.1. Modulation of the cell cycle 
The phosphoproteins ppUL69 and ppUL82 are capable of imposing a G1/S-like block that 
deregulates the expression of many cell cycle regulated gene products (Lu and Shenk, 
1999). Delivery of ppUL69, found within the virion, has been shown to impose a G1 block 
that is independent of synthesis of additional ppUL69 from the virion genome (Hayashi et 
al., 2000). Whereas, ppUL82 accelerates progression through the G1 phase and activates 
IE gene expression (Kalejta and Shenk, 2003). ppUL82 has also been shown to dysregulate 
the cell cycle by targeting members of the retinoblastoma family of proteins (p105, p107 
and p130) for degradation; which are general repressors of cell proliferation (Kalejta et al., 
2003). 
 
1.5.2. Apoptosis 
The IE1 (UL123) and IE2 (UL122) proteins have been shown to inhibit apoptosis by 
activating the PI3 kinase pathway via the cellular kinase Akt (Yu and Alwine, 2002). 
Additionally, IE2 appears to lead infected cells into senescence after arresting the cell 
cycle and inhibiting apoptosis thought to occur through the p16 (INK4a) and p53 pathways 
(Noris et al., 2002).  
The viral non-coding RNA, β2.7, binds mitochondrial complex I and prevents the 
relocalisation of the essential subunit genes associated with retinoid/interferon-induced 
mortality-19 (GRIM-19) complex, thereby inhibiting proapoptotic signals (Reeves et al., 
2007). This interaction stabilises mitochondrial membrane potential allowing the 
maintenance of ATP production late into infection, and is critical for the successful 
completion of the virus life cycle (Reeves et al., 2007). 
UL36 encodes for a viral inhibitor of caspase activation (vICA), which has been shown to 
protect cells from extrinsic apoptosis induced via the death receptors TNFR1, Fas/CD95 or 
Trail (Park et al., 1996). Expression of ppUL36 inhibits Fas-mediated apoptosis via the 
binding to the pro-domain of caspase-8, preventing its activation (Skaletskaya et al., 2001).  
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HCMV also encodes a viral mitochondrial inhibitor of apoptosis (vMIA), encoded for by 
UL37. Two independent studies identified UL37 to bind with Bax in the mitochondria via 
a UL37-Bax complex, preventing Bax-mediated mitochondrial membrane 
permeabilisation and consequent cytochrome C leakage (Arnoult et al., 2004, Poncet et al., 
2004). 
UL38 also inhibits apoptosis and encodes a cell death protein (Terhune et al., 2007). 
Although the mechanism of UL38 action is unclear, it is thought that UL38 supports 
HCMV infection at least in part by blocking cellular responses to stress. TSC1/2 integrates 
stress signals and regulates mammalian target of rapamycin complex 1 (mTORC1), a 
protein complex that responds to stress by limiting protein synthesis and growth. pUL38 
has been shown to interact with TSC1 and TSC2 in HCMV infected cells (Moorman et al., 
2008). Additionally three pathways, collectively termed the unfolded protein response 
(UPR), are activated in response to ER stress and will resolve in apoptotic cell death if cell 
stress cannot be alleviated. In infection, pUL38 has been shown to modulate the of PKR-
like ER kinase (PERK) pathway, one aspect of the UPR, and the α subunit of eukaryotic 
initiation factor 2 (eIF-2α), as well as induce accumulation of activating transcriptional 
factor 4 (ATF4) and to suppress the persistent phosphorylation of c-Jun N-terminal kinase 
(JNK) (Xuan et al., 2009). These activities appear crucial for protecting cells against ER 
stress induced by HCMV infection.  
 
1.5.3. Cytokine and chemokine homologues 
UL111a encodes a viral homologue of human IL10 (cmv-IL10) that shares only ~27% 
amino sequence identity with human IL10, but importantly has been shown to still signal 
through the IL10-receptor (Kotenko et al., 2000). Cmv-IL10 recovered from infected cell 
supernatants and Escherichia coli-derived recombinant –IL10 were both shown to inhibit 
proliferation of, and cytokine synthesis by, mitogen stimulated peripheral blood 
mononuclear cells (PBMC) with the potency of human IL10 (Rousset et al., 1992). 
Additionally,  cmv-IL10 was shown to reduce cell surface expression of MHC class I and 
MHC class II on PBMC, analogous to human IL10 (Spencer et al., 2002). More recently 
cmv-IL10 has been described as down-regulating CD4
+
 T-cell recognition of latently 
infected cells (Cheung et al., 2009).  
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UL144 is a TNF-alpha-like receptor. However, it does not bind any known TNF-related 
ligands (Benedict et al., 1999, Lurain et al., 1999). To date, only one ligand, the Ig 
superfamily member B and T lymphocyte attenuator (BTLA), has been shown to bind to 
the UL144 protein and inhibit T-cell proliferation in-vitro (Cheung et al., 2005). This may 
decrease the lymphocyte response to HCMV. More recently, UL144 has been shown to 
activate TNFR-activated receptor 6 (TRAF6) leading to NF-κB activation (Poole et al., 
2006).  
The HCMV gene UL146 encodes a CXC chemokine (vCXC-1), a 117 amino acid 
glycoprotein that, when secreted, has been shown to attract neutrophils, binds CXCR2, and 
induces calcium mobilisation and degranulation with similar potency to IL8 (Penfold et al., 
1999). UL146 is termed a hypervariable protein and shows high degrees of variability 
within its coding sequence across multiple isolates (Hassan-Walker et al., 2004, Stanton et 
al., 2005). UL147 also encodes a CXC chemokine (vCXC-2). Unlike UL146, UL147 has 
only limited variability in the coding region for the mature protein, but is highly variable in 
the signal sequence of UL147.  
The HCMV genome encodes four putative seven-transmembrane domain chemokine-like 
proteins that show sequence similarity with chemokine receptors belonging to the family 
of G-protein coupled receptors (US27, US28, UL33 and UL78). Although important in 
viral pathogenesis, little is known about the function of these proteins and most study has 
been aimed at US28.  
The gpUS28 binds multiple CC chemokines, with highest affinity for fractalkine, but is 
also able to bind RANTES (Released upon Activation, Normal T-cell Expressed and 
Secreted), MCP-1 (Monocyte Chemo attractant protein-1) and MIP-1α and β (macrophage 
inflammatory protein) (Kledal et al 1998; (Kuhn et al., 1995, Gao and Murphy, 1994, 
Kledal et al., 1998, Billstrom et al., 1998, McLean et al., 2004). Located in endocytic 
vesicles, gpUS28 undergoes constitutive endocytosis and recycling to the cell surface, 
resulting in continuous internalisation of chemokines by gpUS28 and a reduction of 
extracellular chemokine concentration (Bodaghi et al., 1998, Fraile-Ramos et al., 2001). 
Following interaction with chemokines, gpUS28 couples with specific G proteins and, 
through these associations, activates intracellular calcium flux and the MAP kinase 
pathway thereby modulating the activity of transcription factors NFAT (nuclear factor of 
activated T-cells) and CREB (cAmp response element) (Billstrom et al., 1998, McLean et 
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al., 2004). gpUS28 has also been implicated in vascular smooth muscle cell migration 
(Streblow et al., 1999).  
Additionally, HCMV also encodes a small soluble secreted RANTES binding protein, 
pUL21A, which acts as a decoy receptor (Wang et al., 2004). pUL21A and pUS28 may 
work in harness to suppress chemokine function during productive HCMV infection. 
 
1.5.4. Modulation of the Interferon response 
Interferon’s (IFNs) are multifunctional cytokines with antiviral activity that are rapidly 
induced and released from infected cells.  Released IFN then binds target cells and induces 
an antiviral state. HCMV is generally considered to be relatively resistant to IFN. 
However, in cell culture, IFN treatment can inhibit viral production (Taylor and 
Bresnahan, 2005). While mice lacking the IFN receptors suffer greatly increased mortality 
following MCMV infection (Presti et al., 1998).  
Binding and cell entry of HCMV, or treatment with gB or gH, triggers a proinflammatory 
transcriptional profile resembling an alpha/beta interferon (IFNα/β) response, even in the 
absence of de-novo viral gene expression (Zhu et al., 1998, Boyle et al., 1999). The virion 
associated proteins are recognised by the cell as pathogen-associated molecular patterns 
(PAMPs) resulting in the activation of IRF3 and NF-κB. Activation of the IFN-like 
response is controlled by NF-κB, which may be beneficial to viral infection due to the 
large distribution of NF-κB binding sites on the viral genome therefore driving 
transcription of viral genes (Preston et al., 2001, Netterwald et al., 2005).  
HCMV infection results in decreased accumulation and phosphorylation of the IFN 
signalling kinase STAT2 through pUL123 (Paulus et al., 2006), which inhibits 
transcriptional activation of IFN-regulated genes, Figure 1.8. Infection also causes a 
reduction in the abundance of p48/IRF9, a component of the ISGF3 transcription factor 
complex. During infection HCMV IE and/or E genes disable Jak/STAT signal transduction 
by decreasing JAK-1 expression, which inhibits IFNγ stimulated signal transduction, 
(Miller et al., 1998a)Figure 1.8. Inhibiting IFNγ signalling prevents the up-regulation of 
ISG class II transactivar (CIITA) and thereby preventing protein-protein interactions 
between CIITA and classII promoter-binding proteins that are believed to be required for 
MHC-II transcription.  
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Figure 1.8. Summary of HCMV inhibition of IFN signalling through the Jak/STAT pathway.  
In type II IFN signalling the activation, tyrosine phosphorylation by JAK-1 activates STAT-1 which 
homodimerises and translocates to the nucleus where it activates IRSEs for ISGs involved in the expression 
of MHC-II genes such as CIITA that promotes the expression of MHC-II. During infection HCMV IE 
and/or E genes disable Jak/STAT signal transduction by decreasing JAK-1 expression, which inhibits IFNγ 
stimulated signal transduction. HCMV has also been shown to inhibit STAT-1 and prevents the upregulation 
of CIITA. In type I IFN signalling JAK1 and STAT1 are also inhibited. pUL123 inhibits transcriptional 
activation of ISGs. HCMV infection also results in a reduction in the abundance of IRF9, a component of the 
ISGF3 transcription factor complex.  
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As HCMV progresses through the infection cycle, phosphoprotein ppUL83 (pp65) 
accumulates in both the nucleus and cytoplasm and has been reported to prevent IFN 
response. Two similarly designed experiments utilising in-vitro infection of HCMV with a 
deletion of ppUL83, or WT virus agree in concluding that ppUL83 delivered to the cell 
with the viral tegument functions to block IFN pathway genes very early after entry (Abate 
et al., 2004, Browne and Shenk, 2003). However, whether the effect of ppUL83 is to block 
IRF3, IRF1 and/or NFκB is not clear (Abate et al., 2004, Taylor and Bresnahan, 2005, 
Browne and Shenk, 2003, DeFilippis et al., 2006).  
Of those ISGs transcribed as a result of IFN signalling, Protein kinase R (PKR) is an ISG 
that senses dsRNA and activates cellular pathways that result in the shutdown of protein 
synthesis and activation of the IFN response. As a result of a conformational change 
induced by binding to dsRNA, PKR dimerises and phosphorylates translation initiation 
factor eIF2α on serine 51. Phosphorylated eIF2α results in the formation of an inactive 
complex that involves eIF2α–tRNAmet–GTP ternary complex preventing translation 
initiation, and entirely eliminating viral replication. HCMV proteins pIRS1 and pTRS1 are 
present in the virion and expressed from immediate early times throughout infection 
(Romanowski et al., 1997). Both have been identified as dsRNA binding proteins required 
for viral evasion of Protein Kinase R (PKR). Infection with HCMV lacking both IRS1 and 
TRS1 results in phosphorylation of eIF2α and the shutdown of translation (Hakki and 
Geballe, 2005). Thus, the PKR pathway creates an intrinsic antiviral environment and 
IRS1 and TRS1 serve essential functions in preventing PKR binding to dsRNA preventing 
the shutdown on translation and induction of IFN response. 
 
1.5.5. Protection from complement  
HCMV encodes two IgG Fc receptors, RL11 and UL119, which are present on the plasma 
membrane of infected cells and on the envelope of the virions (Atalay et al., 2002, Lilley et 
al., 2001, Murayama et al., 1989). IgG-Fc receptors bind the constant Fc region of IgG 
molecules. A process called antibody bipolar binding and is thought to protect the virus 
from the complement pathway. Antibody bipolar binding is described as the Fc receptor 
binding the Fc region of an immunoglobulin molecule while the Fab region binds to its 
antigen on the virion. This process has been shown to resist complement-mediated 
40 
 
neutralisation and antibody-dependent cellular cytotoxicity (ADCC) in HSV (Dubin et al., 
1991).  
HCMV also controls the complement pathway by up-regulating the host regulators of 
complement activation CD55 and CD46 (Spiller et al., 1996). Host regulators of 
complement activation suppress the activation of C3 convertase on virus-infected cells 
providing a mechanism to protect HCMV-infected cells from complement mediated lysis. 
This technique is also utilised by virions as CD55 and another complement control protein, 
CD59, are incorporated into the virion envelope (Spear et al., 1995). 
 
1.5.6. Modulation of antigen presentation 
CD8F
+
 T-cell recognition relies on the interaction of the T-cell receptor with antigen 
presented on Major histocompatibility complex (MHC) class I proteins and costimulatory 
complex on target cells. During their formation, newly synthesised MHC class I heavy 
chain associate with β2m in the ER. The heterodimer then associates with the transporter 
associated with antigen presentation (TAP) and other antigen processing machinery 
components to form a ‘peptide loading complex’. In the cytosol, antigenic peptides 
processed by the proteasome are delivered to the ER lumen via the TAP complex, which is 
physically linked to the MHC class I molecule through the ER resident protein tapasin, 
which, in turn, facilitates peptide loading onto the MCH class I/β2m heterodimer. The 
trimeric complex is then transported through Golgi compartments to the cell surface where 
it can be recognised by surveying T-cells. 
CD4
+
 T-helper cell recognition relies on the interaction of the T-cell receptor with antigen 
presented on MHC class II proteins. The priming of HLA II-restricted CD4
+
 T-cells by 
professional antigen presenting cells (APCs) is crucial for the control of HCMV infection 
(Gamadia et al., 2003). These cells are direct antiviral effectors and also provide help for 
maintenance of CD8
+
 T-cell antiviral response. Exogenous antigen is endocytosed by an 
APC and destroyed by the endosomal and lysosomal proteases into peptide fragments 
containing 13~18 amino acid residues. The nascent assembled HLA II molecule associated 
with an accessory peptide, the invariant chain or Ii occupied the binding groove in the ER 
where it prevents MHC-II molecules from loading exogenous peptide in the ER lumen, 
and directs transport through the Golgi apparatus to the endosome, where Ii is destroyed by 
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proteases to yield a fragment called CLIP bound to HLA II molecules. CLIP is then 
removed by the HLA-DM, freeing all HLA-II molecules to load peptides and the 
HLAII/peptide complexes are transported to the cell surface where they can be recognised 
by CD4
+
 T-cells.  
HCMV infection results in the down-regulation of both MHC class I and class II thereby 
inhibiting antigen presentation to CD8
+
 MHC class I restricted cytotoxic lymphocytes and 
CD4
+
 MHC class II restricted T-helper lymphocytes. Four HCMV gene products have 
been implicated in the modulation of MHC class I. While two viral proteins have been 
shown to down-regulate both MHC- class I and class II. 
  
1.5.6.1. Modulation of MHC class I  
CD8+ T-cell recognition relies on the interaction of the T-cell receptor with antigen 
presented on MHC class I proteins and costimulatory complex on target cells.  A cluster of 
genes located in the US region of HCMV (US2-11) have been identified as immune-
modulatory glycoproteins (gpUS2, gpUS3, gpUS6 and gpUS11), which all act to decrease 
the cell surface expression of MHC class 1 proteins at various stages of the maturation 
process. Each of these four glycoproteins are expressed during viral infection and each is 
independently capable of preventing MHC class I expression at the infected cells surface. 
The reduction of MHC class I expression at the surface of infected cells effectively 
prevents the presentation of endogenous peptides to CD8
+
 CTLs, thereby impeding 
cytotoxic T-cell immune surveillance, Figure 1.9. (Hengel et al 1995). 
 
1.5.6.1.1. US2 
Detected 12 hours p.i., the US2 transcript increases in abundance throughout infection 
(Park et al., 2002). The product of US2, gpUS2, is an ER resident, 24 kDa type I 
membrane glycoprotein that targets MHC class I molecules for proteasome-dependent 
degradation (Gewurz et al., 2002). An Ig-like ER-luminal domain of gpUS2 is essential for 
this process and engages the α2/α3 domain of the MHC class I heavy chain (Gewurz et al., 
2001a, Gewurz et al., 2001b). Using a truncated mutant of gpUS2, Furman et al (2003) 
demonstrated the need for the cytoplasmic domain of US2 in catalysing the degradation of 
MHC class I heavy chains. The cytosolic domain was later shown to catalyse the 
42 
 
  
Figure 1.9. Summary of HCMV mediated MHC-1 degradation.  
A) CD8+ T-cell recognition relies on the interaction of the T-cell receptor with antigen presented on Major 
histocompatibility complex (MHC) class I proteins and costimulatory complex on target cells. During their formation, 
newly synthesised MHC class I heavy chain associate with β2m in the ER. The heterodimer then associates with the 
transporter associated with antigen presentation (TAP) and other antigen processing machinery components to form a 
‘peptide loading complex’. In the cytosol, antigenic peptides processed by the proteasome are delivered to the ER lumen 
via the TAP complex, which is physically linked to the HLA class I molecule through the ER resident protein tapasin, 
which, in turn, facilitates peptide loading onto the MCH class I/β2m heterodimer. The trimeric complex is then 
transported through Golgi compartments to the surface where it can be recognised by surveying. B) During infection, 
HCMV prevents the cell surface expression of MHC-1 via different mechanism. During immediate early infection US3 
bind to MHC-HC/β2M heterodimer prior to peptide loading resulting in ER retention. At early time points pot infection 
US6 inhibits ATP binding to TAP, preventing TAP mediated delivery of cytosolic peptides to the ER for loading. While 
both uS2 and US11 both target MHC-I for proteasome mediated degradation.  
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degradation of MHC class I by recruiting p97 ATPase into the ER associated degradation 
complexes (Chevalier and Johnson, 2003). P97 ATPase binds polyubiquinated proteins 
and functions by extracting substrates from the ER membrane before the substrate meets 
the proteasome (Rabinovich et al., 2002). However, whilst ubiquitination of MHC class I 
occurs when gpUS2 and MHC class I are bound, it was not found to be required for the 
initial steps of US2 mediated dislocation from the ER (Furman et al., 2003).      
 
1.5.6.1.2. US3 
gpUS3 is expressed as an 22kDa IE glycoprotein, but through alternative splicing can 
produce two smaller products,17kDa and 3.5kDa, US3 products are produced, which 
function as a dominant negative inhibitor of the full length, 22kDa, form (Liu et al., 2002, 
Shin et al., 2006, Ahn et al., 1996). gpUS3 forms a complex with β2m associated MHC 
class I heavy chains with high affinity (Ahn et al., 1996, Jones et al., 1996). This impairs 
the maturation and intracellular transportation of MHC heavy chains by binding to the 
MHC-HC/β2m heterodimer, prior to peptide loading in the ER(Lee et al., 2003). 
Consequently, the assembled MHC/peptide complex is retained in the ER, preventing 
translocation to the cell surface due to a retention signal in US3 (Lee et al., 2003). This 
mechanism causes a lack of MHC-1 molecules at the cell surface and means infected cells 
cannot be detected by T-cells that use MHC-1/foreign peptide complexes to illicit a 
cytotoxic response. However, US3 has also been shown to bind to tapasin, inhibiting 
tapasin-dependent loading of peptide to MHC class I molecules (Park et al., 2004). This 
mechanism only affects those HLA alleles that are dependent on tapasin for their surface 
expression (Park et al., 2004). Other HLA allelic products that are not tapasin dependant 
could express at the cell surface on US3-expressing cell lines (Park et al., 2004).  
 
1.5.6.1.3. US6 
gpUS6 contains a double-arginine motif, an ER retention signal in the C-terminal 
cytoplasmic domain. US6 inhibits the ATP binding to the subunit TAP1 (Hewitt et al., 
2001). As a consequence, the TAP-mediated delivery of cytosolic peptides to the ER for 
loading to the ‘peptide loading complex’ is impaired. Thus TAP-dependant peptides are 
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unable to be loaded, resulting in retention of MHC class I in the ER and a consequent 
reduction of class I molecules at the surface.  
 
1.5.6.1.4. US11  
US11 encodes a type I membrane glycoprotein that resides in the ER and causes rapid 
dislocation of newly synthesised HLA class I heavy chains from the ER to the cytosol, 
where they are degraded by the proteasome. In a similar mechanism as described for US2 
mediated degradation. HCMV gene products US2 and US11 differ in their ability to attack 
MHC class I, with US11 superior over US2 (Rehm et al., 2002). US11+ cells have been 
shown to reduce the half-life of newly synthesised MHC class I molecules from > 6 hours 
to < 2minutes (Wiertz et al., 1996). Like US2, the US11 transcript can be detected as early 
as 12hrs post infection (Park et al., 2002).  
Heavy chain dislocation by US11 is mediated by its transmembrane domain, which 
contains a glutamine residue at position 192 critical for dislocation but not for interaction 
with MHC-1 (Lilley et al., 2003). However, unlike US2 tertiary structure has no effect on 
US11 mediated degradation. Screening of cellular proteins interacting with US11 but not 
the Gln-mutant identified Derlin-1 as an interacting protein for US11 (Lilley and Ploegh, 
2004).  In yeast the Derlin-1 homologue is required for the degradation of a subset of ER 
proteins (Lilley and Ploegh, 2004). Derlin-1 was identified as a multiple transmembrane 
protein responsible for recruiting to the ER the cytosolic ATPase p97, a protein required 
for reterotranslocation (Ye et al., 2004).   
 
1.5.6.2. Modulation of MHC class II 
Unlike MHC-I proteins, which are ubiquitously expressed, MHC-II proteins are mainly 
restricted to APCs, B-cells, macrophages and DCs, that take up and express exogenous 
antigen to CD4
+
 T-cells. IFN signal transduction (JAK/STAT pathway) and class II 
transactivator (CIITA) are required for IFN stimulated MHC-II expression on non APCs. 
IFNγ is the most potent inducer of MHC-II expression in non APCs, such as endothelial 
cells and fibroblasts (Boss, 1997).  
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IFNγ signal transduction (JAK/STAT pathway) and class II transactivator (CIITA) are 
required for IFNγ stimulated MHC-II expression. CTIIA is believed to activate 
transcription by interacting with ubiquitous DNA binding proteins at MHCII promoters 
(Steimle et al., 1994, Jabrane-Ferrat et al., 1996, Moreno et al., 1995). MHC-II-α and –β 
chains are assembled in the ER with an invariant chain (Li) that prevents loading of 
peptides. The α/β/Ii complexes are then transported to the MHC-II compartment, a 
lysosome –like compartment where α/β dimers are loaded with peptides, normally derived 
from extracellular protein. HCMV infects MHC-II expressing monocyte/macrophage and 
endothelial cells and prevents MHC class II expression at the cell surface by varying 
mechanisms in both APCs and non-APCs (Lee et al., 2006, Soderberg-Naucler et al., 1997, 
Soderberg-Naucler et al., 1998).  
Two HCMV genes target both MHC-I and MHC–II: gpUS2 binds to both HLA-DRα and 
HLA-DMα in the ER and promotes their degradation via the proteasome (Hegde and 
Johnson, 2003, Tomazin et al., 1999) . gpUS3 binding to class II α/β complexes preventing 
their association with the invariant chain Ii (Hegde et al., 2002). The gpUS3-MHC-II 
complex moves from the ER to the Golgi apparatus bypassing the MHC-II loading 
compartment, resulting in a reduction of peptide-loaded MHC class II complexes at the 
cell surface. MHC-II transcription is also suppressed by HCMV infection causing the 
degradation of the cellular kinase JAK, which in turn inhibits a key transcription factor 
(CTIIA) (Miller et al., 1998b). cmvIL10 has also been shown to down-regulate MHC class 
II expression on macrophages (Kotenko et al., 2000, Redpath et al., 2001). HCMV 
ppUL83 has also been reported to promote degradation of MHC class II by mediating the 
accumulation of HLA-DR in lysosomes and promoting the destruction of the HLA-DR α 
chain (Odeberg et al., 2003).  
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1.6. MODULATION OF NATURAL KILLER CELL RESPONSE BY 
HCMV. 
Natural Killer (NK) cells comprise of ~10% of circulating lymphocytes and participate in 
early innate immune defence against viral infections and tumour transformation. These 
cytotoxic lymphocytes do not require antigen-specific recognition to lyse target cells but 
instead require an overriding activating signal to achieve effector function.  The activation 
of signalling pathways results in the development of cell-mediated killing through the 
release of cytotoxic granules containing perforin and granzyme, as well as the expression 
of cytokines and chemokines that modulate subsequent steps in the adaptive immune 
response. NK receptors do not undergo somatic recombination like TCR genes of T-cells, 
or Ig genes of B-cells. Instead they are diverse and rapidly co-evolving with their ligands. 
Mature NK cells do not express CD34 like other lymphocytes, and are minimally defined 
by the CD3
-
CD56
+
 phenotype. Although they do not express CD34, NK cells are derived 
from CD34 lymphocytes as Cytolytic NK cells can be derived in-vitro from CD34
+
 
progenitors (Miller et al., 1992). Previous studies have demonstrated the presence of two 
distinct subsets of NK cells based on different levels of expression of CD56 (Cooper et al., 
2001). CD56
Dim 
NK cells express high levels of CD16 (CD56
Dim
CD16
Bright
) and function 
as potent cytolytic effector cells representing approximately 90% of NK cells in normal 
PBMC.  
In contrast, CD56
bright
 cells do not express CD16 and are not potent cytolytic effector cells. 
CD56
bright
 cells appear to have more of a regulatory role, secreting large amounts of 
cytokines, including INF-γ TNF-α, lymphotoxin and IL-10(Farag and Caligiuri, 2006). NK 
cells therefore, have a role in inflammatory reaction(s) typically initiated as a result of the 
detection of foreign tissue, and are also implicated in inflammatory reaction(s) triggered by 
non-foreign tissue such as in autoimmunity. CD56
bright 
NK cells are predominately present 
in lymph nodes where they appear to interact with both dendritic cells and T-cells to 
enhance antigen presentation (Fehniger et al., 2003). 
 
1.6.1. NK cytotoxicity 
MHC class I receptor:ligand interaction can induce inhibitory signals that represent a 
major failsafe mechanism preventing killing of normal MHC class I autologous cells. In 
contrast down-regulation or loss of MHC class I expression, during viral infection or 
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carcinogenesis, shifts the balance towards NK cell activation and target cell destruction by 
removing this inhibitory signal. Thus NK cells are tolerant towards host cells, but in 
disease or infection this tolerance can be readily broken. This theory where ‘loss’ of self 
antigen, namely MHC class I, leads to NK cell activation was initially described as the 
‘missing self hypothesis’. However, with greater appreciation of cell biology, this theory 
has been fine-tuned. NK cell function is determined by multiple competing activating and 
inhibiting receptors. The main ligands for NK these receptors are MHC class I and class-I 
like molecules, for example, HLA-A, -B, -C, -E, MICA, MICB and others, Figure 1.10. 
The inhibitory receptors counteract activating receptor signals and lead to NK cell 
inhibition. However, precisely how signals from competing activating and inhibitory 
receptors are integrated and resolved is not completely understood. 
 
1.6.1.1. Inhibitory NK receptors 
Several inhibitory receptors have been identified, but there are two main families involved 
in human NK regulation: the killer cell Immunoglobulin-like receptors (KIRs) and the C-
type lectin-like receptors e.g. CD94/NKG2A.  
In humans, killer immunoglobulin like receptors (KIRs) are primarily responsible for the 
recognition of allotypic determinants that are shared by different MHC class I alleles. The 
KIRs are type I membrane proteins encoded on chromosome 19 in a region called the 
leukocyte receptor complex (LRC), which spans approximately 1Mb (Wende et al., 1999). 
They contain either 2 or 3 extracellular domains (KIR2D or KIR3D, respectively) and are 
further grouped according to their function, which may be inhibitory or stimulatory. 
Inhibitory KIRs have a long cytoplasmic tail (L) and contain 1 or 2 Immunoreceptor 
tyrosine-based inhibitory motifs (ITIMs) (Dohring et al., 1996, Lanier, 1998). The best 
characterised members of this family are the inhibitory KIRs with specificity for HLA-C 
ligands. HLA-C molecules are divided into type I and type II allotypes that differ in an 
asparagine or a lysine residue at aa 80 respectively. KIR2DL2 and KIR2DL3 bind type I 
HLA-C allotypes, while KIR2DL1 binds type II HLA-C allotypes (Winter et al., 1998). 
Other inhibitory KIRs have specificity for determinants of HLA-B (KIR3DL1), HLA-A 
(KIR3DL2) and HLA-G (KIR2DL4) (Dohring et al., 1996, Rajagopalan and Long, 2005, 
Long and Rajagopalan, 2000).  
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  Figure 1.10. Selection of NK cell activatory and inhibitory receptors and their cognate ligands.  
NK activation programmes result from the integration of multiple activating and inhibitory signals that 
vary depending on the interacting cell. Inhibitory receptors on the NK cell are in blue and their cognate 
ligand expressed on the target cell are also in blue. Activatory receptors are in purple and their cognate 
ligand expressed on the target cell is also in purple., Selection of activatory and inhibitory ligands and 
their cognate ligands. Adapted from Viver et al (2008)  
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1.6.1.2. Activating NK receptors 
Activating receptors can be split into two categories. Those that recognise MHC class I 
alleles, predominantly activating KIRs, and those that recognise non-MHC ligands such as 
the natural cytotoxicity receptors (NCRs).  
Activating KIRs are primarily responsible for the recognition of allotypic determinants 
shared by different MHC class I alleles. The external part of the molecule interacts with 
ligands on the target cells, while the internal part of the molecule contains a short 
cytoplasmic tail and associates with adaptor molecules that provide the activating signal 
through Immunoreceptor tyrosine-based activatory motifs (ITAMs). Activatory KIRs 
include KIR2DS1 that binds HLA-Cw6, as well as KIR2DS2, KIR2DS3, KIRR2DS4, 
KIR2DS5 and KIR3DS1, all of which have no known activatory ligands (Stewart et al., 
2005).  
Activating receptors that recognise non-MHC ligands on target cells include the natural 
cytotoxicity receptors (NCRs), NKG2D, DNAM-1, CD16 among others, Figure1.10. 
The NCRs comprise of NKp30, NKp44 and NKp46 (Pende et al., 1999, Vitale et al., 1998, 
Sivori et al., 1997, Pessino et al., 1998). NCRs exhibit no homology to each other but 
expression is restricted to NK cells. NKp30 is a polypeptide characterised by an 
extracellular region forming an Ig like domain connected to a transmembrane domain by a 
region of hydrophobic amino acids (Pende et al., 1999). The ligands for NKp30 include 
HLA-B associated transcript 3 (BAT3) and B7-H6 (Pogge von Strandmann et al., 2007, 
Brandt et al., 2009). NKp46 is characterised by 2 extracellular Ig domains (Pessino et al., 
1998), while no cellular ligand has been identified for NKp46, it has been shown to bind to 
viral haemagluttinin (Mandelboim et al., 2001). Both NKp30 and NKp46 associate with 
the CD3ζ adaptor proteins that contain ITAM motifs (Pende et al., 1999, Pessino et al., 
1998). The third NCR, NKp44, is a glycoprotein that associates with adaptor protein 
DAP12. Unlike the other NCRs, NKp44 is selectively expressed by IL2 activated NK cells 
(Vitale et al., 1998).  
NKG2D is an activating receptor expressed on all NK cells, some T-cells and activated 
macrophages and associates with the adaptor protein DAP10 (Bauer et al., 1999, Wu et al., 
1999) (Bauer et al 1999, Wu et al 1999, Li et al 2001). NKG2D has been shown to bind 
multiple MHC class I-like molecules. These include MICA, MICB, ULBP1-3, 
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ULBP4/RAETIE, RAETIG, RAETIL (Steinle et al., 2001, Cosman et al., 2001, Bacon et 
al., 2004).  
DNAM-1 is a transmembrane Ig-like molecule expressed in NK-cells, monocytes, T-cells 
and platelets. Two DNAM-1 ligands have been identified, CD155 and CD112. Other 
activating receptors include CD16 that binds the Fc portion of IgG, CRTAM that 
recognises Necl2 and CD96 (Tactilie) that recognises CD155. Further activating ligands 
can be found summarised in Figure 1.10.  
 
1.6.2. Modulation of NK cell function  
The HCMV gene UL40 was the first virus gene shown to definitively protect against NK 
cell attack through the up-regulation of cell surface HLA-E, a non-classical MHC-1 
molecule (Ulbrecht, 2000, Tomasec P, 2000, Wang, 2002). Since then more HCMV genes 
have been shown to modulate NK cell function. To date this includes six HCMV genes 
encoding proteins (UL16, UL18, UL40, UL83, UL141 and UL142) and one encoding a 
microRNA (miR-UL112) have been indentified in HCMV immunomodulation of NK 
cells, table 3 taken from Wilkinson (2008).  
 
Table 1.3. HCMV genes implicated in NK cell modulation. Taken from Wilkinson 
(2008).  
HCMV gene Comment  Acts on inhibitory receptor 
UL18 MHC-I homologue LIR1 (ILT2) 
UL40 Up-regulates HLA-E CD94/NKG2A 
   
HCMV gene Comment  Acts on activating receptor 
UL16 Sequesters MICB, ULBP1-2 NKG2D 
UL83 Direct binding NKp30 
miR-UL112 Suppresses MICB NKG2D 
UL141 Sequesters CD155, acts on  
CD112 
DNAM-1, CD96 
UL142 Acts on MICA NKG2D 
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1.6.2.1. Modulation of NKG2D ligands 
UL16, UL142 and miR-UL112 all act in concert to suppress cell surface presentation of 
NKG2D ligands (NKG2DL), which act as powerful activating-ligands for NK cells via 
signalling through the NKG2D receptors.  The prevention of the surface expression of 
NKG2DLs allows the modulation of NK cell effector function by reducing NK cell 
activation. As well as NK cells, NKG2D is also expressed on IFN-producing killer 
dendritic cells, αβ T-cells and γδ T-cells and is associated with the signal transducing 
adaptor protein DAP12 (Bauer et al., 1999, Wu et al., 1999, Li et al., 2001). In contrast to 
the other NKG2 proteins, the NKG2D receptor is present as a homodimer on the surface of 
cells and is able to recognise a wide range of target cell ligands (NKG2DL) on target cells, 
including MICA, MICB, ULBP1-4, RAET1E and RAET1G (Eagle and Trowsdale, 2007). 
Unlike MHC class I molecules, MICA and MICB are expressed in response to stress, do 
not associate with β2M and do not present peptide (Groh et al., 1996).  Such stress events 
include viral infection and HCMV IE1 and IE2 proteins have been reported to be potent 
activators of these ligands (Routes et al., 2005, Tomasec et al., 2007). 
The cellular UL16-binding protein (ULBP) family was identified and named on the basis 
of the ULBP1 and ULBP2 proteins to bind gpUL16. In total gpUL16 has been shown to 
directly bind and sequester MICB, ULBP1 and ULBP2 in the Endoplasmic Reticulum 
(ER), preventing cell surface expression and consequent NK cell activation (Cosman et al., 
2001, Kubin, 2001, Welte, 2003).   
Together with gpUL18, UL142 constitutes the HCMV UL18 gene family. Analysis 
predicted that UL142 encoded intact MHC class I related α1 and α2 domains and a 
truncated α3 domain. When expressed from a RAd vector, gpUL142 provided efficient 
protection against NK cytotoxicity in autologous NK cells, while siRNA knock-down of 
UL142 enhanced NK cell killing (Wills, 2005). gpUL142 has also been shown to down-
regulate the cell surface expression of MICA, through gpUL142 retention in the cis-Golgi 
(Ashiru et al., 2009). However, the truncated MICA*008 allele was not down-regulated by 
gpUL142 (Chalupny et al., 2006).  
Micro RNAs are associated with both gene silencing and stress responses. The ORF 
UL112 encodes for a microRNA miR-UL112 that mediates the  knockdown of MICB 
expression by the 3’ targeting of the MICB transcript (Stern-Ginossar, 2007). Deletion of 
the miR-UL112 function from strains AD169 or TB40/E enabled restoration of cell surface 
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MICB expression and was associated with enhanced sensitivity to NK cell recognition 
(Sten-Ginossar et al 2007). In addition, miR-UL112 has also been shown to down-regulate 
IE gene expression and has been hypothesised to be involved in the induction of latency 
(Murphy et al., 2008). 
 
1.6.2.2. Modulation of LIR-1 
UL18 was first identified as an MHC-I homologue during the original sequencing of the 
HCMV laboratory strain AD169 genome (Beck and Barrell, 1988). There are two forms 
expressed, one a 69kDa endoglycosidase H (EndoH)-sensitive species, and the other a 
fully processed 110-160kDa Endo-H resistant protein (Griffin et al., 2005, Kim et al., 
2004). Two conflicting reports reported that gpUL18 was both able to activate and inhibit 
NK cells. One report showed that gpUL18 expressed in a class I negative cell line was 
capable of eliciting protection against NK cell cytolysis (Reyburn et al., 1997). While a 
second independent study showed that gpUL18 expressing cells were more efficiently 
killed by NK cells (Leong et al., 1998).  This apparent conflict was later resolved in a 
complex analysis of NK clone activity against gpUL18 expressing targets (Prod'homme et 
al., 2007).  It was observed that expression of UL18 inhibited LIR
+
 NK cells, but 
stimulated LIR- NK cells (Prod'homme et al., 2007).  This study is consistent with a direct 
interaction of gpUL18 with LIR-1 resulting in a suppression of NK cell function. Whilst 
also implying that an additional interaction that is LIR1-independent occurs in which 
gpUL18 promotes NK cell recognition.  
 
1.6.2.3. Modulation of CD94/NKG2A 
The nine amino acid sequence (VMAPRTLIL) in the UL40 leader sequence was identified 
as an exact match to a HLA-E binding peptide (Tomasec P, 2000, Ulbrecht, 2000). HLA-E 
is a non-classical MHC class I molecule that binds a restricted set of peptides derived from 
the leader sequences of classical MHC-I molecules and HLA-G. Following peptide 
binding, HLA-E is transported to the cell surface where it is recognised by the NK cell 
inhibitory receptor complex CD94/NKG2A, suppressing NK cytotoxicity (Lee et al., 
1998). gpUS6 blocks transport of peptides to the ER by inhibiting TAP, thus inhibiting cell 
surface expression of MHC class I including that of HLA-E. To counter this effect, UL40 
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–derived peptide up-regulates the cell surface expression of HLA-E, independent of TAP  
(Tomasec et al., 2000). Deletion of UL40 renders infected cells more susceptible to NK 
cytotoxicity (Wang et al., 2002). 
 
1.6.2.4. Modulation of NK cytotoxicity receptor NKp30 
As described earlier, UL83 encodes an abundant HCMV tegument protein that acts 
immediately post infection to suppress the induction of the IFN response (Browne and 
Shenk, 2003). It has also been shown to directly bind the NK cell activating receptor 
NKp30, in order to suppress transmission of an activating signal through adapter molecule 
CD3ζ, preventing NK activation (Arnon et al., 2005). However, ppUL83 has not been 
shown to be secreted or expressed at the cell surface. It is hypothesised therefore, that  
ppUL83 suppression may require its release during lysis of infected cells by an, as yet, 
uncharacterised mechanism(Browne and Shenk, 2003).   
 
1.6.2.5. Modulation of DNAM-1 and CD96 
CD155 (Necl-5/PVR) is a nectin-like molecule involved in NK cell activation via 
engagement of DNAM-1 (CD226) and CD96 (TACTILE) NK activating receptors 
(Bottino, 2003, Tahara-Hanaoka et al., 2004). CD112 (nectin-2) is another ligand for 
DNAM-1 (CD226) but not CD96 (Fuchs et al., 2004). The HCMV gpUL141 suppresses 
cell surface expression of CD155 via retention in the Endoplasmic reticulum (ER) and 
expression of gpUL141 from a RAd resulted in an inhibition of NK cytotoxicity (Tomasec 
et al., 2005).  
While signalling through DNAM-1 directly promotes NK cytolysis, CD96 does not 
directly promote NK killing, rather it increases the stability of the cell-cell contact (Fuchs 
et al., 2004). The increased stability of the cell-cell interactions allows for more efficient 
killing. CD96 was first identified as a T-cell activation antigen and originally termed 
Tactile (T-cell activation, increased late expression (Wang et al., 1992). CD96 is an 
Immunoglobulin superfamily member with homology to both CD155 and 22% homology 
to DNAM-1 (Wang et al., 1992, Shibuya et al., 1996).  
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1.7. ADHESION MOLECULES: INVOLVEMENT IN THE IMMUNE 
SYSTEM.  
Adhesion molecules are a group of cell surface proteins involved in cell-to-cell binding or 
binding to the extracellular matrix (ECM). They play critical roles in many biological 
processes. In development they play key roles in cell migration, tissue morphogenesis and 
axon guidance. In the immune system they allow enhanced pairing between low avidity 
receptors and their ligands and some adhesion molecules have also been identified as 
activatory ligands in their own right. Other adhesion molecules can transmit signals that 
direct specific effector functions during the inflammatory response and some have been 
identified to play a major role in the processes of metastatic tumour dissemination. 
Adhesion molecules are broadly divided into 4 main groups: Integrins, lectins, cadherins 
and the Ig-superfamily (Ig-SF) cell adhesion molecules (CAMs). All adhesion molecules 
are integral membrane proteins containing cytoplasmic, transmembrane and extracellular 
domains. The cytoplasmic domain often interacts with cytoskeletal proteins and/or 
accessory proteins to carry out function. The extracellular domain extends from the cell 
and binds to other cells, or the ECM, by binding to other adhesion molecules of the same 
or different type, or an intermediary linker.  
 
1.7.1. Nectins and nectin like molecules: Members of the Ig-superfamily 
The human nectin family members are part of the Ca2
+
 independent Ig-SF family of cell 
adhesion molecules. The family can be subdivided into nectin and nectin-like (necl) 
molecules that have similar domain structures but differ in their ability to bind Afadin 
through a PDZ binding domain found in nectin, but not necl, molecules (Takai et al., 
2003).  
Both nectins and necls have been shown to play major roles in cell-cell adhesion, 
polarisation, movement and proliferation. Generally nectins are primarily involved in the 
regulation of various types of cell-cell contacts including adherens junctions (AJs) and the 
formation of tight junctions (TJs). While nectins localise to AJs, along with Cadherins, 
necls do not.  Instead Necls appear to have more diverse functions including mediating 
interactions between axons and glial cells, regulation of cell movement and proliferation 
(Ikeda et al., 2004, Kakunaga et al., 2005, Spiegel et al., 2007, Takai et al., 2008b).  
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The nectins consist of four molecules: nectin-1, -2, -3 and -4 and Necls five molecules: 
Necl-1, -2, -3, -4 and -5. Initially, nectin1 and nectin2 were identified as cell adhesion 
molecules, shortly after so were nectin3 and nectin4 (Takahashi et al., 1999, Reymond et 
al., 2001, Satoh-Horikawa et al., 2000, Lopez et al., 1998). All nectin family members 
have two or three splice variants, nectin 1α, -1β, -1γ, -2α, -2δ, -3α, -3β, and 3-γ. Most 
nectins, with the exception of nectin -1β, -3γ and 4, contain a conserved 4 aa motif at their 
C-terminus (E/A-X-Y-V, with X being any amino acid) that binds to the PDZ domain of 
afadin, Figure 1.11. Nectin-4 lacks this conserved motif but is still able to bind the PDZ 
domain of afadin at its C-terminus (Reymond et al., 2001). Afadin is an actin filament-
binding protein that has multiple domains allowing binding to many proteins and is an 
intermediary molecule associating nectin molecules with the actin cytoskeleton. There are 
two isoforms of afadin, I-Afadin is ubiquitously expressed, whereas s-afadin is mainly 
expressed in neural tissue, although it is expressed at low levels in various other tissue 
types (Mandai et al., 1997, Boettner et al., 2000).  
Nectins and Necls predominantly form stable interactions with other members of the 
nectin family. Characteristically, nectins and necls are expressed as cis-homodimers on the 
plasma membrane and these homodimers participate in homophilic or heterophilic trans 
interactions with their partners on an adjacent cell, Figure 1.12. (Tachibana et al 2000). 
Together with members of the cadherin family, nectins form cell-cell contacts connected to 
the cytoskeleton (Tachibana et al., 2000, Takahashi et al., 1999). In addition to afadin, the 
cytoplasmic regions of nectins can also associate with tctex-1 (Mandai et al., 1997, 
Mueller et al., 2002). Thus far heterophilic interactions between nectin-3/nectin-1, nectin-
3/nectin-2, nectin-1/nectin-4 and nectin-3/necl-5 have been identified, reviewed in (Takai 
et al., 2008a).  
Originally nectin-1, -2 and -3 were termed poliovirus receptor related protein -1 (PRR-1), 
PRR-2 and PRR-3 due to their homology to poliovirus receptor (PVR) otherwise known as 
necl-5 or CD155. The extracellular domains of the PRR family contain three-Ig-like 
domains that share 30 to 555 amino acid identities. However, none of them were reported 
to actually serve as poliovirus receptors. PRR-1 and PRR-2 were later shown to serve as 
receptors for the alphaherpesvirinae and were termed HveC and HveB respectively 
(Geraghty et al., 1998, Warner et al., 1998). PRR-1/HveC, PRR-2/HveB and PRR-3 were 
then later assigned as CD111, CD112 and CD113 respectively. From now on the CD 
nomenclature will be used to refer to individual members of the nectin family. 
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Figure 1.11. Nectin structure and proposed model for intercellular adhesion 
activity.  
A) Nectin molecules contain 3 IgG-like loops and a C-terminal PDZ binding domain  
(E/A-X-Y-V) that associates nectin molecules with the afadin, an actin filament binding 
protein that has multiple domains allowing binding to many proteins. Therefore linking 
Nectins with the actin cytoskeleton.  B) Characteristically nectins and necl’s are 
expressed as cis-homodimers at the cell surface and these homodimers participate in 
homophilic  or heterophilic interactions with their partners on an adjacent cell.  Figures 
taken from Takai and Nakanishi (2003)  
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Figure 1.12. Interactions between the Nectin family and IGSF.  
Nectins (Blue), Necl’s (Red) and other immunoglobulin super family members (Purple) 
interact with each other by forming heterophilic tans-dimers (straight lines) or homophilic cis -
or trans-dimers (curved arrows). Adapted from Takai et al (2008).  
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1.7.2. Nectins involved in cell-cell contact 
CD111, CD112 and CD113 are expressed on a variety of cells including fibroblasts, 
epithelial cells and neurons. CD112 and CD113 are also expressed in cells that lack 
cadherins, such as B-cells, monocytes and spermatids, while human nectin4 is expressed 
mainly in the placenta (Lopez et al., 1998, Bouchard et al., 2000, Reymond et al., 2001, 
Ozaki-Kuroda et al., 2002).  
In polarised epithelial cells, cell-cell adhesion is mediated through a junctional complex 
comprised of tight junctions (TJs), cell-cell adherens junctions (AJs) and desmosomes 
(DSs) (Farquhar and Palade, 1963). AJs are the sites of cell recognition and adhesion and 
are required for the later formation and maintenance of TJs and DSs (Tsukita and Furuse, 
1999). Nectin-nectin trans-interactions initiate the formation of AJs and recruit cadherins 
to the site of cell-cell contact and cooperatively form AJs in epithelial cells, fibroblasts and 
synapses in neurons (Takai and Nakanishi, 2003, Takai et al., 2003, Takahashi et al., 
1999).  Once Cadherins are incorporated into the AJ, the cytoplasmic tail of cadherin binds 
the F-actin binding proteins α-catenin, α-actinin and vincilin which anchor cadherins to the 
actin cytoskeleton (Tachibana et al., 2000).  
Nectins are also involved in the formation of TJs in epithelial cells by first recruiting 
junctional adhesion molecules and then claudins to the apical side of AJs in cooperation 
with cadherins. Junctional adhesion molecules recruit the cell polarity complex, consisting 
of Par3, atypical PKC and Par6 by direct binding to Par3 (Ohno, 2001). CD111 and 
CD113, but not CD112, also play a role in cell polarisation by directly binding Par-3 
(Takekuni et al., 2003).  
Following trans-interactions a series of signalling reactions occur that results in the 
reorganisation of the structural components of the cell including the actin cytoskeleton, 
filopodia formation and lamellipodia formation, Figure 1.13. Fukuyama et al (2005) 
described how following nectin-nectin interaction the tyrosine kinase Src is recruited and 
activated at cell-cell contact sites. C-Src then activates the small G protein Rap1 through 
the adapter proteins Crk and C3G, a Rap1-GDP/GTP exchange factor, Figure 1.13. 
Activated Rap1 activates phosphorylated FRG, which activates Cdc42. C-Src also 
activates Cdc42 through FRG, a cdc42-GDP/GTP exchange factor. Activated Cdc42 can 
then mediate the formation of filopodia.  
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Figure 1.13 Nectin Intracellular signalling pathway. 
A schematic model for the intracellular signalling pathway from trans interacting 
Nectin molecules to the activation of Cdc42 or Rac resulting in the reorganisation of 
the actin cytoskeleton. Taken form Fukuyama et al (2005).  
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Additionally c-Src phosphorylates Vav2, a GDP/GTP exchange factor for Rac. FRG 
activated Cdc42 then activates phosphorylated Vav2, which induces the activation of Rac 
(Fukuhara et al., 2004). The activation of Rac then induces the formation of lamellipodia 
(Nobes and Hall, 1995, Takahashi et al., 2008). While filopodia and lamellipodia 
protrusions are generally associated with cell movement they are also hypothesised to 
increase the number of cell-cell contacts and reduces the distance between cells enhancing 
cell-cell adhesion (Vasioukhin et al., 2000).  
It remains unclear how c-Src and FRG are recruited and activated at the nectin-based cell-
cell adhesion sites, but afadin is not likely to  be necessary for this recruitment or 
activation because it has previously been shown that afadin is not necessary for the nectin 
induced, Cdc42 and Rac-mediated formation of filopodia and lamellipodia, respectively, in 
CD111-L cells (Kawakatsu et al., 2002). As all the work in cell signalling following trans 
interactions involved the use of CD111-L transfected cell lines this signalling cascade may 
only be relevant to CD111 and not the nectin family as a whole. 
 
1.7.3. CD112 and CD155 
Both CD112 and CD155 molecules are transmembrane glycoproteins that contain 3 Ig 
domains of V, C2 and C2 types in their extracellular regions and share 51% identity. Both 
have been described as an activatory receptor for DNAM-1 and a low avidity receptor for 
inhibitory receptor TIGIT (Bottino, 2003, Tahara-Hanaoka et al., 2004, Stanietsky et al., 
2009). Both have shown to interact with CD113 and both are widely expressed in human 
tissue, including haematopoietic cells (Takai et al., 2008a).  
 
1.7.3.1. CD112 
CD112 was originally isolated as the murine homolog of human PVR but turned out to be 
another poliovirus-receptor-related protein and was named PRR2 (Morrison and 
RAcaniello 1992). The CD112 gene was mapped to 19q13.2-q13.4 by isotopic 
hybridisation, the same chromosomal region as CD155 (Eberle et al., 1995). Freitas et al 
(1998) further mapped the PRR2 gene to chromosome 19q13.2 by genome sequence 
analysis where it lies centromeric to the TOMM40 gene and the APOE-APC2 gene cluster.  
Diseases of q13.2 have mainly been associated to APOE but variations in CD112 have 
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been linked to T-cell non Hodgkin lymphomas and Nonsyndromic cleft lip, with or 
without cleft lip (nsCL/P) (Almire et al., 2007, Chengle et al., 2010, Jagomagi et al., 
2010). In murine knockdown studies CD112 (-/-) males are infertile, while heterozygous 
males (+/-) and CD112 (-/-) females are fertile. The production of normal numbers of 
spermatozoa containing normal levels of DNA suggest CD112 is expressed in the testes 
only during the later stages of spermatogenesis (Bouchard et al., 2000). While the 
structural defects in spermatozoa on CD112 (-/-) mice suggest a role for CD112 for 
organising and reorganisation of the cytoskeleton during spermatogenesis at sertoli-cell 
junctions.  
CD112 is a component of cell-cell AJs and interacts with I-afadin, an F-actin binding 
protein. The normal function of members of the nectin family is to mediate cell-cell 
adhesion through homotypic and heterotypic nectin-nectin interactions in cadherin based 
AJs. CD112-α and –δ can cis-homodimerise (α/α and δ/δ dimers) or cis-heterodimerise 
(α/δ dimers) (Lopez et al., 1998).  An antibody against CD112 (R2.477) showed that 
CD112 was expressed in 96% of CD34
+
, 88% of CD33
+
 and 95% of CD14
+
 
haematopoietic lineages (Lopez et al., 1998). CD112 was also expressed at the intercellular 
junctions of adjacent cells but not at the free cellular edges (Lopez et al., 1998).  
Struyf et al (2002) examined mutations in three equivalent regions of the N-terminal V-
like domains of CD112 to test the effects on entry of various alphaherpesviruses, nectin-
nectin interactions and with gD. Mutations in region I impaired HSV-1 entry but not PRV 
and did not effect nectin expression. Mutations in region II enhanced intracellular 
accumulation of CD111 and CD112 and had a deleterious effect on all of the activities 
under the study. Mutations in region III impaired entry of PRV and reduced HSV entry 
activity.  
 
1.7.3.2. CD155 
The first member of the nectin and necl family to be characterised, CD155 was initially 
identified as the cellular receptor for poliovirus (PVR). Located at 19q13.2, the CD155 
gene produces four variants CD155:α, β, γ and δ through alternative splicing. CD155-α 
and -δ are transmembrane proteins while CD155-β and -γ are secreted (Baury et al., 2003). 
Little is known about the function of alternative spliced variants. However soluble CD155 
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is present in human serum at nanomolar concentrations and can compete with membrane 
bound CD155 to inhibit poliovirus entry (Baury et al., 2003).   
CD155 was identified as a cognate receptor for poliovirus. Based on sequence homology 
to CD155, three poliovirus receptor related genes (CD111, CD112 and CD113) were 
indentified. However, neither CD111 nor CD112 bind poliovirus and it is assumed that 
their physiological functions differ from CD155. CD155 undergoes cell-matrix 
interactions by binding to the extracellular matrix protein vitronectin, binding with a 
dissociation constant (K(d)) of 72nM (Lange et al., 2001). Both CD155 and vitronectin co-
localise to follicular dendritic cells and B-cells inside the germinal centres of secondary 
lymphoid tissues (tonsils) suggesting that the CD155/vitronectin interaction could be 
required for the establishment of a proper immune response at these sites (Lange et al., 
2001).  
In ligand binding assays, CD155 was shown to bind CD113 and the putative murine 
homologue of CD155, Tage4 (Mueller and Wimmer, 2003). Co-culture of CD113 and 
CD155 expressing Hela cells led to CD155-dependant recruitment of CD113 to cell-cell 
contacts. CD155 was also found to co-distribute with αV integrin microdomains on the 
surface of mouse transfected fibroblasts and at amniotic epithelial cell junctions (Mueller 
and Wimmer, 2003). These experiments show the possible trans interaction between cell-
cell adherens type system (adherin/nectin) and the cell-matrix adhesion system. 
The adhesion receptor CD96 (TACTILE) is a transmembrane glycoprotein and possesses 3 
extracellular IG-like domains. Among peripheral blood cells, CD96 is expressed on T-cells 
as well as NK cells and a subpopulation of B-cells. CD96 has been reported to function as 
an adhesion receptor promoting NK-target cell interaction, promoting NK mediated 
cytolysis (Fuchs et al., 2004). CD96 has been described as a marker in acute myeloid 
leukaemia (AML) and acute lymphocytic leukaemia (ALL) (Hosen et al., 2007). CD96 
binds to CD155 and CD111. In humans CD96 has 2 variants as a result of alternative 
splicing (Meyer et al., 2009). Variant 2 was shown to be predominant in AML tumour 
samples. Other evidence suggests that mutations in human CD96 correlate with the 
occurrence of a rare form of C syndrome (Opitz trigonocephaly) (Kaname et al., 2007). 
One such mutation causing a single amino acid change in the third domain of human 
CD96, which resulted in a decreased capacity of both variants to bind to CD155 suggesting 
that CD96 driven adhesion to CD155 may be crucial in development.   
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1.7.4. CD112 and CD155 in oncogenesis 
While not attributed to be stress molecules CD112 and CD155 appear to be up-regulated 
on the cell surface of certain transformed cell lines. Both CD112 and CD155 have been 
shown to have involvement in NK mediated cell lysis of tumours, particularly melanoma 
(Pende et al., 2005a). Many cancerous cell lines and primary tumours constitutively over 
express CD155, which can efficiently prime cell-mediated tumour specific immunity  
(Tahara-Hanaoka et al., 2006). NK cells have been shown to kill ovarian carcinoma cells, 
neuroblastoma cells, myeloid leukaemia’s and lymphoblastic leukaemia’s mediated by a 
CD155-DNAM-1 interaction (Pende et al., 2005b, Carlsten et al., 2007, Castriconi et al., 
2004, Pende et al., 2005a). The DNAM-1 ligand interaction is likely part of tumour 
immunosurveillance by circulating NK cells. In addition to NK cells, DNAM-1 is also 
expressed on a subset of T-cells and has been identified as being involved in the 
differentiation of Th1 T-cells, regulating their expansion and effector functions (Dardalhon 
et al., 2005), and may protect against Fas ligand induced apoptosis as DNAM-1 deficiency 
results in high sensitivity to apoptosis in NK T-cells in patients with systemic lupus (Tao 
et al., 2005). CD112 is expressed on CD34
+
 Leukemic lymphocytes in both Acute myeloid 
Leukaemia (AML) and acute lymphocytic Leukaemia but not on ‘normal lymphocytes’, as 
determined by expression of CD48.  Pende et al (2005b) showed that it was the DNAM-1 
interaction and not the NKG2D interaction that was responsible for NK cell mediated lysis 
of these leukaemia’s (Pende et al., 2005b). 
CD155 expression is restricted to primates and features during the development of 
ventrally-derived structures within the central nervous system. Significantly it is re-
expressed/overexpressed on neoplastic glia. CD155 has been proposed as playing a key 
role in glioma motility and invasion whereby glioma invasion was demonstrated in to be a 
function of CD155-mediated regulation of adhesion signalling and focal adhesion 
dynamics (Sloan et al., 2004). RNAi knockdown of CD155 in cultured glioma cells altered 
cell morphology to a larger, fusiform phenotype which resulted in reduced migration. 
Targeting CD155 has already been used in therapeutic targeting of glioma for regional 
delivery of recombinant poliovirus to achieve an oncolytic effect (Merrill et al., 2004, 
Sloan et al., 2005). 
The CD155-DNAM-1 interaction has been described as being capable of enhancing 
metastasis. The interaction between CD155 on cancerous cells and DNAM-1 on platelets 
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resulted in the arrest of cancerous cells in pulmonary vessels and subsequent entry into 
tissue (Morimoto et al., 2007).  Depletion of platelets in BALB/c mice resulted in a 
reduction of lung metastasis, suggesting that platelets mediate CD115-dependant tumour 
cell attachment to pulmonary vessels.  
 
1.7.5. NK-cell and T-cell activation and inhibition 
Cytotoxic lymphocytes, such as NK cells and CD8
+
 T-cells, require adhesion molecules to 
migrate to sites of infection/tumour microenvironment and establish tight contact with 
virally infected or tumour cells. In addition, in secondary lymphoid organs, adhesion 
molecules facilitate CD8
+
 T-cell and NK cell interactions with APCs, which induce their 
activation, expansion and differentiation. Adhesion molecules can either act directly as 
signalling molecules, initiating intracellular pathways, or as accessory molecules, 
sustaining cell contact that are necessary for T-cell receptors and NK cell receptors to 
engage their cognate ligands.   
Both CD112 and CD155 have been identified as ligands for the activating receptor 
DNAM-1 and inhibitory receptor TIGIT (Bottino, 2003, Tahara-Hanaoka et al., 2004). 
Both DNAM-1 and TIGIT are expressed on NK cells and a subset of T-cells. In a review 
by Shibuya et al (2005) a hypothesis is put forward whereby a threshold is required to be 
exceeded in order for an activatory signal to override an inhibitory one. Constitutive 
CD155 expression results in an inhibitory signal overriding the activatory one. During 
infection/malignancy whereby CD155 cell surface expression is increased, a threshold is 
crossed and the activatory signal becomes dominant. During HCMV infection CD155 is 
down-regulated below normal cell surface expression levels and as a result is well below 
the threshold requirement for an activatory signal to become dominant. 
 
1.7.5.1. Activatory receptor DNAM-1   
DNAM-1 is a transmembrane immunoglobulin-like molecule that was initially identified 
as a T-cell specific activation marker (originally named TLiSA-1) (Burns et al., 1985).  In 
humans, DNAM-1 is mapped to chromosome 18q22.3 and appears to be expressed on NK 
cells, monocytes, CD4
+
 and CD8
+ 
T-cells, platelets and a subset of B-cells (Reymond et 
al., 2004, Shibuya et al., 1996, Scott et al., 1989, Shibuya et al., 1999, Shibuya et al., 
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2003). Binding of DNAM-1 to its ligands triggers NK cell cytotoxicity and mediates 
adhesion of monocytes to endothelial cells facilitating transendothelial cell migration.  
DNAM-1 signalling is dependent on physical association of DNAM-1 with co-receptor 
LFA-1 integrin (αLβ2) in lipid rafts and modulates its activation and capacity to bind 
intracellular adhesion molecules 1 (ICAM-1, CD54). LFA-1 is part of a family of 
leukocyte integrins that are recognised by their common β-chains (CD18) and is expressed 
on all T-cells, B-cells, macrophages and neutrophils. LFA-1 also has a distinct α chain 
(CD11a) (Kurzinger et al., 1981, Keizer et al., 1985). Mechanistically, engagement of 
DNAM-1 by its ligands results in phosphorylation of the cytoplasmic domain by protein 
kinase C. In turn this activates the tyrosine kinase Fyn recruiting actin-binding proteins 
4.1G and human discs large (Ralston et al., 2004). This results in rearrangement of the 
actin cytoskeleton, promoting clustering of LFA-1 and formation of an adhesive complex 
that polarises lymphocytes towards other cells, recruiting them to sites of infection 
(Shibuya et al., 1999, Shibuya et al., 1996, Shibuya et al., 2003, Ralston et al., 2004).  
The DNAM-1 ligands were independently indentified by two groups using two different 
strategies. Bottino et al (2003) generated a mAb that blocked NK cell-mediated 
cytotoxicity against certain tumours and purified the unknown protein expressed on the 
tumour target recognised by the mAb, identifying CD155 as the protein to which the mAb 
bound  (Bottino et al., 2003). Concomitantly Tahara-Hanaoka et al (2004) generated a 
fusion protein of the extracellular portion of DNAM-1 with the human IgG Fc portion 
(DNAM-1-Fc) and used this as a probe against a retroviral cDNA library prepared from a 
human osteosarcoma cell line (Tahara-Hanaoka et al., 2004). Both groups identified the 
human poliovirus receptor (PVR) α (CD155) and its isoform PVRδ as ligands for DNAM-
1. CD155 is a member of the poliovirus receptor-related (PRR) family and CD112 was the 
only other member of this family to be identified as a ligand for DNAM-1.  Interestingly, 
activated T-cells and NK cells express CD96 (Tactile), which only shows ~20%homology 
with DNAM-1, but has also been shown to recognise CD155 as its ligand and promote NK 
cell adhesion and activation.  
Despite the binding affinities between CD155-Fc or CD112-FC and DNAM-1-Fc being 
comparable (Kd = 2.3 x 10
-7
 M and 3.1 x 10
-7
 M, respectively), a BW5147 transfectant cell 
line expressing CD112 bound to soluble DNAM-1-Fc to a lesser extent than to a 
transfectant cell line expressing CD155 (Bottino, 2003). This was hypothesised to have 
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been caused by the homophilic interaction of CD112, but not CD155. The authors were 
also able to improve DNAM-1-Fc binding to the CD112 transfectant cell line with the pre-
treatment of the cell line with a mAb that blocked the homophilic (cis) interaction of 
CD112, suggesting that DNAM-1 binding to CD112 on the cell surface may be impaired 
by homophilic interaction of CD112.  
 
1.7.5.2. Inhibitory receptor TIGIT  
TIGIT was identified by searching for genes that are expressed by immune cells and that 
might function as immunomodulatory receptors owing to a protein structure comprising an 
immunoglobulin domain, a transmembrane domain and an ITIM (Yu et al., 2008). 
Consistent with the search criteria, TIGIT was found to be expressed on the surface of 
CD4
+
CD25
+
 regulatory T-cells, memory T-cells and NK cells. Knockdown of TIGIT 
expression in primary human T-cells by RNAi had no effect on T-cell proliferation or 
cytokine production in-vitro, and exposure of T-cells  to a TIGIT-specific antibody did not 
influence their activation (Yu et al., 2008). However, when T-cells were cultured with 
autologous DCs, the presence of a TIGIT-specific antibody led to a four-fold increase in 
interferon-γ production. Conversely the use of a TIGIT-Fc fusion protein to ligate PVR 
inhibited IFNγ production by T-cells in T-cell-DC co-cultures. Suggesting TIGIT might 
regulate T-cell responses by interacting with PVR expressed by DC’s.  
Exposure of monocyte-derived DCs (MDDCs) to TIGIT-Fc (or CD226-Fc) resulted in 
increased production of the immunosuppressive cytokine IL-10 and decreased production 
of IL12 following stimulation. Further analysis revealed that TIGIT-Fc engagement of 
CD155 on DCs induced the phosphorylation of CD155 and the downstream activation of 
extracellular-signal-related kinase (ERK), which is probably involved in the observed 
effects of CD155 ligation on DC cytokine production (Yu et al., 2008). 
Yu et al (2008) then showed that TIGIT-FC treated MDDCs, but not control MDDCs, 
inhibited T-cell proliferation in a mixed lymphocyte response assay and that this 
suppression was associated with high levels of IL-10. Importantly, the suppressive effects 
of TIGIT-Fc were confirmed in an in-vivo delayed type hypersensitivity (DTH) assay; 
treatment of wild type, but not IL10-/- mice with TIGIT-Fc reduced DTH responsiveness. 
Finally DC’s isolated from TIGIT-Fc treated mice contained more IL10 mRNA and less 
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IL12 mRNA that DCs from control mice is consistent with the idea that TIGIT-mediated 
modulation of DCs is responsible for the immunosuppressive effects of TIGIT in-vivo. 
Both CD155 and CD112 were shown to be ligands for TIGIT, although TIGIT was shown 
to bind with lower avidity to CD112 (Stanietsky et al., 2009). However it was 
hypothesised that this might be due to the ability of CD112 to form homophilic 
interactions that might have inhibited the CD112/TIGIT interaction in a similar way that 
was observed by Bottino et al (2003) with the CD112/DNAM-1 interaction.  
 
1.7.6. CD112 in other aspects of the immune response 
In addition to those functions discussed thus far. CD112 has also showed functions in 
other aspects of the immune system 
Monocytes differentiate into immature DC’s (iDCs), which in turn differentiate into 
mature DC’s (mDCs) upon appropriate stimulation. CD112 expression appears to increase 
with each stage of the differentiation process, unlike CD155 which is only up-regulated 
during the differentiation of iDC’s to mDC’s (Pende et al., 2006). Mature DC’s are 
protected from NK-mediated lysis by high surface expression of HLA class 1 molecules on 
their cell surface which inhibit NK cell cytolysis. Immature DC’s are efficiently killed by 
NK cells, with one of the strongest signals transmitting through CD226 (DNAM-1). 
Signalling through CD226 seemed to be strongest through CD112 expression (Pende et al., 
2006). Therefore CD112 expression during DC maturation may play a role in NK 
mediated ‘quality control’ by selecting for those DC’s that show high expression of HLA 
class I molecules and costimulatory ligands, optimising for an ability to prime T-cells.  
 Mast cells have effector functions in various immune settings. In allergic inflammation, 
mast cells interact with tissue-infiltrating eosinophils, forming a regulatory unit in the late 
and chronic phase of the allergic process. Mast cells express CD226, while eosinophils 
express CD112 (Bachelet et al., 2006). Engagement of CD226 by CD112 expressing 
eosinophils results in mast cell degranulation. When CD112 cell surface expression on 
eosinophils was blocked with neutralising antibodies, the hyperactivity resulting from IgE-
dependant activation of mast cells was normalised during in-vitro co-culture of these two 
cell types (Bachelet et al., 2006).  
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1.8. CONCLUSION AND AIMS 
CD112 is involved in a variety of functions including cell adhesion, contact inhibition and 
NK-cell activation. Specifically, CD112 signals via CD226 (DNAM-1) activating 
receptors to modulate NK-cell cytotoxicity. Since CD226-activating ligand, CD155, is 
down-regulated from cell surface during HCMV infection (Tomasec, 2005) it was 
important to address whether CD112 was also down-regulated from the cell surface during 
productive HCMV infection. 
Preliminary screening of cell surface proteome of HCMV-infected cells performed in this 
laboratory identified that CD112 was down-regulated in HCMV-infected cells (P. 
Tomasec, unpublished observations). The deletion of UL141 from HCMV genome was 
able to restore CD112 cell surface expression in HCMV-infected cells (Prod'homme et al., 
2010). Expression of UL141 on its own had no effect on CD112 cell surface expression 
(Tomasec, 2005). Since UL141 appeared necessary but not sufficient to modulate CD112 
expression, this thesis investigated a hypothesis whereby UL141 was acting in a 
conjunction with another HCMV protein.  
The aims of this project were 
1)  Perform detailed examination the effect of CMV infection on CD112 expression and 
analyse the effect of UL141 on CD112 in the context of CMV infection.  
2) Utilise a RAd-library expressing individual HMCV ORFs to identify additional HCMV 
gene(s) involved in the down-regulation of CD112.  
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2.0. METHODS AND MATERIALS 
2.1. SOLUTIONS 
W/V = WEIGHT/VOLUME SOLUTION, V/V = VOLUME/VOLUME SOLUTION 
Ampicillin Stock: 50 mg/mL Ampicillin (Sigma-Aldrich) was dissolved in deionised 
water (diH2O) and stored at -20°C.  
Ampicillin selection plates: Once LB agar autoclaved and cooled to ‘hand hot’, Ampicillin 
(1:1000 of 50 mg/mL stock), Chloramphenicol (1:1000 of 
12.5mg/mL stock), X-gal (1:500 of 40mg/mL stock) and IPTG 
(1:500 of 100mM stock) were added before allowing to set in plates. 
Caesium chloride (heavy):  
5.45g/mL Caesium Chloride (Sigma-Aldrich) in 5mM Tris-HCL 
Caesium Chloride (light):  
1.33g/mL in 1mM EDTA, 5mM Tris, pH adjusted to pH7.8. 
Chloramphenicol stock: 12.5mg/mL Choloramphenicol (Sigma-Aldrich) was dissolved in 
ethanol (Fisher Scientific) and stored at -20°C 
DMEM-10: Dulbeco’s Modified Eagle Medium with 10% Foetal calf serum 
(FCS)  (Gibco), 10mL of  Penicillin(5,000 IU/mL penicillin) and 
Streptomycin (5000µg/mL) (Gibco).  
DOG plates: 20% (v/v) 5xM63, 1mM magnesium sulphate heptahydrate (Sigma 
Aldrich) and 1.5% (w/v) agar (Fisher Scientific) added before 
autoclaving. Once autoclaved and cooled to ‘hand hot’ 
Chloramphenicol (1:1000 of 12.5mg/mL stock), 0.2% 2-deoxy-
galactose (Sigma Alrdich), 1mg/mL Biotin (Fisher Scientific), 
45mg/mL Leucine (Sigma Aldrich)  were added before allowing to 
set in plates 
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DNA loading buffer: 30% glycerol (Fisher Scientific) in diH2O with 0.25% (w/v) 
bromophenol blue (Sigma-Aldrich) in 0.25% (w/v) xylene cyanol 
FF (Sigma-Aldrich). 
Freezing mixture: 90% Foetal calf serum (FCS) (Gibco) and 10% (v/v) dimethyl 
sulphoxide (DMSO) (Sigma-Aldrich).  
Glycerol 10%: 10% Glycerol (Fisher Scientific) in diH2O. Autoclaved.   
IF buffer: 1% BSA (Fisher Scientific), 0.2% Saponin (Sigma) and 0.05% 
Sodium Azide (Sigma). 
IPTG stock: 100mM stock solution generated by dissolving 23.8mg Isopropyl β-
D-1-thiogalactopyranoside (IPTG) (Melford) in 1mL diH2O. 
Kanamycin stock: 50mg/mL Kanamycin (Roche) dissolved in diH2O and stored at -
20°C.  
Kanamycin selection plates (positive selection): 
 Once LB agar autoclaved and cooled to ‘hand hot’, Kanamycin 
(1:1000 of 25mg/L stock), Chloramphenicol (1:1000 of 12.5mg/mL 
stock), X-gal (1:500 of 40mg/mL stock) and IPTG (1:500 of 
100mM stock) were added before allowing to set in plates. 
LB broth: 1% (w/v) tryptone (Sigma Aldrich), 1% (w/v) sodium chloride 
(NaCl) (Sigma Aldrich), 0.5% yeast extract (Sigma Aldrich) 
dissolved in diH2O then autoclaved.   
Luria Bertani (LB) agar: as for LB broth but with 1.5% (w/v) agar (Fisher Scientific) 
added before autoclaving. Antibiotics were added before setting in 
plates.  
LB sucrose selection plates:  
1% (w/v) tryptone, 0.5% (w/v) yeast extract (Melford), 5% (w/v) 
sucrose (Fisher Scientific) and 1.5% (w/v) agar (Fisher Scientific) 
added before autoclaving. Once autoclaved and cooled to ‘hand hot’ 
Chloramphenicol (1:1000 of 12.5mg/mL stock), X-gal (1:500 of 
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40mg/mL stock) and IPTG (1:500 of 100mM stock) were added 
before allowing to set in plates. 
MOPS buffer: 5% 20x MOPS buffer dissolved in diH2O 
MM9 salts: 6 g/L sodium phosphate bibasic (Sigma Aldrich), 3 g/L 
monopotassium sulphate (Sigma Aldrich), 1 g/L Ammonium 
Chloride (Sigma Aldrich), 0.5 g/L Sodium Chloride (Sigma 
Aldrich) dissolved in diH2O then autoclaved.   
5 x M63: 10 g/L ammonium sulphate (Sigma Aldrich), 68 g/L 
monopotassium phosphate, 2.5mg/L Ferrous sulphate heptgydrate 
(Sigma Aldrich) dissolved in diH2O thenpH adjusted to pH7.8. 
M63 minimal media plates: 
20% (v/v) 5xM63, 1mM magnesium sulphate heptahydrate (Sigma 
Aldrich) and 1.5% (w/v) agar (Fisher Scientific) added before 
autoclaving. Once autoclaved and cooled to ‘hand hot’ 
Chloramphenicol (1:1000 of 12.5mg/mL stock), 0.2% Galactose 
(Sigma ALrdich), 1mg/mL Biotin (Fisher Scientific), 45mg/mL 
Leucine (Sigma Aldrich)  were added before allowing to set in 
plates. 
Paraformaldehyde (4%):   
4% (w/v) Paraformaldehyde dissolved in diH2O, pre-warmed to 
~70°C. Once dissolved solution was cooled and filtered through a 
0.22µm filter t to remove any particulate and stored at 4 °C 
PBS:   For cell culture PBS was purchased directly from Sigma Aldrich. 
For all other work PBS was constituted. One phosphate buffered 
saline (PBS) tablet (Sigma Aldrich) was dissolved per 100mL 
diH2O to generate PBS containing 0.8% (w/v) Sodium Chloride 
(NaCl), 0.2% (w/v) potassium chloride (KCl), 1.15% (w/v) 
disodium hydrogen phosphate and o.2% (w/v) potassium 
dihydrogen phosphate at pH7.3.  
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PBST:   PBS with 0.1% (v/v) Tween-20 (Fisher Scientific). 
Semi-dry transfer buffer:  
10% (v/v) NuPAGE® Transfer buffer (Invitrogen ), 10% (v/v) 
Methanol Fisher Scientific) dissolved in diH2O. 
Streptomycin selection plates (negative selection): 
 Once LB agar autoclaved and cooled to ‘hand hot’ Streptomycin 
(1:1000 of 200mg/mL stock), Chloramphenicol (1:1000 of 
12.5mg/mL stock), X-gal (1:500 of 40mg/mL stock) and IPTG 
(1:500 of 100mM stock) were added before allowing to set in plates. 
Streptomycin stock: 200mg/mL Streptomycin (Roche) dissolved in diH2O and stored at -
20°C.  
TAE (50x):  242g Tris base, 57.1ml glacial acetic acid (Fisher scientific) and 
100ml 0.5M ethylenediaminetetraacetic acid (EDTA), pH8.0 were 
mixed with water in a final volume of 1 L. 
0.7%  TAE Agarose gel:0.7g agarose (Invitrogen) was dissolved in 100mL TAE buffer by 
heating. Ethidium bromide (Sigma) was added and then poured into 
a mould and left to set at room temperature.  
TPBST: PBS with 0.1% (v/v) Tween-20 (Fisher Scientific) and 0.1% (v.v) 
Triton X-100 (Fisher Scientific)  
Tris buffer: 10 mL of 1M Tris-Cl pH7.4 was mixed with 2 mL 0.5M EDTA, pH 
8.0 and water added to a final volume of 1L.  
1M Tris-Cl 121.1g Tris-Cl (Fisher Scientific) was dissolved in 1L diH2O and 
pH adjusted to pH 7.4.     
X-gal stock: 5-bromo-4-chloro-3-indoyl-β-D-galactopyranoside (X-gal) 
(Melford) was dissolved in DMSO (Sigma) to generate a 40mg/mL 
stock solution. Aliquots were stored at -20°C.   
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2.2. CELL CULTURE:  
2.2.1. Established cell lines 
All cell lines used are summarised in Table 2.1. Human foetal foreskin fibroblasts (HFFF) 
were kindly supplied by Dr G. Farrar, Porton Down. HFFFs were immortalised with 
human telomerase reverse transcriptase (HFFF-hTert) and transfected with the Coxsakie 
Adenovirus Receptor (HFFF-hCAR) by S Llewellyn-Lacey as described in McSharry et al 
(2001). The 293 T-REx
TM
 cell line was obtained from Invitrogen and the human 
embryonic retinoblast cells, 911 were obtained from Crucell, Leiden. The human epithelial 
colorectal adenocarcinoma cell line Caco-2 and the human breast cancer cell line, MCF-7, 
were obtained from American Type Ceulture Collection (ATCC).  
The human cervical epithelial adenocarcinoma cell line, Hela was obtained from ATCC. 
The transfectant cell lines Hela-US2 and Hela-US11 were kindly provided by Dr 
Emmaneual Weirtz,. The transfectant cell lines 293-GFP and 293-UL141-GFP cell lines 
were kindly provided by Dr P Tomasec, Cardiff, as described in Tomasec et al (2005). 
 
2.2.2. Tissue culture media 
All cell lines were grown in DMEM supplemented with 10% Foetal calf serum (FCS) 
(Gibco) and 20mL/L Penicillin-Streptomycin (Invitrogen), referred to here on in as 
DMEM-10. Most cell lines were maintained in standard 175cm
2
 tissue culture flasks. 293 
T-REx
TM
 and 911 cells were maintained in 175cm
2 
tissue culture flasks coated with 
Cellbind which aids cell adherence to the flask. All cells were incubated in a static 
incubator (Heraeus) at 37°C and 5% CO2. Media was warmed to 37°C before use. 
 
2.2.3. Passage of cell lines 
Confluent layers of adherent cells were passaged by first removing medium, washing the 
cell layer in PBS and incubating in the presence of 1 – 5 mL Trypsin/EDTA (Invitrogen) 
until the cells detached and fell into suspension. Once detached, cells were resuspended in 
10 mL of fresh DMEM-10 and the cells were split between 1:2 and 1:5, into 175cm
2
 tissue 
culture flasks containing fresh DMEM-10. 
74 
 
Table 2.1. List of cell lines. 
  
 
 
 
  
Cell line / 
Abbreviation 
Comment Publication/Reference 
293 T- RExTM  A cell line containing a tetracycline regulated 
expression system.  
Invitrogen  
293-GFP Human Embryonic Kidney (HEK) cell line containing 
GFP.  
Tomasec et al 2005 
293-UL141GFP 293 cell line expressing UL141 C-terminally tagged 
with GFP 
Tomasec et al 2005 
293-UL14GFP 293 cell line expressing UL14 C-terminally tagged 
with GFP  
Tomasec et al 2005 
911 Human embryonic retinoblast cells.transfected 
with Ad E1 and E3 regions.  
Crucell 
Caco-2 Human epithelial colorectal adenocarcinoma cell 
line 
ATCC 
HFFF Human Foetal Foreskin Fibroblasts  Obtained from Dr 
Graham Farrar (CAMR, 
Sailsbury UK) 
HFFF-hCAR HFFF immortalised by the in-house insertion of 
hTERT and expressing coxsakie/adenovirus 
receptor (CAR).  
McSharry et al 2001 
HFFF-hTert HFFF immortalised but the in-house insertion of 
hTERT. 
McSharry et al 2001 
Hela Human cervical epithelial adenocarcinoma cell line ATCC 
Hela-US2 Hela cell line expressing HCMV ORF US2  
Hela-US11 Hela cell line expressing HCMV ORF US11  
MCF-7 Human breast adenocarcinoma cell line ATCC 
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2.2.4. Cell counting 
A 10 µL aliquot of cell suspension was diluted 1:1 with Trypan Blue and counted on a 
bright line haemocytometer (Sigma) under white light. Viable cells were identified by the 
exclusion of the blue dye. The total number of cells present was determined using the 
following formula: 
Total No cells/mL = (No cells in grid) x 1 x 10
4
) x 2 
 
2.2.5. Cryopreservation of cell lines 
Adherent cells in the log phase of growth were re-suspended and counted using a 
haemocytometer as described in section 2.4. The suspended cells were then recovered by 
placing them in a 15 mL tube and centrifuging at 1,500rpm for 3minutes at RT. The 
supernatant was discarded and the cell pellet re-suspended in an appropriate volume of 
freezing mixture (90% Foetal Calf Serum (Gibco), 10% DMSO (Gibco)) to give a final 
cell concentration of 1 x 10
6
 cells/mL. 1 mL aliquots were dispensed into cryovials 
(Greiner) and placed in a Nalgene 5100 cryo 1°C freezing container (Merk), which 
contained isopropanol (Fisher Scientific) at RT. The freezing container was stored at -
70°C for ~24hrs before being transferred to liquid nitrogen storage until required.  
To resurrect cells from liquid nitrogen storage, cells were rapidly thawed in a 37°C 
waterbath (Grant). Once thawed cells were transferred to a 15 mL tube containing 10 mL 
pre-warmed DMEM-10. The cells were centrifuged at 1,500rpm for 5minutes at RT and 
the supernatant discarded. The cells were re-suspended in fresh DMEM-10 and transferred 
to a 25cm
2
 tissue culture flask and incubated at 37°C, 5% CO2. 
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2.3. VIRUSES 
2.3.1. Propagation of HCMV 
HCMV strains were all propagated in HFFF-hTerts. Cells were cultured in 2 L roller bottle 
tissue culture flasks until cells reached ~80% confluency. Once at the correct confluence, 
cells were infected with the desired HCMV at a multiplicity of infection (MOI) 0.1 in ~40 
mLs DMEM-10. Rollers were placed in an incubator containing a rolling platform 
(Heraeus) at 30 rotations a minute at 37°C, 5%CO2. The following day medium was 
removed and replaced with fresh DMEM-10. Cells were monitored for cytopathic effect 
(cpe) and media was changed as required. When extensive cpe was observed throughout 
the cell monolayer (~80-90% cpe), media was removed and stored at -70°C as HCMV is 
secreted into the medium. Fresh 25mL media was added to the cells. During the following 
days media was replaced and stored at -80°C until the infection was completed.  
 
2.3.2. HCMV purification 
Frozen aliquots from respective HCMV infections were removed from storage at -80°C 
and defrosted in a pre-warmed 37°C waterbath. Cell debris was removed by centrifugation 
at 2,500rpm for 5 minutes at RT. The supernatant was pooled and decanted into pre 
autoclaved 250 mL Sorvall centrifuge pots (Sorvall) and centrifuged at 23,000 rpm for 120 
minutes in an ultracentrifuge (Heraeus) using a SLA1500 rotor, which pelleted the virus. 
Following centrifugation the supernatant was discarded and the pellet was re-suspended in 
DMEM-10. The re-suspended pellet was gently aspirated through a 21 gauge needle to 
reduce the aggregation of the virus. Once resuspended the virus pellet was frozen at -80°C 
in 1mL aliquots until required. Infectious titres of HCMV stocks were calculated by 
titration. All HCMVs used in this study can be found in Table 2.2. 
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Table 2.2. List of HCMV's used in this study 
  
Laboratory 
designation  
Comment  
RCMV1111 Merlin BAC derived virus 
RCMV1149 Merlin BAC derived virus, ΔUL141 
RCMV1278 Merlin BAC derived virus, ΔUL16 ΔUL18 UL32-GFP tagged 
RCMV1293 Merlin BAC derived virus, ΔUL16 ΔUL18 UL32-GFP tagged. ΔUL2-11 
RCMV1294 Merlin BAC derived virus, ΔUL16 ΔUL18 UL32-GFP tagged. ΔUL13-20 
RCMV1295 Merlin BAC derived virus, ΔUL16 ΔUL18 UL32-GFP tagged. ΔUL22A-
UL25 
RCMV1297 Merlin BAC derived virus, ΔUL16 ΔUL18 UL32-GFP tagged. ΔUS12-US17 
RCMV1299 Merlin BAC derived virus, ΔUL16 ΔUL18 UL32-GFP tagged. ΔUS27-28 
RCMV1300 Merlin BAC derived virus, ΔUL16 ΔUL18 UL32-GFP tagged. ΔUS29-
US34A 
RCMV1318 Merlin BAC derived virus, ΔUL16 ΔUL18 UL32-GFP tagged. ΔUS18-22 
RCMV1332 Merlin BAC derived virus, ΔUL16 ΔUL18 UL32-GFP tagged. ΔRL1-RL6 
RCMV1333 Merlin BAC derived virus, ΔUL16 ΔUL18 UL32-GFP tagged. ΔRL10-UL1 
RCMV1528 Merlin BAC derived virus, ΔUL16 ΔUL18 UL32-GFP tagged. ΔUS1-US11 
RCMV1579 Merlin BAC derived virus,  ΔUS11 
Merlin Wild Type Merlin. Dolan et al (2004) 
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2.3.3. HCMV titration  
HCMV viruses were titrated by limiting dilution assay in 1 x 10
6
 HFFF cells that were 
seeded into 25cm
2
 tissue culture flasks and allowed to adhere overnight. The following day 
serial dilutions between 10
-2
 and 10
-8
 of the virus stock were made in DMEM-10. 1mL of 
each HCMV dilution was added to two 25cm
2
 tissue culture flasks, to give duplicate 
infections. Viruses were incubated on a rocking incubator for 2 hours before removing the 
media and replacing with 10 mL of overlay medium containing 1% Avicel 
(FMCBiopolymer), to prevent CMV infection from spreading throughout the flask. After 
14 days medium was removed and cells were washed thoroughly in PBS to remove all 
avicel. Cells were fixed in Methanol and observed microscopically for plaques. The 
number of plaques at each dilution were counted and averaged between the duplicates to 
give a concentration of PFU/mL. 
 
2.3.4. HCMV Growth curve 
In order to generate a single step HCMV growth curve, 1 x 10
6
 HFFF cells were seeded 
into 25cm
2
 tissue culture flasks and allowed to adhere overnight. The following day cells 
were infected with HCMV at MOI 1. At day 1 and then every subsequent 2 days 1mL 
supernatant was taken and replaced with fresh media of equal volume. Aliquots were then 
titred to calculate amount of virus present in the supernatant.     
 
2.3.5. Propagation of Recombinant Adenovirus (RAd) stocks 
Recombinant Adenovirus (RAd) stocks were grown in 293-T-REx
TM
 cells in 175cm
2
 
tissue culture flasks. T-Rex
TM
 cells contain the tetracycline repressor protein that allows 
extremely low expression levels of the transgene in the repressed state, making this cell 
line ideal for the growth of RAd’s that potentially express genes with cytotoxic effects. 
293-T-Rex
TM cells were seeded into 175cm2 cellbind tissue culture flask. A total of 5 
flasks were used to culture a single RAd. When cells reached ~80% confluence, 10µL of 
unknown titred stock, or MOI 0.1 of titred stock, was added to each flask and incubated 
overnight at 37°C. The following day the inoculum was removed and fresh DMEM-10 was 
added. After 3-7days, when maximum cpe was observed, the cells and supernatant were 
transferred to 50mL falcon tubes and centrifuged at 1,500rpm for 5 minutes at RT. The 
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supernatant was discarded and the cell pellet was re-suspended in 10 mL PBS and 
centrifuged again at 1,500rpm for 5minutes at RT. The supernatant was discarded and the 
cell pellet was stored at -70°C until required.  
 
2.3.6. RAd purification by Caesium Chloride 
Firstly a Caesium Chloride density gradient was made. 1.6 mL of 3.6M Caesium Chloride 
(CsCl) solution (1.45 g / mL in 5mM Tris HCL, pH 7.8) was first pipetted into 14x89mm 
Ultra clear Beckman centrifuge tubes (Beckman) for an SW41 Ti rotor. Then 3 mL of less 
dense 2.5M CsCl solution (1.33 g/mL in 1mM EDTA, 5mM Tris HCL, pH 7.8) was gently 
layered on top.  
Once the CsCl gradient was made, the cell pellet was defrosted in a 37°C waterbath and 
resuspended in ~10mL warm PBS. An equal volume (10 mL) of Tetrachloroethylene 
(Fisher) was added and mixed vigorously and centrifuged at 2,000rpm for 20minutes. The 
upper aqueous phase, containing the RAd was removed and gently pipetted onto the 
previously made CsCl gradient until the tube was filled to 2.5mm from the top. Samples 
were centrifuged at 23,000rpm for 120 minutes at RT using L8-M ultracentrifuge 
(Beckman) and SW41 Ti rotor. The virus appeared as an opalescent layer between the 
higher and lower density CsCl solutions. A second band higher up, resting on top of the 
low density CsCl solution was derived from cellular components. The virus was harvested 
by puncturing the tube with a 19g needle and gently pulling the lower band corresponding 
to the virus into a 2 mL syringe. The virus was then dialysed against 1mM MgCl2; 
135mM NaCL; 10mM Tris HCL, pH 7.8; containing 10% glycerol with one change of 
buffer after 2hours and then left to dialyse overnight. The following day the virus diluted 
with autoclaved dialysis fluid to make up to 5mL volume, aliquoted as 500 µL aliquots and 
stored at -70°C. A list of all RAd’s used in this study can be found in table2.3.    
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Table 2.3. List of Recombinant Adenoviruses used. 
    RAd Comment Background Desgination 
RAd-Control Empty vector  AdZ Rad-1253 
RAd-UL141 Expresses HCMV strain Merlin UL141 AdEasy RAd-587 
RAd-CD112-
mCherry Expresses CD112 with a C-terminal mCherry tag AdEasy RAd-1222 
RAd-CD155-
mCherry Expresses CD155 with a C-terminal mCherry tag AdEasy RAd-1225 
RAd-GFP Expresses EGFP AdEasy RAd-502 
RAd-β.7 Expresses HCMV strain Merlin β2.7 with a C-terminal V5 tag AdZ / 
RAd-RL1 Expresses HCMV strain Merlin RL1 with a C-terminal V5 tag AdZ / 
RAd-RL5A Expresses HCMV strain Merlin RL5A with a C-terminal V5 tag AdZ / 
RAd-RL6 Expresses HCMV strain Merlin RL6 with a C-terminal V5 tag AdZ / 
RAd-RL8A Expresses HCMV strain Merlin RL8A with a C-terminal V5 tag AdZ / 
RAd-RL9 Expresses HCMV strain Merlin RL9 with a C-terminal V5 tag AdZ / 
RAd-RL10 Expresses HCMV strain Merlin RL10 with a C-terminal V5 tag AdZ / 
RAd-RL11 Expresses HCMV strain Merlin RL11 with a C-terminal V5 tag AdZ / 
RAd-RL12 Expresses HCMV strain Merlin RL12 with a C-terminal V5 tag AdZ / 
RAd-RL13 Expresses HCMV strain Merlin RL13 with a C-terminal V5 tag AdZ / 
RAd-UL1 Expresses HCMV strain Merlin UL1 with a C-terminal V5 tag AdZ / 
RAd-UL2 Expresses HCMV strain Merlin UL2 with a C-terminal V5 tag AdZ / 
RAd-UL4 Expresses HCMV strain Merlin UL4 with a C-terminal V5 tag AdZ / 
RAd-UL5 Expresses HCMV strain Merlin UL5 with a C-terminal V5 tag AdZ / 
RAd-UL6 Expresses HCMV strain Merlin UL6 with a C-terminal V5 tag AdZ / 
RAd-UL7 Expresses HCMV strain Merlin UL7 with a C-terminal V5 tag AdZ / 
RAd-UL7/8 Expresses HCMV strain Merlin UL7/8 with a C-terminal V5 tag AdZ / 
RAd-UL8 Expresses HCMV strain Merlin UL8 with a C-terminal V5 tag AdZ / 
RAd-UL9 Expresses HCMV strain Merlin UL9 with a C-terminal V5 tag AdZ / 
RAd-UL10 Expresses HCMV strain Merlin UL10 with a C-terminal V5 tag AdZ / 
RAd-UL11 Expresses HCMV strain Merlin UL11 with a C-terminal V5 tag AdZ / 
RAd-UL13 Expresses HCMV strain Merlin UL13 with a C-terminal V5 tag AdZ / 
RAd-UL14 Expresses HCMV strain Merlin UL14 AdZ / 
RAd-UL15A Expresses HCMV strain Merlin UL15A with a C-terminal V5 tag AdZ / 
RAd-UL16 Expresses HCMV strain Merlin UL16 with a C-terminal V5 tag AdZ / 
RAd-UL17 Expresses HCMV strain Merlin UL17 with a C-terminal V5 tag AdZ / 
RAd-UL18 Expresses HCMV strain Merlin UL18 with a C-terminal V5 tag AdZ / 
RAd-UL19 Expresses HCMV strain Merlin UL19 with a C-terminal V5 tag AdZ / 
RAd-UL20 Expresses HCMV strain Merlin UL20 with a C-terminal V5 tag AdZ / 
RAd-UL21A Expresses HCMV strain Merlin UL21A with a C-terminal V5 tag AdZ / 
RAd-UL22A Expresses HCMV strain Merlin UL22A with a C-terminal V5 tag AdZ / 
RAd-UL23 Expresses HCMV strain Merlin UL23 with a C-terminal V5 tag AdZ / 
RAd-UL24 Expresses HCMV strain Merlin UL24 with a C-terminal V5 tag AdZ / 
RAd-UL25 Expresses HCMV strain Merlin UL25 with a C-terminal V5 tag AdZ / 
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RAd-UL26 Expresses HCMV strain Merlin UL26 with a C-terminal V5 tag AdZ / 
RAd-UL27 Expresses HCMV strain Merlin UL27 with a C-terminal V5 tag AdZ / 
RAd-UL28/29 Expresses HCMV strain Merlin UL28/29 with a C-terminal V5 tag AdZ / 
RAd-UL30 Expresses HCMV strain Merlin UL30 with a C-terminal V5 tag AdZ / 
RAd-UL31 Expresses HCMV strain Merlin UL31 with a C-terminal V5 tag AdZ / 
RAd-UL32 Expresses HCMV strain Merlin UL32 with a C-terminal V5 tag AdZ / 
RAd-UL33 Expresses HCMV strain Merlin UL33 with a C-terminal V5 tag AdZ / 
RAd-UL34 Expresses HCMV strain Merlin UL34 with a C-terminal V5 tag AdZ / 
RAd-UL35 Expresses HCMV strain Merlin UL35 with a C-terminal V5 tag AdZ / 
RAd-UL36 Expresses HCMV strain Merlin UL36 with a C-terminal V5 tag AdZ / 
RAd-UL37 Expresses HCMV strain Merlin UL37 with a C-terminal V5 tag AdZ / 
RAd-UL38 Expresses HCMV strain Merlin UL38 with a C-terminal V5 tag AdZ / 
RAd-UL40 Expresses HCMV strain Merlin UL40 with a C-terminal V5 tag AdZ / 
RAd-UL41A Expresses HCMV strain Merlin UL41A with a C-terminal V5 tag AdZ / 
RAd-UL42 Expresses HCMV strain Merlin UL42 with a C-terminal V5 tag AdZ / 
RAd-UL43 Expresses HCMV strain Merlin UL43 with a C-terminal V5 tag AdZ / 
RAd-UL44 Expresses HCMV strain Merlin UL44 with a C-terminal V5 tag AdZ / 
RAd-UL45 Expresses HCMV strain Merlin UL45 with a C-terminal V5 tag AdZ / 
RAd-UL46 Expresses HCMV strain Merlin UL46 with a C-terminal V5 tag AdZ / 
RAd-UL47 Expresses HCMV strain Merlin UL47 with a C-terminal V5 tag AdZ / 
RAd-UL48 Expresses HCMV strain Merlin UL48 with a C-terminal V5 tag AdZ / 
RAd-UL49 Expresses HCMV strain Merlin UL49 with a C-terminal V5 tag AdZ / 
RAd-UL50 Expresses HCMV strain Merlin UL50 with a C-terminal V5 tag AdZ / 
RAd-UL51 Expresses HCMV strain Merlin UL51 with a C-terminal V5 tag AdZ / 
RAd-UL52 Expresses HCMV strain Merlin UL52 with a C-terminal V5 tag AdZ / 
RAd-UL53 Expresses HCMV strain Merlin UL53 with a C-terminal V5 tag AdZ / 
RAd-UL54 Expresses HCMV strain Merlin UL54 with a C-terminal V5 tag AdZ / 
RAd-UL55 Expresses HCMV strain Merlin UL55 with a C-terminal V5 tag AdZ / 
RAd-UL56 Expresses HCMV strain Merlin UL56 with a C-terminal V5 tag AdZ / 
RAd-UL57 Expresses HCMV strain Merlin UL57 with a C-terminal V5 tag AdZ / 
RAd-UL69 Expresses HCMV strain Merlin UL69 with a C-terminal V5 tag AdZ / 
RAd-UL70 Expresses HCMV strain Merlin UL70 with a C-terminal V5 tag AdZ / 
RAd-UL71 Expresses HCMV strain Merlin UL71 with a C-terminal V5 tag AdZ / 
RAd-UL72 Expresses HCMV strain Merlin UL72 with a C-terminal V5 tag AdZ / 
RAd-UL73 Expresses HCMV strain Merlin UL73 with a C-terminal V5 tag AdZ / 
RAd-UL74 Expresses HCMV strain Merlin UL74 with a C-terminal V5 tag AdZ / 
RAd-UL75 Expresses HCMV strain Merlin UL75 with a C-terminal V5 tag AdZ / 
RAd-UL76 Expresses HCMV strain Merlin UL76 with a C-terminal V5 tag AdZ / 
RAd-UL77 Expresses HCMV strain Merlin UL77 with a C-terminal V5 tag AdZ / 
RAd-UL78 Expresses HCMV strain Merlin UL78 with a C-terminal V5 tag AdZ / 
RAd-UL79 Expresses HCMV strain Merlin UL79 with a C-terminal V5 tag AdZ / 
RAd-UL80 Expresses HCMV strain Merlin UL80 with a C-terminal V5 tag AdZ / 
RAd-UL80.5 Expresses HCMV strain Merlin UL80.5 with a C-terminal V5 tag AdZ / 
RAd-UL82 Expresses HCMV strain Merlin UL82 with a C-terminal V5 tag AdZ / 
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RAd-UL83 Expresses HCMV strain Merlin UL83 with a C-terminal V5 tag AdZ / 
RAd-UL84 Expresses HCMV strain Merlin UL84 with a C-terminal V5 tag AdZ / 
RAd-UL85 Expresses HCMV strain Merlin UL85 with a C-terminal V5 tag AdZ / 
RAd-UL86 Expresses HCMV strain Merlin UL86 with a C-terminal V5 tag AdZ / 
RAd-UL87 Expresses HCMV strain Merlin UL87 with a C-terminal V5 tag AdZ / 
RAd-UL88 Expresses HCMV strain Merlin UL88 with a C-terminal V5 tag AdZ / 
RAd-UL89 Expresses HCMV strain Merlin UL89 with a C-terminal V5 tag AdZ / 
RAd-UL91 Expresses HCMV strain Merlin UL91 with a C-terminal V5 tag AdZ / 
RAd-UL92 Expresses HCMV strain Merlin UL92 with a C-terminal V5 tag AdZ / 
RAd-UL93 Expresses HCMV strain Merlin UL93 with a C-terminal V5 tag AdZ / 
RAd-UL94 Expresses HCMV strain Merlin UL94 with a C-terminal V5 tag AdZ / 
RAd-UL95 Expresses HCMV strain Merlin UL95 with a C-terminal V5 tag AdZ / 
RAd-UL96 Expresses HCMV strain Merlin UL96 with a C-terminal V5 tag AdZ / 
RAd-UL97 Expresses HCMV strain Merlin UL97 with a C-terminal V5 tag AdZ / 
RAd-UL98 Expresses HCMV strain Merlin UL98 with a C-terminal V5 tag AdZ / 
RAd-UL99 Expresses HCMV strain Merlin UL99 with a C-terminal V5 tag AdZ / 
RAd-UL100 Expresses HCMV strain Merlin UL100 with a C-terminal V5 tag AdZ / 
RAd-UL102 Expresses HCMV strain Merlin UL102 with a C-terminal V5 tag AdZ / 
RAd-UL103 Expresses HCMV strain Merlin UL103 with a C-terminal V5 tag AdZ / 
RAd-UL104 Expresses HCMV strain Merlin UL104 with a C-terminal V5 tag AdZ / 
RAd-UL105 Expresses HCMV strain Merlin UL105 with a C-terminal V5 tag AdZ / 
RAd-UL111A Expresses HCMV strain Merlin UL111A with a C-terminal V5 tag AdZ / 
RAd-UL112 Expresses HCMV strain Merlin UL112 with a C-terminal V5 tag AdZ / 
RAd-UL114 Expresses HCMV strain Merlin UL114 with a C-terminal V5 tag AdZ / 
RAd-UL115 Expresses HCMV strain Merlin UL115 with a C-terminal V5 tag AdZ / 
RAd-UL116 Expresses HCMV strain Merlin UL116 with a C-terminal V5 tag AdZ / 
RAd-UL117 Expresses HCMV strain Merlin UL117 with a C-terminal V5 tag AdZ / 
RAd-UL119 Expresses HCMV strain Merlin UL119 with a C-terminal V5 tag AdZ / 
RAd-UL120 Expresses HCMV strain Merlin UL120 with a C-terminal V5 tag AdZ / 
RAd-UL121 Expresses HCMV strain Merlin UL121 with a C-terminal V5 tag AdZ / 
RAd-UL122 Expresses HCMV strain Merlin UL122 with a C-terminal V5 tag AdZ / 
RAd-UL123 Expresses HCMV strain Merlin UL123 with a C-terminal V5 tag AdZ / 
RAd-UL124 Expresses HCMV strain Merlin UL124 with a C-terminal V5 tag AdZ / 
RAd-UL128 Expresses HCMV strain Merlin UL128 with a C-terminal V5 tag AdZ / 
RAd-UL130 Expresses HCMV strain Merlin UL130 with a C-terminal V5 tag AdZ / 
RAd-UL131A Expresses HCMV strain Merlin UL131A with a C-terminal V5 tag AdZ / 
RAd-UL132 Expresses HCMV strain Merlin UL132 with a C-terminal V5 tag AdZ / 
RAd-UL133 Expresses HCMV strain Merlin UL133 with a C-terminal V5 tag AdZ / 
RAd-UL135 Expresses HCMV strain Merlin UL135 with a C-terminal V5 tag AdZ / 
RAd-UL136 Expresses HCMV strain Merlin UL136 with a C-terminal V5 tag AdZ / 
RAd-UL138 Expresses HCMV strain Merlin UL138 with a C-terminal V5 tag AdZ / 
RAd-UL139 Expresses HCMV strain Merlin UL139 with a C-terminal V5 tag AdZ / 
RAd-UL140 Expresses HCMV strain Merlin UL140 with a C-terminal V5 tag AdZ / 
RAd-UL142 Expresses HCMV strain Merlin UL142 with a C-terminal V5 tag AdZ / 
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RAd-UL144 Expresses HCMV strain Merlin UL144 with a C-terminal V5 tag AdZ / 
RAd-UL145 Expresses HCMV strain Merlin UL145 with a C-terminal V5 tag AdZ / 
RAd-UL146 Expresses HCMV strain Merlin UL1446with a C-terminal V5 tag AdZ / 
RAd-UL147 Expresses HCMV strain Merlin UL147 with a C-terminal V5 tag AdZ / 
RAd-UL147A Expresses HCMV strain Merlin UL147A with a C-terminal V5 tag AdZ / 
RAd-UL148 Expresses HCMV strain Merlin UL148 with a C-terminal V5 tag AdZ / 
RAdUL148A Expresses HCMV strain Merlin UL148A with a C-terminal V5 tag AdZ / 
RAd-UL148B Expresses HCMV strain Merlin UL148B with a C-terminal V5 tag AdZ / 
RAd-UL148C Expresses HCMV strain Merlin UL148C with a C-terminal V5 tag AdZ / 
RAd-UL148D Expresses HCMV strain Merlin UL148D with a C-terminal V5 tag AdZ / 
RAd-UL150 Expresses HCMV strain Merlin UL150 with a C-terminal V5 tag AdZ / 
RAd-TRS1 Expresses HCMV strain Merlin TRS1 with a C-terminal V5 tag AdZ / 
RAd-IRS1 Expresses HCMV strain Merlin IRS1 with a C-terminal V5 tag AdZ / 
RAd-US1 Expresses HCMV strain Merlin US1 with a C-terminal V5 tag AdZ / 
RAd-US2 Expresses HCMV strain Merlin US2 with a C-terminal V5 tag AdZ / 
RAd-US3 Expresses HCMV strain Merlin US3 with a C-terminal V5 tag AdZ / 
RAd-US6 Expresses HCMV strain Merlin US6 with a C-terminal V5 tag AdZ / 
RAd-US7 Expresses HCMV strain Merlin US7 with a C-terminal V5 tag AdZ / 
RAd-US8 Expresses HCMV strain Merlin US8 with a C-terminal V5 tag AdZ / 
RAd-US9 Expresses HCMV strain Merlin US9 with a C-terminal V5 tag AdZ / 
RAd-US10 Expresses HCMV strain Merlin US10 with a C-terminal V5 tag AdZ / 
RAd-US11 Expresses HCMV strain Merlin US11 with a C-terminal V5 tag AdZ / 
RAd-US12 Expresses HCMV strain Merlin US12 with a C-terminal V5 tag AdZ / 
RAd-US13 Expresses HCMV strain Merlin US13 with a C-terminal V5 tag AdZ / 
RAd-US14 Expresses HCMV strain Merlin US14 with a C-terminal V5 tag AdZ / 
RAd-US15 Expresses HCMV strain Merlin US15 with a C-terminal V5 tag AdZ / 
RAd-US16 Expresses HCMV strain Merlin US16 with a C-terminal V5 tag AdZ / 
RAd-US17 Expresses HCMV strain Merlin US17 with a C-terminal V5 tag AdZ / 
RAd-US18 Expresses HCMV strain Merlin US18 with a C-terminal V5 tag AdZ / 
RAd-US19 Expresses HCMV strain Merlin US19 with a C-terminal V5 tag AdZ / 
RAd-US20 Expresses HCMV strain Merlin US20 with a C-terminal V5 tag AdZ / 
RAd-US21 Expresses HCMV strain Merlin US21 with a C-terminal V5 tag AdZ / 
RAd-US22 Expresses HCMV strain Merlin US22 with a C-terminal V5 tag AdZ / 
RAd-US23 Expresses HCMV strain Merlin US23 with a C-terminal V5 tag AdZ / 
RAd-US24 Expresses HCMV strain Merlin US24 with a C-terminal V5 tag AdZ / 
RAd-US26 Expresses HCMV strain Merlin US26 with a C-terminal V5 tag AdZ / 
RAd-US27 Expresses HCMV strain Merlin US27 with a C-terminal V5 tag AdZ / 
RAd-US28 Expresses HCMV strain Merlin US28 with a C-terminal V5 tag AdZ / 
RAd-US29 Expresses HCMV strain Merlin US29 with a C-terminal V5 tag AdZ / 
RAd-US30 Expresses HCMV strain Merlin US30 with a C-terminal V5 tag AdZ / 
RAd-US31 Expresses HCMV strain Merlin US31 with a C-terminal V5 tag AdZ / 
RAd-US32 Expresses HCMV strain Merlin US32 with a C-terminal V5 tag AdZ / 
RAd-US34 Expresses HCMV strain Merlin US34 with a C-terminal V5 tag AdZ / 
RAd-US34A Expresses HCMV strain Merlin US34A with a C-terminal V5 tag AdZ / 
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2.3.7. RAd titration  
RAd viruses were titrated by limiting dilution assay. A total of 1 x 10
6
 911 cells were 
seeded into a flat bottomed 96 well plate (Nunc) and allowed to adhere overnight. The 
following day serial dilutions between 1 x 10
2
 and 1 x 10
10 
of the virus stock were made in 
DMEM-10. 200µL of each RAd dilution was added to one row (12 wells) of a 96 well 
plate. After 10-14 days cells were observed microscopically for cpe and those wells that 
exhibited evidence of viral growth were marked. Virus titre was calculated as TCID50 
units using the formula of Reed and Meunch (1938). For convenience, TCID50 were 
converted to pfu/mL using an accepted conversion factor (1 TCID50 unit = 0.7 infectious 
units). 
 
2.3.8. Single infection of cells for assays 
Primary HFFFs or HFFF-hTert’s were normally infected with HCMV at MOI 10 pfu/cell 
or with RAds at a MOI of 100 pfu/cell for use in western blot and flow cytometry. HFFF-
hCAR cells were infected with both HCMV and RAds at a MOI of 10 for use in western 
blot and flow cytometry. Hela, Hela-US2 and Hela-US11 were infected at MOI100 for use 
in flow cytometry.  
Cells were seeded to the required density 24 hours prior to infection. The cell media was 
removed and virus inoculumn was added in minimal, yet consistent volume of media. 
Cells were incubated with virus inoculums for 120 minutes on a rocking platform in an 
incubator at 37°C, 5% CO2, after which time the inoculums was removed and replaced 
with fresh DMEM-10.  
All viral infections include a control: An empty RAd vector for RAd infections and a mock 
infection (medium only) for HCMV infections.   
 
2.3.9. Co-infection of cells for assays 
For RAd-RAd co-infections of HFFF-hCARs, cells were infected at MOI10 for each virus. 
Each virus was added to the cell inoculums. The inoculum was then added to cells before 
incubation for 2hrs on a rocking platform in an incubator at 37oC, 5% CO2, after which 
time the inoculums was removed and replaced with fresh DMEM-10 
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For RAd-HCMV co-infections of HFFF, cells were infected with RAd at MOI100 and 
HCMV MOI 30. Each virus was added to the cell inoculum. The inoculum were then 
added to cells before incubation for 120 minutes on a rocking platform in an incubator at 
37°C, 5% CO2, after which time the inoculums was removed and replaced with fresh 
DMEM-10 .  
 
2.3.10. Magnetofection 
 Magnetofection is a process of introducing nucleic acids or viruses into cells using 
magnetic nanoparticles coated with cationinc molecules. RAds were incubated with the 
magnetofection reagent, Combimag, for 20 minutes before being added to the cells pre 
seeded 24hours earlier in a 96 well-plate. The 96well plate was then placed on top of a 
magnetic plate for 20 minutes which drew the virus-bound magnetic nanoparticles onto the 
cell membrane thus facilitating efficient infection. 
 
2.4. MOLECULAR BIOLOGY  
2.4.1. PCR 
Polymerase chain reactions (PCRs) were performed using the Expand Hi-Fi polymerase 
(Roche) in the manufacturers buffer (Containing Magnesium), 0.5µL dNTPs (10mM) and 
0.5µL of each primer (100pmol/mL) (made to order from Invitrogen). The following 
thermocycling reaction was used: 
1) 95°C for 2minutes 
2) 95°C for 30 seconds 
3) 58°C for 30 seconds  Steps 2) – 4) were repeated for 35 cycles.  
4) 72°C for 90 seconds 
5) 4°C hold.    
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2.4.2. Agarose gel electrophoresis 
Separation of DNA fragments on the basis of size was performed by electrophoresis with a 
0.7% (w/v) TAE agarose gel containing Ethidium Bromide. DNA samples were mixed 
with DNA loading buffer (6x) before adding to wells of the pre set agarose gel. DNA 
standards were run in parallel. Gels were run at 70-100V for 1-2hours depending on the 
resolution required before being visualised by UV illumination at 365nm (. 
 
2.4.3. Isolation of DNA from an Agarose gel 
Where DNA had been separated by gel electrophoresis, to be used in cloning or 
sequencing, bands of the expected size were excised from the gel using a clean scalpel and 
the DNA extracted using the illustra GFX PCR DNA and Gel band purification kit (GE 
healthcare).  The kit is based on the principal that DNA adsorbs to silica in the presence of 
high salt, while contaminants will pass through. Impurities are washed away and the DNA 
eluted using an elution buffer.  
Using a UV spectrophotometer DNA was excised from the agarose gel using a scalpel and 
transferred to a 1.5mL tube. Gel slices were weighed and 10µL Capture buffer 3 for every 
10mg of gel slice was added (1g =1mL) and heated to 60°C for 15-30 minutes until the 
agarose was completely dissolved. For each purification performed one GFX microspin 
column was placed into one collection tube. 800µL of sample mix at a time was added to 
the assembled GFX microspin column and collection tube and incubated at room 
temperature for one minute before centrifuged at 13,000rpm for 30seconds at RT. The 
flow through was discarded and the sample binding steps were repeated as necessary until 
the entire sample was loaded. Once all the sample mix had been spun through the column, 
500µL of wash buffer type 1 was added to the GFX MicroSpin column and centrifuged at 
13,000rpm for 30 seconds at room temperature to remove impurities. The collection tube 
was discarded and the column transferred to a fresh DNAse-free 1.5mL tube. DNA was 
then eluted in 30µL of Elution buffer type 4 (10mM Tris-HCL, pH 8.0). Purified DNA can 
was stored at -20°C until required.     
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2.4.5. DNA extraction from solution 
The basic principle involves to capturing of DNA in solution is the same for capturing 
DNA from agarose gel. For each purification performed, one GFX microspin column was 
placed into one collection tube. DNA in solution was captured in capture buffer 3 and the 
sample capture mixture loaded into a GFX MicroSpin column and centrifuged at 
13,000rpm for 30 seconds at RT. The sample binds to the column and the supernatant is 
discarded. 500µL of wash buffer type 1 was then added to the GFX MicorSpin column and 
centrifuged at 13,000rpm for 30 seconds at RT to remove impurities. The collection tube 
was discarded and the column transferred to a fresh DNase-free 1.5mL tube. DNA was 
then eluted in 30µL of Elution buffer type 4 (10mM Tris-HCL, pH 8.0). Purified DNA was 
stored at -20°C until required.     
 
2.4.6. Plasmid DNA minipreps 
Small scale plasmid preparations were performed using Qiagen spin miniprep kits 
according to manufacturer’s instructions (Qiagen). The kit is based on the alkaline lysis of 
bacterial cells and the adsorption of DNA to a silica gel membrane in the presence of high 
salt. DNA is then washed to remove impurities and eluted into Tris buffer. Bacterial cells 
containing the plasmid of interest were grown in an overnight culture at 32°C in 5 mL LB 
containing chloramphenicol (1 in 1,000 of stock solution). From the overnight culture, 4.5 
mLs was pelleted by centrifugation at 4,000 rpm for 5 minutes at RT. DNA was then 
obtained using a spin miniprep kit (Qiagen) as described in the manufactures instructions. 
In brief the cell pellet is re-suspended in 250µL buffer P1 and transferred to a 1.5 mL tube. 
To this, 250µL of buffer P2 was added and incubated for 5 minutes at RT. Post incubation 
250 µL of buffer N3 was added and mixed several times by inversion, followed by 
centrifugation at 13,000rpm for 10 minutes at RT. The supernatant was transferred to a 
new 1.5 mL tube and the pellet discarded. DNA was precipitated by adding 750µL of 
isopropanol, mixing by inversion and centrifuging at 13,000rpm for 10 minutes at 4°C. 
The supernatant was discarded and the cell pellet re-suspended in 500 µL 70% ethanol 
followed by centrifugation at 13,000rpm for 5 minutes. The supernatant was discarded and 
air-dried for 15 minutes in a 37°C waterbath. Finally the DNA was re-dissolved in 30µL 
EB buffer (10mM Tris, pH8.5).  
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2.4.7. Plasmid DNA maxipreps  
The BacMAX 100 kit (Machery Nagel) was used for the large scale plasmid preparation to 
generate transfection-quality DNA, as described in the manufacturer’s instructions using 
the filtration method. For this procedure bacteria are subject to alkaline lysis, followed by 
binding to an anion-exchange resin and finally eluted after washing of the column. For 
large scale plasmid purification, a colony of bacteria containing plasmid of interest was 
used to inoculate 250mL LB media and incubated overnight in a shaking incubator at 
32oC. Bacterial cells were recovered by centrifugation at 6,000 RPM for15 minutes at 4°C 
using 250 mL pots (Sovall) and rotor SLA1500. Supernatant was discarded and the cell 
pellet resuspended in 12mL manufacturers supplied buffer S1 containing RNAse. Bacteria 
were lysed by the addition of equal volume, 12 mL, of manufacturer lysis buffer S2 and 
incubated for 5minutes at RT before the addition of 12 mL manufacturers neutralisation 
buffer S3That contains potassium acetate that causes the formation of a precipitate 
containing chromosomal DNA and other cellular components. The resulting solution and 
precipitate was then centrifuged at 6,000 RPM for15 minutes at 4°C during which time the 
manufacturers BAC 100 column was equilibrated with 5mL manufactures buffer N2. Once 
centrifuged the lysate was poured into a funnel containing filter paper above the pre-
equilibrated BAC 100 column. The flow through was allowed to empty through the 
column by gravity flow. Once emptied the column was washed with 2 x 18 mL 
manufactures wash bufferN3 to remove impurities and the DNA was eluted into pre 
autoclaved pots (Sorvall) with 15mL manufactures elution buffer N5 pre heated to 50°C. 
To precipitate the DNA, 11 mL of isopropanol was added to the elute followed by 
centrifugation at 15,000 RPM for 30 minutes at 4°C. The DNA precipitate was washed 
with 70% (v/v) ethanol followed by centrifugation at 15,000 RPM for 10minutes at RT 
and the pellet air dried before being resuspended in 100µL of manufacturers buffer TE.  
 
2.4.8. Estimation of DNA concentration  
To estimate DNA concentration, DNA from plasmid preparations were analysed by 
spectrophotometer (Biopharamacia Biotech Ultrospec 3000). Using the spectrophotometer, 
absorbance of a DNA solution at 260nm was compared with that of a control sample 
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2.4.9. Restriction enzyme digestion  
Restriction enzyme digestion of DNA was undertaken according to the manufactures 
instructions (New England Biolabs). 10 µL reaction mixtures were set up containing: 8µL 
DNA, 1 µL 10x buffer and 1µL restriction enzyme. Reaction mixtures were incubated at 
37°C for 2 hours or overnight. Following digestion, DNA was separated by TAE 
electrophoresis.  
 
2.4.10. Glycerol stock generation   
Plasmids of interest were stored as glycerol stocks, generated by mixing 500μL of an 
overnight bacterial culture with an equal volume of 80% (v/v) glycerol in a cryovial. 
Glycerol stocks were stored at -70°C.  
 
2.4.11. DNA sequencing  
DNA samples were sequenced using the ‘Big Dye; terminator cycle sequencing kit 
(Perkin-Elmer, Boston, USA) and dideoxy terminator cycle sequencing. The sequencing 
reaction mixture consisted of DNA sample, 4μL reaction mix, 1µL sequencing primer (see 
table 2.4 for primer sequences) and distilled water to a total reaction volume of 10μL. The 
following thermocycling reaction condition was used: 
 
Denaturation: 96°C x 30s 
Annealing 50°C x 15s   x 99 cycles 
Elongation  60°C x 4min 
 
Following the thermocylcing reaction, the sequencing products were cleaned up using 
Performa DTR columns, according to the manufacturer’s instructions. One Performa DTR 
column for each sequencing reaction was placed in a tube and centrifuged at 3,000rpm for 
3 minutes at RT using a microfuge. The column was moved to a fresh 1.5 mL tube and the 
entire sequencing reaction was added to the column before being centrifuges at 3,000rpm 
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Table 2.4. Primer sequences used. All primer sequences are 5' --> 3' and were produced to order from Invitrogen (Paisley, UK) 
Primer sequences Direction  Comment  
CCGCACCATCCCGTACTGCATGTTCCACATGTACGCGCTAGACGTGTAATCCACTCGCAGTTCGGGGACGCAACGCAGCCTGTGACG
GAAGATCACTTCG 
Forward Insert selection cassette in the middle of US2 
GAACGTGCGGAACTTAGATGTGATGCCGATCTTCGAGACGCTAGCCCTGCGTCTGGTACTGCAAGGGGATGTGATCTGCCTGAGGTT
CTTATGGCTCTTG 
Reverse US2 Reverse for SACB 
CCGCACCATCCCGTACTGCATGTTCCACATGTACGCGCTAGACGTGTAATCCACTCGCAGTTCGGGGACGCAACGCAGCCTGTTGAC
AATTAATCATCGGCA 
Forward US2 Forward for GALK 
GAACGTGCGGAACTTAGATGTGATGCCGATCTTCGAGACGCTAGCCCTGCGTCTGGTACTGCAAGGGGATGTGATCTGTCAGCACTG
TCCTGCTCCTT 
Reverse US2 Reverse for GALK 
ATGGGTGCTCGTGGCTACATTTATTGAAACAAACCGCGATCCCGGGCGTCGGTGAAACAGCGTGTGGACTGTACGCTCTTTCCCAAG
TTATATCCCAGAG 
oligonucleotide Removes US2 
GCACTCTACATAATAAGTTTGGCATTGATGACAGGGGGAAAAGTAGAACAACACGAGTTTTGTGCGTTGGCCTGTTGACAATTAATC
ATCGGCA 
Forward US11 Forward for GALK 
GATCGAGTGCCGACGCCGGTGGAGGACATCTCCGAAAGCCTCGTCGCAAAACGCTACTGGCTCCGGGACTATCGTGTTCCTCAGCAC
TGTCCTGCTCCTT 
Reverse US11 Reverse for GALK 
GGTGAGTCGTTTCCGAGCGACTCGAGATGCACTCCGCTTCAGTCTATATATCTGTCTTACAAGGGAAGGCTGTTCCCCTGTCTAGACT
CAAAAGCTGTAAGGCTATCTTA 
oligonucleotide removes US11 
ACCTCCGCGGCCGAAAAAATGTCAAACACACGCCCCTCACCACGTTCATCATTGAAAGTCTCTCCAGTCCCTATGTTGCCTGTGACGG
AAGATCACTTCG 
Forward US1-11 Forward for SACB 
CGTGCAAGACTACATGCTATAAGATAGCCTTACAGCTTTTGAGTCTAGACAGGGGAACAGCCTTCCCTTGTAAGACAGACTGAGGTT
CTTATGGCTCTTG 
Reverse US1-11 Reverse for SACB 
CACGCCCCTCACCACGTTCATCATTGAAAGTCTCTCCAGTCCCTATGTTGTCTGTCTTACAAGGGAAGGCTGTTCCCCTGTCTAGACTC
AAAAGCTGTAA 
oligonucleotide Removes US1-11 
CTCGTGGCTACATTTATTGA Forward Forward sequencing primer to confirm US2 removal 
GTGCTATGGCTGCTCAATGC Reverse Reverse sequencing primer to confirm US2 removal 
AAGTAGGTAGGTTCTCTCGT Forward Forward sequencing primer to confirm US11 removal 
ATGTTTCTGCTCGTGGTAGT Reverse Reverse sequencing primer to confirm US11 removal 
CATCTGGTATCCAAACTACGCC Forward Sequence to confirm US1-11 deletion 
AATGTCGTAACAACTCCG Forward From CMV promoter 
ACCTGATGGTGATAAGAAG Reverse From CMV polyA 
TGCACCACCAACTGCTTAGC Forward GAPDH 
CTGGAACGGTGAAGGTGACA Forward Β-Actin 
CCGGATCTCCTGGCTCTCA Forward CD112 
TGGACGGCAAGAATGTGACC Forward CD155 
GGCATGGACTGTGGTCATGAG Reverse GAPDH 
AAGGGACTTCCTGTAACAATGCA Reverse Β-Actin 
TGAAGCGGCTGGTGACAGT Reverse CD112 
ATCATAGCCAGAGATGGATACC Reverse CD155 
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for 3minues at RT. The flowthrough was moved to a new 0.5 mL tube and the sequencing 
products separated in-house on an ABI model sequencer (Applied Biosystems, Foster City, 
USA) by a dedicated technician at Central Biotechnology Services (Cardiff University).  
 
2.5. RECOMBINEERING  
2.5.1. The recombineering principle 
Recombinant viruses were produced using a novel system that exploits DNA 
recombineering technology (2008). This utilises the E.coli bacterial strain SW102 that 
contains a single copy genome inserted into a single copy prokaryotic BAC (bacterial 
artificial chromosome) plasmid. The vector AdZ vector contains a selection cassette 
encoding Ampicillin resistance, LacZ and sucrose sensitivity (AmpR/LacZ/SacB) driven by 
the HCMV major IE promoter. The LacZ gene encodes a β-galactosidase that turns blue 
when the sugar galactose is metabolised. Colonies that contain the selection cassette are 
therefore resistant to Ampicillin, sensitive to sucrose and blue. The SW102 strain that 
maintains the vector contains a defective phage expressing the lambda red genes, which 
are transiently induced by heatshock and mediate homologous recombination between the 
vector and an oligonucleotide containing the gene of interest plus short arms of homology. 
A successful homologous recombination event replaces the selection cassette with the gene 
of interest resulting in a change in resistance, colony colour and sucrose sensitivity. 
Colonies that have lost the selection cassette are therefore sensitive to Ampicillin, able to 
grow on sucrose and white. Once sequenced to confirm correct modification, DNA is 
maxipreped and transfected into the relevant cell type to generate a recombinant virus. For 
a detailed breakdown of the recombineering protocol see Stanton et al (2008). Although a 
generalised protocol is described as follows: 
 
2.5.2. Generalised recombineering protocol 
Recombineering was performed as follows: 500µL of an overnight culture was diluted in 
25 mL Luria-Bertani (LB) medium with chloramphenicol selection (12.5 ug/mL) in a 50 
ML Duran bottle and grown at 32°C in a shaking incubator to an OD600 of 0.6. The culture 
was then transferred to a 50mL Falcon tube and heat shocked in a 42° C waterbath for 
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exactly 15 minutes. After 15 minutes the samples were cooled on ice, on a rocking 
platform for 20 minutes before pelleted at 4,000rpm for 5 mins at 0°C. The supernatant 
was discarded and the pellet resuspended in 1 mL ice cold ddH2O. Once resuspended 
24mL ice-cold ddH2O was added and the samples pelleted again at 4,000rpm for 5mins at 
0°C. This step was repeated once more. After the second washing and centrifugation step, 
the supernatant was discarded and the now competent cells were resuspended in the 
remaining supernatant (~200uL) and were kept on ice until electroporated with 4uL of gel-
purified PCR product or 1µL oligonucleotide. A 25µL aliquot of competent cells was used 
for each electroporation in a 0.2cm cuvette (BioRad) at 2.5 Kv. After electroporation the 
bacteria were recovered in 5 mL LB for 4 hours in a 32°C shaking incubator. Recovery 
time depended on whether the selection cassette was inserted or removed. Post recovery 
200µL bacteria were plated out onto agar selection plates and left in a 32°C incubator. 
After 48-72 hours correct (White) colonies were picked and grown overnight in 5 mL LB 
containing chloramphenicol at 32°C in a shaking incubator. DNA was minipreped, 
digested and sequenced to confirm correct modification. Once sequencing confirmed a 
correct modification, DNA was maxipreped and transfected into the relevant cell type to 
generate a recombinant virus. 
 
2.5.3. Recombineering using the AdZ vector 
The AdZ-5 vector contains a single copy replication deficient Ad5 (E1
-
, E3
-
) genome that 
is inserted into a single copy prokaryotic BAC (bacterial artificial chromosome) plasmid in 
SW102 bacteria, Figure 2.1 . The vector contains an AmpR/LacZ/SacB selection cassette 
that provides ampicillin resistance, LacZ and sucrose sensitivity, as described earlier. The 
AdZ vector also encodes a I-sceI cassette that allows the self excision of the RAd genome 
following transfection into 293 cells. The 293 cells contain the Adenovirus E1 region that 
allows for replicating Adenovirus to be produced and viral stocks to be grown.   
Recombineering using the AdZ vector was carried out as described in the general 
recombineering protocol, section 2.5.2., the primers used to amplify a desired ORF were 
designed with regions on homology flanking the AmpR/LacZ/SacB selection cassette, and 
were designed as follows: 
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Figure 2.1. The Adz-5 vector  
 The AdZ-5 vector contains the Ad5 vector genome, deleted for E1 & E3 regions (rendering 
the vector non-replicative) in a single copy vector. It contains the HCMV major immediate 
early promoter & PolyA signal sequence, with a cassette in the MCS encoding ampicillin 
resistance, lacZα & SacB. SacB encodes for a gene giving sensitivity to sucrose, lacZα 
provides blue/white screening. The AdZ CMV promoter is repressible by tet repressors, thus 
if the vector is grown in 293TREx cells expression from the CMV promoter is prevented 
during growth. This allows the cloning of toxic genes, or genes which would otherwise 
interfere with the Ad replication. Adapted from www.Adz.cf.ac.uk Stanton et al (2008).  
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Forward 
5’AACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAA
GACACCGGGACCGATCCAGCCTGGATCC----- required primer sequence (~20bp)----- 
Reverse 
TATAGAGTATACAATAGTGACGTGGGATCCCTACGTAGAATCAAGACCTAGGA
GCGGGTTAGGGATTGGCTTACCAGCGCT----- required primer sequence (~20bp)----- 
Following a successful recombination event the selection cassette is lost and replaced with 
the desired ORF.  
 
2.5.4. Recombineering to construct HCMV deletions 
Bacteria containing the desired viral genome BAC to be modified were chosen and 
recombineering was carried out as described in the general recombineering protocol 
section 2.5.2. The following modifications were made dependant on which selection 
cassette was used:  
 
2.5.4.1. Recombineering with the AmpR/LacZ/SacB selection cassette 
Making deletions in CMV required a two-step recombineering protocol, Figure 2.2. 
(Stanton et al., 2010).  
Bacteria containing the desired viral genome BAC to be modified were chosen and 
recombineering was carried out as described in the General recombineering protocol, 
section 2.5.2, with the following modifications:  
During the first round a PCR product containing the selection cassette plus short arms of 
homology to an area of the genome to be deleted were used, Figure 2.2. Primers used to 
amplify AmpR/LacZ/SacB selection cassette were designed as follows: 
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Figure 2.2. Generating HCMV deletions using AmpR/SacB/LacZ or RpsL/Neo/LacZ 
selection cassettes.   
 A two step recombineering approach is required to generate HCMV deletions. In the first round 
of recombineering a selection cassette is amplified using a 100bp primer. The primer is designed 
so that it contains ~20bp that will allow amplification of the desired selection cassette and ~ 80bp 
that is homologous to a region in the HCMV BAC where the selection cassette is to be inserted. 
Following a successful first round of recombination Blue colonies should be present. A blue 
colony is picked and streaked onto both positive and negative selection plates in order to check 
for correct inhibition. If correctly inhibited the colony is used for a second round of 
recombineering. During the second round a 100bp oligonucleotide is used, which is designed so 
that it contains50bp of homology to regions flanking either side of the genomic region to be 
removed. A successful recombination event will result in loss of the selection cassette and the 
desired genomic material. Due to the loss of the selection cassette correct colonies will be white.  
 
96 
 
Forward: 
5’-------------80bp homology------------CCTGTGACGGAAGATCACTTCG 
Reverse: 
5’-------------80bp homology------------CCTGAGGTTCTTATGGCTCTTG 
Following electroporation, bacteria were recovered in 1mL LB for 1hr in 32 shaking 
incubator. After recovery the 1mL was transferred to a tube, centrifuged at 13,000rpm for 
30s, supernatant poured off and discarded. The cell pellet was resuspended in the 
remaining supernatant and plated onto LB-agar plates and left in an incubator at 32°C. 
After 48-72 hrs blue colonies were picked and sucrose sensitivity tested by spreading an 
individual colony onto both LB-agar and LB-sucrose selection plates.  
Once sucrose sensitivity was confirmed correct colonies were picked and grown overnight 
in chloramphenicol and ampicillin. A second round of recombineering was then carried out 
as described In general recombineering protocol, section 2.5.2.   
 
2.5.4.2. Recombineering with the GalK selection cassette 
The GalK selection system was used to make deletions where the AmpR/LacZ/SacB 
selection cassette has failed. The GalK allows for a positive/negative selection system for 
manipulation of BAC’s (Warming et al., 2005). The E.coli galactose operon consists of 
four genes GalE, GalT, GalK and GalM, which are necessary for the growth and 
metabolism of galactose when the only carbon source. The GalK product galactokinase 
catalyses the first step in the galactose degradation pathway, phosphorylating galatcose-1-
phophate. The galactokinase also catalyses the phosphorylation of a galactose analog, 2-
dexygalactose-1-phosphate (DOG). The product of this reaction cannot be further 
metabolised, leading to a toxic build-up of 2-deoxygalactose-1-phosphate. Thus both 
positive and negative selection can be conferred by GalK, which is absent in the E.coli 
SW102 strain.   
The GalK selection system requires two rounds of recombination, Figure 2.3: In the first 
the GalK cassette, containing homology to a specified position in the BAC is inserted by 
homologous recombination. The recombinant will now be able to grow on minimal media  
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Figure 2.3. Generating HCMV deletions using GalK selection cassettes.   
 A two step recombineering approach is required to generate HCMV deletions. In the first round of 
recombineering the GalK election cassette is amplified using a 100bp primer. The primer is designed so that it 
contains ~20bp that will allow amplification of the GalK cassette and ~ 80bp that is homologous to a region in 
the HCMV BAC where the selection cassette is to be inserted. Following a successful first round of 
recombination white colonies appear on minimal media plates. A white colony is picked and streaked onto 
MacConkey agar plates. If GalK is present and functional colonies are pink. If correct a pink colony is picked 
and is used for a second round of recombineering. During the second round a 100bp oligonucleotide is used, 
which is designed so that it contains50bp of homology to regions flanking either side of the genomic region to 
be removed. A successful recombination event will result in loss of the selection cassette and the desired 
genomic material. A white colony is picked and, BAC DNA miniprepred and sequenced to confirm correct 
deletion. . 
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where galactose is the only carbon source. In the second round the GalK cassette is 
removed using a gel-purified PCR product or oligonucleotide. Correct colonies are 
achieved by selecting against the GalK cassette by resistance to 2-deoxy-galactose (DOG) 
on minimal plates with glycerol as the carbon source. DOG is harmless, unless 
phosphorylated by GalK.   
Primers used to amplify the GalK selection cassette were designed as follows: 
Forward: 
5’-------------80bp homology------------CCTGTTGACAATTAATCATCGGCA 
Reverse: 
5’------------80bp homology-------------TCAGCACTGTCCTGCTCCTT 
 
Round 1; is carried out as described in section 2.5.2. with the following modifications: 
During the first round of recombination a gel-purified PCR product encoding GalK is 
used. Following electroporation bacteria are recovered in 1mL LB for 1hr in a 32°C 
shaking incubator.  
 After recovery periods, the bacteria were washed twice in 1xM9 salts as follows: 1 ML 
culture was pelleted in a 1.5 mL tube by centrifugation at 13,000rpm for 30s at RT and the 
supernatant removed with a pipette. The pellet was resuspended in 1mL of 1xM9 salts 
before plating in serial dilutions (100ul, 100ul each of 1:10, 1:100 and 1:1000 dilutions) on 
M63 minimal medium plates. Washing in M9 slats is necessary to remove any rich media 
prior to selection on M63 minimal media plates and incubated at 32°C. Colonies appear 
after 5-6days on M63 media plates where galactose is the only carbon source. Individual 
colonies are picked and streaked onto MacConkey indicator plates. Gal- colonies will be 
white/colourless and the Gal+ bacteria will be bright red/pink due to a pH change resulting 
from fermented galactose after an overnight incubation at 32°C. 
Round 2 (counter-selection); A red/pink colony was chosen from overnight incubation on 
MacConkey plates was inoculated in 5mL LB and choloramphenicol. Recombineering was 
then carried out as described in general recombineering protocol section 2.5.2, using an 
oligonucleotide to remove the desired part of the genome and the selection cassette. After 
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electroportation bacteria were recovered in 10mL LB for 4hrs at 32°C in a shaking 
incubator and washed in M9 salts as described in Round 1.  Serial dilutions (100ul, 100ul 
each of 1:10, 1:100 and 1:1000 dilutions) were plated onto M63 DOG minimal medium 
plates and incubated for 3days at 32°. Correct colonies were picked and grown overnight 
at 32°C in chloramphenicol and DNA minipreped, digested and sequenced to confirm 
correct modification.  
 
2.5.4.3. Recombineering with the rpsL-Neo-LacZ selection cassette  
The SacB selection cassette is 4.5kB and its large size results in lower recombination 
efficiency. The rpsL-Neo-LacZ selection cassette is ~1.5kB and its smaller size allowed for 
higher recombination efficiency (www.genebridges.com) (Kasem et al., 2010).   
The rpsL-Neo selection cassette (genbridges) was used to make deletions where the SacB 
and GalK selection cassettes had failed. The rpsL-Neo cassette was modified in house by 
Dr R Stanton to also contain LacZ. The rpsL-Neo-LacZ system takes advantage of the fact 
that the S12 ribosomal protein is the target of streptomycin. Most commonly used E.coli 
strains, including SW102, carry a mutation in the rpsL gene that confers streptomycin 
resistance. If the wild type rpsL gene is introduced then the strain will become 
streptomycin sensitive. The bacterial neomycin-kanamycin phosphotransferase, type II 
enzyme is encoded by the ‘Neo’ gene and confers resistance to aminoglycoside drugs such 
as neomycin and kanamycin.  When the rpsL-Neo-LacZ cassette is inserted colonies will 
be sensitive to streptomycin and resistant to Kanamycin. When the rpsL-Neo-LacZ cassette 
is lost, colonies will be resistant to streptomycin but sensitive to kanamycin. The presence 
of LacZ in the selection cassette allowed for blue/white screening of colonies.  
The rpsL-Neo selection system requires two rounds of recombination, Figure 2.2. In the 
first round the rpsL-Neo-LacZ cassette, containing homology to a specified position in the 
BAC is inserted by homologous recombination. The recombinant will now be able to grow 
on Kanamycin plates. In the second round the rpsL-Neo-LacZ is removed using an 
oligonucleotide. Correct colonies are achieved by plating onto Streptomycin selection 
plates. 
Primers used to amplify rpsL-Neo-LacZ cassette are the same as primers used to amplify 
the AmpR/SacB/LacZ cassette, if amplified from pAL1622. 
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Round 1; is carried out as described in section 2.5.2. with the following modifications: 
During the first round of recombination a gel-purified PCR product encoding rpsL-Neo-
LacZ  is used. Following electroporation, bacteria are recovered for 1 ML LB for 1hr in a 
32°C shaking incubator. After recovery, 100µL of bacteria were plated onto Kanamycin 
selection plates and incubated overnight in a 32°C incubator.  
Round2: A blue colony is picked and inoculated in 5mL LB and grown overnight. 
Recombineering was carried out as described in general recombineering protocol 
section.... using an oligonucleotide to remove the desired part of the genome and the rpsL-
Neo-LacZ selection cassette. Following electroporation bacteria were recovered in 1 mL 
LB for 1 hour at 32°C shaking incubator. After recovery, 100µL of bacteria were plated 
onto Streptomycin selection plates and incubated overnight in a 32°C incubator. Correct 
white colonies were picked and grown overnight in a 32°C incubator and DNA 
minipreped, digested and sequenced to confirm correct modification.  
 
2.5.5. Generation of RAd  
The AdZ5 genome does not need to be digested and can be transfected as a circular piece 
of maxiprepped DNA. The day before transfection 2 x 10
6
 293-TRExTM cells were 
seeded in a 25cm
2
 tissue culture flask. For transfection, 4 µg vector DNA was diluted in 
100µL DMEM (no FCS or antibiotics). To the diluted DNA was added 40µL polyfect 
transfection reagent (Qiagen) and incubated at RT for 10minutes. During the incubation 
the media was changed on the cells to 3 mL fresh DMEM-10. After the 10 minute 
incubation 1 mL of DMEM-10 was added to the DNA complex and transferred to cells. 
After 24 hours the media was changed and then changed as and when required. Once 
sufficient cpe is observed, usually 7-10 days, cells and virus can be harvested and used to 
grow up further stocks.  
 
2.5.6. Generation of HCMV  
The HCMV genome is replicated using host cell machinery and virus progeny are secreted 
from the infected cell. For transfection 1x10
6
 HFFF-hTert cells were centrifuged at 
1,500rpm for 3minutes at RT and the supernatant discarded. Cells were washed in PBS 
and centrifuged at 1,500rpm for 3minutes at RT. Supernatant was discarded and the cell 
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pellet resuspended in 100 µL of nucleofector reagent (Lonza). To the suspension 2µg of 
BAC DNA was added and the suspension was transferred to supplied cuvettes with 2.5mm 
gap. Cells were electroporated using Amaxa (Amaza Biosystems) and pre-programmed 
setting T16. Following pulsing, cells were allowed to recover for 2 minutes before 1mL 
RPMI media was added to the cuvette and left for 2minutes. After recovery the contents of 
the cuvette were transferred to a 25cm2 T25 flask containing 5 mLs DMEM-10. Cells 
were incubated at 37°C/5%CO2 and monitored for signs of cpe, with regular changes of 
media. Once cpe was observed throughout the monolayer cells were removed through 
trypsinisation and transferred to 5 x 175cm
2
 tissue culture flasks containing confluent 
monolayer of HFFF-hTert and a stock was generated.   
 
2.6. RT-QPCR  
2.6.1. RNA extraction  
At the required day post infection, media were removed from samples, cells washed in 
PBS and then cells lysed in 1 mL of Tri-reagent (Sigma) and stored at -80°C until 
required.  
When required, samples were thawed at RT and 200 µL chloroform added to give a 5:1 
tri:chloroform ratio. 1 mL of each sample was transferred to fresh 1mL RNase free tubes. 
Samples were vortexed for 10s and left at RT for 5 minutes before centrifugation at 12,500 
rpm for 5 minutes at 4°C.  
After centrifugation 500 µL of the aqueous phase was transferred to a fresh RNase free 
tube. Equal volume (500 µL) of isopropanol was added to precipitate the RNA and 1 µL 
(of a 5 mg/mL) glycogen was added to aid in the later visualisation of the RNA pellet. 
Once added the tube was inverted 10 times to ensure adequate mixing and left at -20°C for 
1hour.  
Post incubation samples were centrifuged at 14,000 rpm for 15 minutes at 4°C. 
Supernatant discarded and 500 µL ethanol added followed by centrifugation at 14,000rpm 
for 5minutes at 4°C. The supernatant was discarded and tubes blot dried.  
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RNA was obtained using the RNAeasy minelute (Qiagen) as described in the 
manufacturer’s instructions. In brief: 
The pellet was resuspended in 100µL of RNase free H2O, followed by 350µL of RLT 
buffer and mixed thoroughly by inversion 10 times. This was followed by adding 250µL 
100% Ethanol and mixed by pipetting up and down.  
700µL of sample was passed through a minelute column into 2mL collection tubes by 
centrifugation at 10,000rpm for 30s. The flow through was discarded and the column 
transferred to a fresh collection tube.  
500µL of buffer RPE was added to the column followed by centrifugation at 10,000rpm 
for 30s. The flow through was discarded 
500µL of 80% Ethanol was added to the column. The flow through and collection tube 
was discarded. 
The column was transferred to a new collection tube, the cap left open and centrifuged at 
12,500rpm for 2minutes, any flow through was discarded along with the collection tube.  
To elute the RNA, the column was transferred to a 1.5mL collection tube. 14µL of RNase 
free H2O was added and centrifuged at 12,500rpm for 1minute.  
Once eluted the samples were constantly kept on ice to prevent RNA degradation.  
RNA concentration was assessed using a spectrophotometer (Nanodrop), and RNA 
integrity was assessed using an Agilent 2100 Bioanalyser (Agilent Biosystems), which was 
used to calculate the required amount of total RNA required for the RT reaction. 
 
2.6.2. Reverse Transcription 
A reverse transcription (RT) reaction was carried out using High cap cDNA Reverse 
transcriptase kit, (Applied Biosystmes), as described in the manufacturer’s instructions. 
RT was performed using the random hexamer method. 1 µg of RNA was added to 1µL of 
100µM random hexamers (hexadeoxyribonucleotides, pd[n]6, (Amersham Biosciences), 
5µL of 10nM dNTPs (Amersham Biosciences), 2µL of 10x PCR buffer (Applied 
103 
 
Biosystems), 1 µL of reverse transcriptase, 1µl of (40 units/µL) RNase inhibitor and sterile 
H2O to volume (20µL) were added to each sample and mixed.  
The RT reaction was carried out using GeneAmp PCR system 9700, version 311, 
GeneAmp. The following reaction was used: 
25°C  for 10 minutes 
37°C for 60minutes 
37°C for 60 minutes 
85°C  for 5 seconds 
4°C Hold 
Once completed 80µL of H2O was added and samples were stored at -20°C until required 
2.6.3. QPCR 
QPCR was carried out on cDNA samples obtained from the RT reaction. To each well in a 
96 well plate 20µL of reaction mixture was added consisting of; 10µL syber green (applied 
Biosystems), 0.4µL of each primer, 1µL of diluted cDNA and to volume (20µL) DNase 
free water.   
Samples were run on ABI 7900HT RT-PCR machine and cycling parameters were as 
follows 
95°C  for 10 minutes 
95°C  for 15 seconds 
60°C  for 1 minute 
 The programme included a dissociation curve for RT-QPCR primers used, Figure 2.4.  
Gene expression values were calculated based on the comparative threshold cycle (Ct) 
(Livak and Schmittgen, 2001), in which RNA samples for Actin and GAPDH were 
designated as calibrators to which other samples were compared.  
The Ct data for CD112, CD155 and CD95 (Candidates) and Actin and GAPDH 
(Calibrators) were used to create ΔCt values (Ct Candidate – Ct Calibrator). The ΔΔCt values  
X 40 cycles  
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Figure 2.4. Dissociation curves for RT-QPCR primers. 
The programme for QPCR included an additional reaction to determine the 
melting/dissociation curves for the primers to determine primer specificity.  
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were calculated by subtracting the ΔCt from the normaliser. In this case viral conditions 
were subtracted from the same day control condition for each day post infection. The 
Relative quantities (RQs) were calculated with the equation RQ = 2-
ΔΔCt
, where RQ was 
normalised against the control condition for each day. The data were analysed for 
significance by a Turkey Post test. 
 
2.7. WESTERN BLOTTING 
2.7.1. Sample preparation of total cell lysate 
Cell samples were harvested by removing the media, washing in PBS cold PBS and cells 
removed using a cell scraper.  Detached cells were spun down at 1,500RPM for 3minutes 
at 4°C. The supernatant was discarded and cells washed in PBS and spun again at 
1,500RPM for 3minutes at 4°C. Supernatant was discarded and the cell pellet frozen until 
required.  
The cell pellet was resuspended in lysis buffer (25% 4X NuPAGE LDS sample buffer 
(Invitrogen), 1% protease inhibitor cocktail (Sigma) and 1% DTT (Sigma). Samples were 
sonicated (30 x 1sec pulse at 20%), vortexed for 10s and heated to 99 °C for 5minutes 
before being run.  
 
2.7.2. TritonX114 enrichment of samples 
Cell samples were harvested by removing the media, washing in PBS cold PBS and cells 
removed using a cell scraper.  Detached cells were spun down at 1,500RPM for 3minutes 
at 4°C. The supernatant was discarded and cells washed in PBS and spun again at 
1,500RPM for 3minutes at 4°C. Supernatant was discarded and the cell pellet frozen until 
required.  
Samples were thawed and sonicated (30 x 1sec pulse at 20%) on ice in 300µL of cold lysis 
buffer (2% Triton X-114 in PBS, 1/100 protease inhibitors and 1/1000 1M DTT). Once 
sonicated the lysate was left in a clear non-stick tube on ice for 30minutes. This was 
followed by centrifugation at 13,000RPM at 4°C for 1 hour after which the supernatant 
was transferred to a fresh 1.5 mL non-stick tube. The supernatant was incubated in 37°C 
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waterbath for 5 minutes followed by centrifugation at 13,000rpm for 5 minutes at 37°C. 
The top fraction was removed and frozen for later assays, while the bottom fraction was 
diluted with 300µL of cold PBS and vortexed. Proteins were precipitated using the 2D 
MERCK clean-up kit (539180) as described in the manufacturer’s instructions. 1.2mL of 
cold precipitation reagent was added to the 300 µL sample, which was briefly vortexed 
and incubated between 1hr-overnight. After precipitation samples were centrifuged at 
13,000rpm  for 10 minutes at 4°C. The supernatant was aspirated and discarded. The cell 
pellet was washed with 500µL cold wash solution, vortexed, centrifuged at 13,000rpm for 
10minutes 4°C and the supernatant aspirated and discarded. The cell pellet was finally 
dissolved in 20-60µL of 1.5x SDS PAGE loading buffer and DTT (1in20). Samples were 
either frozen for later use or processed directly for western blotting by heating to 99°C for 
5minutes to denature the proteins.  
 
2.7.3. Deglycosidase treatment  
To deglycosylate proteins, samples were digested with either endoglycosidase H (EndoH) 
(NEB) or peptide N-glycosidase F (PNGase F) (NEB). Samples were prepared using the 
Triton X114 method for the preparation of hydrophobic membrane proteins, as previously 
described, section 3.7.2. However, after precipitation, instead of re-suspending the final 
cell pellet in SDS loading buffer samples were instead re-suspended in denaturing buffer 
(NEB) to a total volume of 90µL and incubated at 99°C for 10 minutes. The sample was 
then split into three aliquots of 30µL for Endo H digestion, PNGase F digestion and a 
control undigested sample processed without any glycosidase enzyme. For Endo H 
digestion; 1µL (500units) enzyme, and 5µL buffer G5 (NEB) were added and made to a 
total of 50µL with PBS. For PNGase F digestion; 1µL (500Units) PNGase F enzyme, 5µL 
of supplied NP40 solution, 5µL of buffer G7 and PBS to a total volume (50µL). For the 
control; 5µL of buffer G5 was added and PBS to total volume, (50µL). All samples were 
then incubated overnight at 37°C. Post incubation samples were mixed with SDSPAGE 
loading buffer and run as described in sections 2.7.4. 
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2.7.4. Western blotting 
Before use all samples were heated to 99°C for 5minutes in order to denature proteins. 
Samples were loaded onto a pre-set 10% Bis-Tris Midi gel Nupage Novex acrylamide gels 
(Invitrogen), 20µL per lane, protein standards (Invitrogen) were run in parallel. Gels were 
used in conjunction with Nupage electrophoresis equipment (Invitrogen) and run in MOPS 
buffer at 200V for 1Hour before being transferred to nitrocellulose membrane.   
Following electrophoresis, proteins were transferred to nitrocellulose membrane (GE 
Biosciences) by semi dry transfer. Blotting paper and nitrocellulose membrane were pre-
soaked in transfer buffer, then layered onto the transfer apparatus (TransferBlot SD, 
BioRad), with the sheet of blotting paper on the negative electrode, then the nitrocellulose 
on top. The polyacrylamide gel was gently removed from the electrophoresis apparatus 
and placed onto the nitrocellulose membrane. A final sheet of blotting paper was then 
layered on top of the gel.  After ensuring that all air bubbles were removed, the transfer 
apparatus was assembled and the proteins were transferred by semi-dry transfer for 1 hour 
at 10V.  
Following transfer, the nitrocellulose membrane was removed from the apparatus. The 
position of the pre-stained protein markers were marked on the membrane using an 
antigen-antibody (mouse) pen (Alpha Diagnostics) before the membrane was blocked with 
5% milk powder in PBST for 1 hour are room temperature, or overnight at 4°C. After 
blocking, the blot was washed for 30minutes in PBST with three changes of buffer. An 
appropriate dilution of primary antibody in 5% milk powder in PBST was added to the 
membrane overnight at 4°C. All primary and secondary antibodies and their dilutions used 
can be found in table 2.5. The blot was then washed for 30minutes in PBST with three 
changes of PBST. Then an appropriate dilution of secondary antibody conjugated to horse-
radish peroxidise (HRP), in 5% milk powder in PBST was added to the blot and incubated 
for 1 hour at room temperature. Blots were washed a final time in PBST before incubation 
with the HRP chemiluminescent substrate (Thermo Scientific) for 5 minutes. The blots 
were then analysed with Chemidoc chemiluminescence imaging system (UVP) or using 
photographic film (Kodak) and a developing machine.  
To re-probe, blots were washed three times in PBST the incubated with ReStore (Pierce) 
for 1 hour before being washed a further three times in PBST. The stripped blots were re- 
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Table 2.5. Antibodies used in Immunoblot  
 
     Antibody  Dilution Isotype Company  Clone 
     Primary Antibodies          
     
α-V5 1:5,000 Mouse IgG2a AbD Serotec 
Sv5 
Pk1 
α-CD112 1:5,000 Mouse IgG R & D AF229 
α-CD155 1:5,000 Mouse IgG (Aoki et al., 1994) 5D1 
α-Actin 1:20,000 Rabbit IgG Sigma A-2066 
α-UL141 1:5,000 Mouse IgG1 Tomasec et al 2005 M550.2 
     
     Secondary Antibodies          
Goat α-rabbit IgG HRP 1:20,000 Goat IgG BioRad 
 Goat α-mouse IgG HRP 1:10,000 Goat IgG BioRad 
 Donkey α-goat IgG HRP 1:20,000 Donkey IgG SantaCruz 
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blocked in 5% milk powder in PBST for 1 hour at RT or overnight at 4°C then staining 
was carried out as described above.      
2.8. MICROSCOPY  
2.8.1. Phase contrast microscopy 
Phase contrast images of cells were detected with a Lecia DMIBRE microscope (Lecia) 
and a Hamamatsu ORCA-ER camera (Hamamatsu) and analysed with Improvision 
Openlab 3 software (Improvision). 
 
2.8.2. Preparation of cells for Immunofluorescence 
HFFF or HFFF-hCAR cells were seeded onto a glass bottomed 96 well plate at a 
concentration of 5 x 105 cells/plate, and infected the following day at a MOI 10. At 72hpi, 
cells were washed in PBS and fixed in 2% Paraformaldehyde for 20 minutes at RT. To 
permeabilise cells, wells were washed twice in PBS then incubated with the relevant IF 
buffer for 1 hour at RT, with 2 changes of buffer.  
Cells were incubated with primary antibody diluted in the relevant IF buffer for 1hour at 
RT. Table 2.6. lists the antibodies used in Immunofluorescence during this study. Wells 
were washed 5x in relevant IF buffer and incubated with secondary antibodies and/or 
relevant counterstains (Table 2.6.) for 1 hour at RT. After incubation wells were washed a 
further 5x in relevant IF to remove excess antibody before being fixed in 2% 
Paraformaldehyde.  Fluorescence was detected with a Lecia DMIBRE microscope (Lecia) 
and a Hamamatsu ORCA-ER camera (Hamamatsu) and analysed with Improvision 
Openlab 3 software (Improvision).  
 
2.8.3. Counterstains  
4',6-diamidino-2-phenylindole (DAPI)  is a fluorescent stain that binds strongly to A-T 
rich regions in DNA and was used as a nuclear counterstain. DAPI has an absorption 
wavelength of 358 nm (ultraviolet) and emission at 461 nm (blue). Phalloidin-AlexaFluor-
488 was used to stain actin filament and was visible on the Green channel (absorption = 
495nm, emission 519nm). Both DPAI and Phalloidin were co-incubated with the relevant 
secondary antibody.  
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Table 2.6. Antibodies used in Immunofluorescence microscopy 
     Antibody  Dilution Isotype Company  Clone 
     Primary Antibodies          
     α-CD112 1:10 Mouse IgG Santacruz BC12 
α-CD112 Failed Goat poly IgG Santacruz N20 
α-CD112 Failed Mouse IgG1 Santacruz 3H1817 
α-CD112 Failed Mouse IgG R & D AF229 
α-CD112 Failed Mouse IgG1 Santacruz R2.525 
α-V5 1:1000 Mouse IgG2a AbD Serotec Sv5 Pk1 
     Secondary Antibodies          
Goat α-mouse ALexaFluor 594 1:1000 F(ab')2 fragment Molecular Probes 
 Goat α-mouse ALexaFluor 488 1:1000 F(ab')2 fragment Molecular Probes 
 
     Other         
DAPI 1:10,000 n/a Invitrogen 
 Phalloidin-AlexaFluor 488 1:50 n/a Molecular Probes 
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2.9. FLOW CYTOMETRY  
2.9.1. Cell surface staining protocol 
At the required timepoint post-infection media was removed, cells were washed in PBS 
and incubated in Trypsin/EDTA until cells detached. Once detached, cells were 
resuspended in 10 mL DMEM-10 to neutralise the Trypsin and transferred to 15 mL tubes 
and centrifuged at 1,500rpm for 3minutes at 4°C. The supernatant was discarded and cells 
resupsended in 5 mL ice cold FACS buffer. Cells were then pelleted by centrifugation at 
1,500rpm for 3minutes at 4°C. This washing step was repeated once more. The supernatant 
was again discarded and the cell pellet was resuspended in the appropriate volume of ice 
cold FACS buffer, 200µL for each stain to be undertaken, and 200 µL of cell suspension 
was added to a well of a V-bottom 96well plate.  
The cell samples were incubated with the appropriate concentration of unconjugated 
antibodies, a list of antibodies and concentrations used can be found in table 2.7. 
Incubation with 1°Ab lasted for 30 minutes in a 4°C fridge, with cells being resuspended 
using a multi-channel pipette after 15minutes. After incubation cells were pelleted by 
centrifugation at 1,500rpm for 1 minute at 4°C. The supernatant was removed and cells 
were washed 5 times in ice cold FACS buffer. One wash step consisted of re-suspending 
cells in ice cold washing buffer followed by centrifugation at 1,500rpm for 1 minute at 4°C 
and discarding the supernatant. Cells were finally re-suspended in secondary antibody 
(2°Ab), diluted in ice cold FACS buffer. Incubation with the 2°Ab lasted 30 minutes, in a 
4°C fridge, with re-suspension of cells after 15minutes. After incubation cells were 
pelleted by centrifugation at 1,500rpm for 1 minute at 4°C as above and washed 3x in ice 
cold FACS buffer as described above. After washing cells were fixed in 2% 
Paraformaldehyde and analysed by flow cytometry using a FACSCalibur 
(Dakocytomation, Cambridge) with CELLQuest PRO software (Becton Dickinson). 
FLOW JO software was also used for data analysis. Cells were selected by standard 
forward scatter and side scatter criteria before analysis using the appropriate laser 
excitation.  
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Table 2.7. Antibodies used in Flow cytometry   
 
     Antibody  Dilution Isotype Company  Clone 
     Primary Antibodies          
     α-CD111 1:100 Mouse IgG1 SantaCruz CK6 
α-CD112 1:100 Mouse IgG2b SantaCruz BC12 
α-CD113 1:100 Mouse SantaCruz N.3.82.5 
α-CD155 1:100 Mouse IgG Abcam D171 
α-MHC-1 1:100 Mouse Serotek W632 
α-MicA/B 1:100 Mouse IgG2a Bamomab BAM01 
α-MicB 1:100 Mouse IgG2a Bamomab BAM02 
α-nectin4 1:100 Goat SantaCruz I15 
α-V5 1:1000 Mouse IgG2a AbD Serotec Sv5 Pk1 
Mouse IgG 1:1000 Mouse Sigma 
 
     
     Conjugated secondary antibodies          
Goat α-mouse AlexaFluor 647 1:1000 F(ab')2 fragment Molecualr Probes 
 Goat α-mouse AlexaFluor 488 1:1000 F(ab')2 fragment Molecular Probes 
 Donkey α-goat AlexaFluor 488 1:1000 IgG Molecular Probes 
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3.0. ANALYSIS OF CD112 EXPRESSION DURING HCMV 
INFECTION.   
3.1. Developing assays for the detection of CD112. 
Before the commencement of investigations into the expression of CD112 during HCMV 
infection; it was first necessary to set up appropriate assays to produce the robust, reliable 
and reproducible detection of CD112.  Three assays were initially identified: Flow 
cytometry detection of cell surface CD112, detection of CD112 by immunofluorescence 
and detection of CD112 by immunoblot.  
 
3.1.1. Flow cytometry detected the cell surface expression of CD112 on a 
range of cell lines. 
Endogenous CD112 is expressed at the targets cell surface where it can engage with its 
activating receptor DNAM-1 on effector cells. Endogenous cell surface CD112 can be 
detected by two step flow cytometry, using a primary antibody against CD112 and a 
fluorescent conjugated secondary antibody. Of the antibodies that were commercially 
available upon commencement of the project, only two antibodies had validated and 
recommended uses for flow cytometry, sc-65333 (Santa Cruz) and MCA1937 (Serotek). 
Of the two antibodies tested only sc-65333 (Santa Cruz) was capable of detecting cell 
surface CD112 expression to a satisfactory degree, Figure 3.1. An antibody titration of sc-
65333 indentified a concentration of 1 in 50 gave optimal staining (data not shown).  
HCMV is capable of infecting a range of cell lines including fibroblasts, epithelial and 
endothelial cells (Sinzger et al., 1995). A range of cell lines were tested in order to 
determine base line cell surface expression of CD112 and the other nectins. These cell 
lines included three fibroblast cell lines, primary HFFF’s, HFFF-hTert and HFFF-hCAR 
and two epithelial adenocarcinoma cell lines Hela and Caco-2. Fibroblast and epithelial 
cell lines were seeded at a concentration of 1x10
6 
and 2x10
6
 respectively in a 25cm
2
 tissue 
culture flask. Three days later cells were trypsinised and stained for the cell surface 
expression of mIgG, CD111, CD112, CD113, nectin4, CD155 and MHC-1, Figure 3.2.  
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Figure 3.1. Testing antibodies for the cell surface detection of CD112 by flow 
cytometry.  
Uninfected HFFFs were stained with two antibodies against CD112,  MCA1937, 
Serotec (black) and sc-65333, Santa Cruz (Blue). mIgG (Grey ) was used as a 
negative staining control. 
 
115 
 
 
  
Figure 3.2.  Cell surface 
expression of Nectin family 
members on several 
fibroblast and epithelial cell 
lines. 
HFFF-hCAR (black), HFFF 
(red), HFFF-hTert (blue), 
CaCo2 (green) and Hela 
(purple) cells were seeded into 
a 25cm
2
 tissue culture flask 
and three days later harvested  
and processed for flow 
cytometry to determine cell 
surface expression of the nectin 
family. This included CD111, 
CD112, CD113 and nectin4 as 
well as the nectin like molecule 
CD155 and also MHC class 1.  
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Mouse-IgG is not expressed on human cell lines and is therefore commonly used as a 
negative staining control for non specific binding of antibody. The peak achieved for 
mIgG was therefore used as a baseline for negative staining. In contrast, MHC-1 is 
commonly used as a positive staining control and was expressed on all cell lines tested. 
The three fibroblast cell lines are commonly used within the laboratory and cell surface 
expression levels of MHC-1 were as expected. Both Hela and Caco-2 cells also express 
MHC-1, but have lower expression levels compared to the expression level on fibroblast 
cell lines.  
The cell surface expression of CD112 was detected on all cell lines and expression levels 
were similar on all cell lines irrespective of whether the cell line was epithelial or 
fibroblast in origin. The expression of CD155 was also detected on all cell lines, with 
higher cell surface expression levels on fibroblast cell lines compared with epithelial cells 
lines.  
Nectin 4 could not be detected on any of the cell lines tested. This was as expected as 
nectin 4 is described in the literature as being predominantly detected in the placenta 
(Reymond et al., 2001). Placental tissue was not used as a positive staining control for 
nectin 4, so it was possible that the anti-nectin 4 antibody did not detect nectin 4.  
CD111 could not be detected in any of the fibroblast cell lines tested but could be 
marginally detected in epithelial cell lines. It is possible that the anti-CD111 antibody was 
not detecting CD111 as there are reports of CD111 being detected on both fibroblasts and 
epithelial cell lines (Cocchi et al., 1998). Both CD111 and nectin 4 were not expected to be 
used further in this study so investigations into further reagents were not carried out.   
CD113 was readily detected on all three fibroblast cell lines with the highest detected on 
HFFF’s. CD113 was not detected on Hela cells and marginally detected on the Caco2 cell 
line. CD113 has been described as being ubiquitously expressed in the literature (Satoh-
Horikawa et al., 2000).  
Flow cytometry detection protocols for the cell surface expression of both DNAM-1 
ligands, CD155 and CD112, were successfully set up for the detection of both proteins in 
fibroblast and epithelial cell lines using antibodies sc-65333 (CD112) and D171 (CD155).   
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3.1.2. Immunofluorescence detected CD112 at inter-cellular junctions. 
Tomasec et al (2005) identified CD155 to be sequestered in the ER during HCMV 
infection, thus preventing its cell surface expression. Therefore, a similar effect on CD112 
would not have been surprising. In order to try and visualise CD112, a panel of five 
monoclonal antibodies that had recommended uses for the detection of CD112 in 
immunofluorescence were tested to try and detect CD112 on the surface of uninfected 
cells. The panel of antibodies were tested in a dilution series against uninfected HFFFs in 
order to try and detect CD112. Of the five antibodies tested only one showed staining 
above background levels, Sc-6533 (Santa cruz), at a concentration of 1 in 10 (data not 
shown). However, HFFF’s appear to have extremely low levels of CD112 expression and 
detection was difficult to visualise with expression as small punctate dots throughout the 
cell (Data not shown). Flow cytometry had identified CD112 to be expressed on epithelial 
cell lines and therefore CD112 expression was analysed on human breast adenocarcinoma 
cell line MCF7 and the human colorectal adenocarcinoma Caco2.   
IF detection clearly showed CD112 at cell-to-cell contact sites, being expressed at the 
inter-cellular junctions of adjacent cells but not at the free cellular edges, Figure 3.3. This 
was true for both MCF-7 and Caco-2 cell lines and is in agreement with previous 
descriptions of CD112 expression in the literature (Lopez et al 1998).  
 
3.1.3. Enrichment of CD112 for immunoblotting. 
Endogenous CD112 proved difficult to detect by immunoblotting when using total cell 
lysate of uninfected HFFF’s, Figure 3.4a. Thus a new method was investigated. When cell 
lysates are treated with the non-ionic detergent Triton X-114, integral membrane proteins 
that are amphiphilic in nature, are recovered in the detergent phase, thus allowing their 
concentration and partial purification (Bordier, 1981).  As CD112 is a transmembrane, 
hydrophobic protein when fractionated with Triton X-114 CD112 was found to stably 
associate with the detergent fraction, Figure 3.4a. Using this method, CD112 was found 
almost exclusively in the detergent fraction where two distinct bands could be identified, 
Figure 3.4a. These two bands were of approximately 60 and 55kDA and correlated to the 
predicted protein sizes of 57.5 kDa (CD112-δ) and 51.4 kDa (CD112-α) respectively, 
which were predicted using the ‘predict pI/Mw’ located on the Swiss Institute of 
bioinformatics Expasy website (http://web.expasy.org)(Gasteiger et al., 2003), which  
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Figure 3.3. Detection of CD112 by Immunofluorescence in human epithelial cell lines MCF-7 and CaCo2.  
MCF-7 or CaCo2 cells were seeded into a glass bottom 96-well plate. 2 days post seeding cells were fixed and stained for CD112 (red). Actin 
filaments were stained green using Phalloidin-AlexaFluor-488 and nuclei were stained blue using DAPI. Images were merged to create an 
overlaid image.   
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Figure 3.4 Characterisation of CD112 by immunoblot.  
A) Uninfected HFFF’s were harvested for western blot and were prepared either using total cell lysate  or 
enrichment using Triton-X114. Three fractions, cell debris after lysis, hydrophobic fraction that associates 
with TritonX114 and hydrophilic fraction which does not associate with triton X114 were compared to 
samples prepared by total cell lysis.  B)  The hydrophobic faction of uninfected HFFF’s prepared by 
TritonX114 fractionation were treated with glycosidases, lane 1, undigested, lane 2, ENDO-H digested and 
lane 3, PNGaseF digested. C) a ClustalW alignment of the two CD112 isoforms performed using European 
Bioinformatics  Institutes online ClustalW programme (www.ebi.ac.uk).  
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predicts Isoeletric point and molecular weight of proteins before post translational 
modification from an inputted AA sequence. There were no bands seen in the non-
detergent fraction or in the fraction that consisted of cell debris spun down after cell lysis. 
The bands produced in the detergent fraction provided a cleaner band when compared to 
total cell lysate, where CD112 was difficult to detect and only a faint band could be seen at 
high exposure (high exposure data not shown).  
Enrichment of CD112 in the detergent fraction of Triton X-114 provided a strong signal 
for CD112 and this method was used for the future detection of CD112 by immunoblot. 
3.2. CD112 is a glycoprotein with two isoforms.  
Immunoblot of CD112 revealed that CD112 had two distinct bands in uninfected HFFF’s. 
This could have been due to the different glycosylation status of one protein, or due to two 
different isoforms. CD112 is known to have two isoforms that share approximately 70% 
indentify. The CD112-δ and CD112-α isoforms are identical over their extracellular and 
transmembrane domains but differ in their cytoplasmic domains where there is a 58aa 
deletion in the C-terminus spanning aa480-538, Figure 3.4c.  
Endoglycosidase H (EndoH) is a recombinant glycosidase that cleaves the chitobase core 
of high mannose and some hybrid oligosaccharides from N-linked glycoproteins (Maley et 
al., 1989). Peptide N-Glycosidase F (PNGase F) is an amidase which cleaves between the 
innermost GlcNAc and asparagines residues of high mannose, hybrid, and complex 
oligosaccharides from N-linked glycoproteins (Maley et al., 1989). In essence, EndoH 
digests simple oligosacharrides whereas PNGaseF will strip all oligosaccharides leaving 
the naked protein.  
Following digestion with EndoH the two bands of CD112 appear to be of the same 
molecular weight as those seen in the undigested sample at approximately 60kDa and 
55kDa respectively, Figure 3.4b. Following digestion with PNGaseF, two bands are again 
indentified. The two bands in PNGaseF digestion are of approximately 55kDa and 50kDa 
respectively. As there is one band of approximately 55kDa in both EndoH and PNGaseF 
digested samples it is unclear whether this band is due to the same protein in both samples. 
It was possible the 60kDa and 55kDA proteins were both deglycosylated to 55kDa and 
50kDa by PNGaseF meaning both proteins were glycosylated. A second possibility was 
that the 55kDa band was the same in both samples meaning that the upper 60kDA band 
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seen in the EndoH digested sample was deglycosylated to the 50kDa form seen in 
PNGaseF digested samples. As the two isoforms only differ in their intracellular domains 
and all glycosylation sites are predicted to be in the extracellular domain. It is assumed that 
the bands are due to the two CD112 isoforms that have both been deglycosylated. CD155 
also appears to be glycosylated with a single band of 60kDA in undigested and EndoH 
digested samples and a single band of approximately 40kDa in PNGaseF digested samples. 
This is as expected for proteins that are expressed at the cell surface as they have been 
processed through the ER/Golgi so are resistant to EndoH digestion due to the complex N-
glycosylation, but are sensitive to PNGaseF digestion.  
 
3.3. The product of UL141 is essential but not sufficient for the down-
regulation of CD112 during HCMV infection.  
Once appropriate assays had been established, investigations began into the fate of CD112 
during HCMV infection. HFFF’s were seeded at 1x106 cells in a 25cm2 tissue culture flask 
and infected with HCMV strain Merlin or MerlinΔUL141 and cell surface CD112 
analysed 3 days p.i. UL141 had previously been shown to effect the cell surface expression 
of the DNAM-1 ligand CD155 and so investigations began with the MerlinΔUL141 virus 
to determine whether UL141 may also effect the other DNAM-1 ligand CD112.  
HFFF cells infected with HCMV strain Merlin down-regulated cell surface expression of 
CD112, but when the UL141 ORF was deleted (Merlin ΔUL141) this effect was lost, 
Figure 3.5a. This demonstrated that UL141 was essential for HCMV mediated down-
regulation of cell surface CD112. When UL141 was expressed from a recombinant 
adenoviral vector (RAd-UL141), there was no effect on cell surface CD112 expression 
levels, Figure 3.5c.  Co-infection with both RAd-UL141 and Merlin ΔUL141 rescued the 
Merlin wild type phenotype of CD112 down-regulation, confirming the requirement of 
UL141 in this process, Figure 3.5c, d, e.  
Immunoblot showed that CD112 could not be detected in HCMV strain Merlin infected 
cells but could be detected in MerlinΔUL141 infected cells 3 days p.i., Figure 3.6.  While 
in HFFF-hCAR cells infected with RAd there was no decrease in CD112 seen in RAd-
UL141 infected cells compared to uninfected of RAd-Ctrl (Rad-1253), Figure 3.6b. In  
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Figure 3.5. UL141- mediated downregulation of cell surface CD155 and CD112 . 
HFFF cells were seeded at 1x10
6
/T25cm
2
. The following day cells were infected with either HCMV, RAd or 
both for 2 hours. Cells were analysed by flow cytometry with mAb BC-12 (Santa Cruz) or D171 (Abcam) to 
detect cell surface expression of CD112 or CD155 respectively. (a) Cell surface CD112 on cells infected 
with strain Merlin (red), MerlinΔUL141(blue) or mock infection (black) (b) CD155 cell surface expression 
after infection with Merlin (red), Merlin ΔUL141 (blue) or mock infection (black) (c), CD112 surface 
expression after infection with  RAd-UL141 (red), RAd control (blue) or mock infection (black) (d), CD155 
cell surface expression after infection with RAd-UL141 (red), RAd control(blue) or mock infection (black) 
(e) CD112 cell surface expression after co-infection with RAd-UL141 + Merlin ΔUL141(red), RAd-Control 
+ Merlin (Purple), RAd-Control + Merlin ΔUL141 (blue) or mock infection (Black).   
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Figure 3.6: UL141- mediated downregulation of CD155 and CD112 in HCMV but 
not RAd infection. 
HFFF cells were seeded at 1x10
6
/T25cm
2
. The following day cells were infected with 
either HCMV or RAd for 2 hours. Cells were analysed by western blot to detect CD112. 
(A) detection of CD112, CD155, UL141 and Actin in cells infected with strain Merlin, 
MerlinΔUL141 or mock infection .(B) CD112, UL141 and actin detected in cells infected 
with RAd-Ctrl vector, Rad-UL141 or mock infected cells  
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conclusion, UL141 appeared to be required for the down-regulation of CD112 from the 
cell surface during Merlin infection and CD112 could no longer be detected by 
immunoblot indicating either that CD112 was degraded, or there was an affect before 
translation. 
    
3.4. UL141-GFP cell line does not down-regulate CD112. 
The cell surface expression of CD155 was down regulated in RAd-UL141 infected HFFF-
hCARs, while the cell surface expression of CD112 remained unaffected. To confirm this 
observation the cell surface expression of the DNAM-1 ligands was analysed on a stable 
cell line expressing either UL141-GFP or GFP. Results mirrored those seen in RAd-
UL141 infection, Figure 3.7. The UL141-GFP cell line had almost no cell surface CD155 
expression compared to a GFP expressing cell line. The cell surface expression of CD112 
remained unaffected and was equivalent on the two cell lines. These results confirmed that 
UL141 expressed in isolation had no effect on cell surface expression levels of CD112.    
 
3.5. UL141 was not essential for viral growth/replication.   
The Merlin strain provides one of the most genetically intact and stable HCMV genomes 
for study. However, the tendency of HCMV to accumulate genomic alterations during in 
vitro passage meant that wild type Merlin (wtMerlin) was unsuitable. Instead a BAC 
derived Merlin strain (RCMV1111) was used for this study. A BAC derived virus 
provided a clonal population for study, which is ideally suited for screening as a clinical 
sample could contain a genetically heterogeneous population.  The RCMV1111 contained 
a premature stop codon in UL128 and a mutation in RL13 that prevents infection of 
endothelial cells but is otherwise genetically identical to wtMerlin.  
For this thesis the recombinant virus RCMV1149 (MerlinΔUL141) was regularly utilised. 
It was therefore important to establish whether deletion of the UL141 ORF had any effect 
on viral growth/replication and plaque formation. A single step growth curve for 
RCMV1149 (MerlinΔUL141BAC derived virus) and RCMV1111 (MerlinBAC derived 
virus) were carried out and plaque size was analysed.  HFFF’s were infected with either  
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Figure 3.7. UL141-GFP 293 cells do not downregulate CD112. 
2 x 10
6
 293-GFP cells (black) and UL141-GFP stable transfected 293 cells (Blue) seeded 
into a 25cm
2
 flasks and 3daye p.i. were harvested and analysed for the or cell surface 
expression of CD112 and CD155 by flow cytometry   
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virus at MOI1, supernatant was sampled at regular intervals post infection and titres for 
each sample were calculated. Results showed that there was no significant difference in 
viral growth between Merlin and MerlinΔUL141, Figure 3.8.   
 
3.6. CD112 is notably down-regulated at 2 days p.i. during HCMV 
infection.  
HCMV expresses different genes at different timepoints during the infection cycle defined 
by immediate early (IE), early (E) and Late (L) gene expression. The HCMV virion also 
contains a variety of proteins that act on various cellular mechanisms immediately post 
infection before viral transcription occurs. Identifying the timepoint for when CD112 is 
first down-regulated from the cell surface would narrow down gene candidates to be 
screened.  
Infections were set up and harvested at three different days post infection with RCMV1111 
(Merlin), RCMV 1149 (MerlinΔUL141) or uninfected HFFF’s and cell surface mIgG, 
CD112, CD155 and MHC-1 was analysed by flow cytometry, Figure 3.9. Concurrent 
infections were also harvested and analysed by western blot, Figure 3.10. Flow cytometry 
allowed the detection of cell surface CD112, while western blot provided information on 
total CD112 and gave indications into the fate of CD112 during HCMV infection.   
In RCMV1111 infected HFFF’s, CD112 cell surface levels appeared to show signs of 
down regulation 1 day post infection. By 2 days post infection there was a clear down-
regulation of cell surface CD112, which was equivalent at days 3 and days 4 p.i. The cell 
surface expression of CD112 remained unaffected in MerlinΔUL141 infection as expected,  
Figure 3.9. 
The cell surface expression of CD155 was used as a control as CD155 was known to be 
down-regulated by Merlin, but not MerlinΔUL141 infected cells. As expected CD155 
became down-regulated from the cell surface in Merlin, but not MerlinΔUL141 infections. 
Interestingly CD155 only began to show signs of down-regulation a day 2 post infection 
and was efficiently down-regulated by day 3 post infection. In Merlin ΔUL141 infection, 
CD155 was slightly up-regulated a day 3 post infections, Figure 3.9.  
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Figure 3.8. UL141 is not essential for HCMV growth. 
1x10
6
 HFFFs were infected with Merlin(1111) or MerlineΔUL141 (1149) at MOI1. 
Supernatant samples were taken at day 1, 3, 5, 7, 9 and  11 post infection and titred to 
determine PFU/mL.  
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Figure  3.9 : Timecourse of cell surface expression of CDC112, CD155 and MHC-1 during 
Merlin infection.  
1 x 10
6
 HFFF’s in 25cm2 flasks were infected with Merlin (red), MerlinΔUL141 (blue) or 
uninfected (mock) at MOI 10. On the relevant day post infection cells were harvested and 
analysed for cell surface expression of CD112, CD155 and MHC-1 by flow cytometry.   
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Figure  3.10 : Timecourse of cell surface expression of CD112 
during Merlin and MerlinΔUL141 infection.  
1 x 10
6
 HFFF’s in 25cm2 flasks were infected with Merlin, 
MerlinΔUL141 or uninfected (mock) at MOI 10. On the relevant day 
post infection cells were harvested and analysed for expression of 
CD112, CD155, UL141 and actin by immunoblot.  
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It therefore appeared that CD155 and CD112 were down regulated from the cell surface 
with different kinetics. This could also possibly indicate a different mechanism of action 
against these proteins, or that different proteins are involved in the down-regulation of 
CD155 and CD112.   
When analysed by immunoblot CD112 was detectable at day 1 and day 2 p.i. but not at 
day 3 and day 4 p.i. in Merlin infected cells, Figure 3.10. CD112 was detected in both 
mock infected and MerlinΔUL141 infected cells throughout the timecourse.   
CD155 was found at a lower molecular weight form, ~50kDa, in Merlin infected cells. In 
uninfected and MerlinΔUL141 infected cells CD155 was found at a higher molecular 
weight form, ~60kDa, and CD155 appeared to increase in concentration throughout 
infection. UL141 could be detected in all Merlin infected HFFF’s from day 2 onwards and 
appeared to increase in concentration as the infection progressed. UL141 was not detected 
in MerlinΔUL141 infected cells as expected.  
It should be pointed out that 100% infection was not achieved during a timecourse of 
HCMV infection, figure 3.9. This is evident in the two peaks observed in during cell 
surface staining. The cell surface of MHC-1 clearly showed two clearly defined peaks, 
Figure 3.9., these peaks are representative of infected cells, which down-regulate MHC-1, 
and uninfected cells that up-regulate MHC-1. While the mixed population of infected and 
uninfected cells was not ideal, definitive conclusions could still be drawn due to the 
distinctive cell populations.   
 
3.7. CD112 transcription is not negatively affected during HCMV 
infection.   
A possible hypothesis for CD112 down-regulation was the reduction of CD112 
transcription during HCMV infection. Lower transcript levels could mean that less CD112 
transcript is translated into protein and could therefore account for the reduced protein 
levels observed at the cell surface, providing a mechanism of targeted CD112 down-
regulation.  
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In order to determine whether the transcription of these proteins was affected during 
HCMV infection RT-QPCR was carried out at three different days post infection with 
RCMV1111, RCMV1149 or mock infection. This would provide Real time quantitative 
information for the transcript levels of CD155 and CD112. The relative quantity (RQ) of 
transcripts were determined by normalising to the concentration of candidate transcripts to 
both Actin and GAPDH separately, which are standard house-keeping genes used in RT-
QPCR techniques.  
The dataset was analysed by Peter Giles in Central Biotechnology services (CBS) for 
statistical analysis using a Post Turkey test and showed no statistically significant 
differences between expression levels in viral infection conditions and the same day mock 
infected cells. However, differences of expression were visually apparent when candidates 
were calibrated to either Actin or GAPDH. Results calibrated to GAPDH appear to show 
more conservative changes in expression than when calibrated to Actin levels. However 
the same general trends emerge: 
Infection of HFFF’s with either RCMV1111 or RCMV1149 appeared to show similar 
trends of increases in transcription for both CD112 and CD155 transcripts. This suggested 
that the deletion of the UL141 gene from the virus had little effect on the transcriptional 
profile of CD112 and CD155. This was an important observation as it demonstrated that 
HCMV infection does not down-regulate CD112 at the transcriptional level.   
During both RCMV1111 and RCMV1149 infections CD112 mRNA appeared to be up-
regulated at Day 1 post-infection with levels remaining at similar levels for the duration of 
the experiment. The same trend was seen when data were normalised against Actin or 
GAPDH. Both the FACS and immunoblot data, Figure 3.9 and Figure 3.10. respectively, 
showed CD112 beginning to become down-regulated at 24 hours post infection and at 
48hours post-infection a solid down-regulation was observed. Therefore, when the RNA 
transcription data was evaluated in conjunction with the protein expression analysis it 
appeared that CD112 was affected at a translational or post-translational level early on in 
the infection cycle, thus likely to be by an early (E) or immediate early (IE) HCMV 
protein.  
In contrast to CD112, the transcript levels of CD155 appeared to be unaffected at Day 1 
post-infection but levels appeared to increase as the infection progressed, Figure 3.11. This 
correlated with western blot data showing the levels of CD155 increased over the course of  
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Figure 3.11. RT-QPCR analysis of CD112 and CD155 transcription during RCMV infection. 
1 x 10
6 
HFFF cells were infected with RCMV1111 (Red), RCMV1149 (Green) or mock infection 
(Blue). At day 1, day 2 or day 3 post-infection cells were lysed in 1 mL of Tri-reagent (Sigma) and 
stored at -80°C until required. RNA was extracted followed by Reverse transcription PCR using the 
random hexamer method. The cDNA was analysed by QPCR using the Sybr green technique. 
Relative quantity (RQ) gene expression values were calculated based on the comparative threshold 
cycle (Ct) as described in Livak and Schmittgen (2001), where both β-Actin and GAPDH were 
independently used as calibrators.  
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an infection, Figure 3.10. Results suggested that mechanisms controlling both the 
expression and down regulation of expression of CD112 and CD155 were controlled 
independently of each other.    
When GAPDH and Actin were normalised to each other, Figure 3.11., expression levels 
gave a RQ of approximately one which was consistent with their use as reference house-
keeping genes and as appropriate calibrators in the analysis and interpretation of RQ PCR 
data.  
However, due to the small dataset it is impossible to perform reliable statistics or make any 
definitive conclusions. Even though in some cases there was an ‘up-regulation’ by two 
fold this is still regarded as not being particularly noticeable above background noise. For 
example in gene chip experiments a difference of greater than 5-fold is generally required 
to register a positive hit. What can be clearly concluded from this data is that the 
transcription of CD112 was not silenced or negatively affected by HCMV infection and 
that transcriptional silencing during HCMV infection is unlikely to be the cause of CD112 
down-regulation. Rather CD112 down-regulation must occur at a translational or post-
translational level.   
 
 3.8. Conclusion 
CD112, an activating ligand for NK receptor DNAM-1, is a glycoprotein expressed as two 
isoforms in uninfected HFFF cells. During HCMV infection CD112 appeared to be down-
regulated from the cell surface from day 2 p.i. onwards. During HCMV infection CD112 is 
no longer detectable by western blot from day 3 p.i. The HCMV gpUL141 appeared to be 
involved in this process as deletion from Merlin prevented CD112 down-regulation. 
However when UL141 was expressed in isolation from a RAd or in a stable cell line there 
appeared to be no effect on CD112 cell surface expression. RT-QPCR showed no 
statistically significant difference in transcript levels between Merlin and MelrinΔUL141 
infected HFFF’s, indicating that transcriptional silencing during HCMV infection was 
unlikely to be the cause of CD112 down-regulation. Instead the down-regulation CD112 
cell surface expression was likely to occur at a translational or post-translational level.     
  
134 
 
4.0. SCREENING STRATEGY FOR THE IDENTIFICATION OF 
GENE(S) RESPONSBILE FOR CD112 DOWN-REGULATION.  
4.1. Identification of screening strategy 
Data presented in chapter 3.0 imply that UL141 acts in concert with at least one other 
HCMV gene product to down-regulate cell surface expression of CD112. The subsequent 
aim of experiments carried out in chapter 4.0 was to identify a second gene essential for 
CD112 down-regulation by the methodical screening of the HCMV genome. Two 
complementary approaches were projected:  
1. Screen of a library of 8 HCMV block deletion mutants, covering 46 genes in the HCMV 
genome, for a loss of the ability to down-regulate CD112. This approach anticipated that 
the second HCMV gene acting with UL141 played an essential role in CD112 down-
regulation and its deletion would restore CD112 cell surface expression.  
2. Screen of a library of 166 RAd vectors encoding individual HCMV genes co-infected 
with RAd-UL141 for a gain of the ability to down-regulate CD112, anticipating that a 
combination of two specific HCMV genes would be sufficient for this effect. 
Both approaches were predicted to independently identify gene(s) involved in CD112 
down-regulation.  
4.2. Identification of appropriate screening assays.   
Before commencing screening an appropriate assay was sought that would provide both 
high throughput potential and a robust and reliable readout in order to efficiently screen 
through the large number of potential targets. Four approaches were identified. 
Approaches 1-3 were based on the finding that CD112 appeared to be degraded during 
HCMV infection. Approach 4 was based on the finding that CD112 cell surface expression 
was down-regulated during HCMV infection.  
1. Co-infection of HCMV with RAd-CD112-mCherry; the RAd vector construct would 
provide expression of fluorescently tagged CD112-mCherry, thus enabling sensitive and 
live monitoring of expression using mCherry fluorescence. 
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2.  Co-infection of RAd-CD112-mCherry with RAd-UL141 and RAd vectors encoding 
individual HCMV genes. This would allow the live monitoring of expression intensity and 
cellular localisation to be monitored. Spectrophotometry would allow the measurement of 
florescence intensity.   
3. Analysis of the expression of endogenous CD112 by immunoblotting. Method was 
optimised in chapter 3.0. to enhance sensitivity.  
4. Analysis of CD112 cell surface expression by Flow cytometry. Method was optimised 
in chapter 3.0. to provide reliable and robust readout.   
A timecourse of CD112 expression in chapter 3.0., figure 3.9 and Figure 3.10., identified 
both CD112 and CD155 to be down-regulated at 3 days p.i. This timepoint was therefore 
chosen for the development of screening assays.  
 
4.2. Developing screening system to detect CD112 down-regulation by 
CD112-mCherry over-expression  
A 96 well plate assay format was sought as a primary screening method in order to exploit 
its high throughput potential. A CD112-mCherry reporter was used as it simultaneously 
allowed the assessment of changes in fluorescence intensity and intracellular localisation 
of CD112-mCherry. Since HCMV UL141 re-localised CD155 from the cell surface to the 
ER, a similar fate befalling CD112 would not have been surprising. Two approaches 
utilising RAd-CD112-mCherry were identified: Co-infection of RAd-CD112-mCherry 
with either (1) HCMV or (2) RAd expressing individual HCMV ORFs.   
 
4.2.1 Co-infection of HCMV and RAd-CD112-mCherry 
During initial assay development, HFFF’s, were co-infected with HCMV strain Toledo 
encoding GFP (HCMV-GFP) and either RAd-CD112-mCherry or RAd-CD155-mCherry. 
RAd-CD155-mCherry was to be used as a control as CD155 is sequestered in the ER 
during HCMV infection (Tomasec et al., 2005). The tracking of productive HCMV 
infection was monitored as GFP fluorescence, expression of GFP being driven by HCMV 
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2.7 early promoter, while the expression of mCherry allowed changes in CD112 
localisation or intensity to be monitored.  
Cells were seeded at 5x10
5
 across a glass bottomed 96-well plate and 3days p.i. infections 
were fixed and fluorescence monitored using fluorescent microscopy.  Interestingly, at 
3days p.i., cells appeared either green (HCMV infection) or red (RAd infection) and the 
proportion of HCMV infected cells (green) decreased with increasing RAd-CD112-
mCherry MOI (red) (figure not shown). This implied: 
a) HCMV infection induced efficient degradation of CD112-mCherry. 
b) Exclusive infections with either HCMV-GFP or RAd-CD112-mCherry. 
c) HCMV infection had a negative effect on the promoter driving CD112-mCherry 
expression. 
d) CD112-mCherry expression had a negative effect on HCMV replication or GFP 
expression.  
In an attempt to address point b), RAd magnetofection (Combimag, OzBiosciences) was 
used to force HCMV and RAd-CD112-mCherry co-infection. Magnetofection is a process 
of enhancing receptor-independent RAd infection using magnetic nanoparticles.  
Cells were infected with Toledo-GFP and 2 hours later magnetofected with RAd-CD112-
mCherry or control RAd-CD155-mCherry. HCMV infection was monitored as green 
fluorescence and CD112-mCherry or CD155-mCherry as red fluorescence. Results clearly 
indicated that successful Toledo-GFP and RAd co-infection occurred using this approach 
as the same cell expressed both GFP and mCherry, although GFP expression was weak in 
cells expressing CD112-mCherry compared to infected cells expressing CD155-mCherry 
(data not shown). This was in agreement with the hypothesis that the over expression of 
CD112-mCherry either a) inhibited the progression of HCMV infection or b) inhibited 
expression of GFP from 2.7 early promoter.  
Following the verification the co-infection of HCMV with RAd using magnetofection 
technique, the assay setup was tested in a final format imitating the projected screen of 
library of HCMV mutants. Cells infected with HCMV Merlin (down-regulates CD112) or 
HCMV MerlinΔUL141 (does not down-regulate CD112) were magnetofected with either 
RAd-CD155-mCherry or RAd-CD112-mCherry. As expected, when HCMV Merlin was  
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co-infected with RAd-CD155-mCherry, the CD155-mCherry formed intracellular foci, 
Figure 4.1. However, in cells infected with RAd-CD112-mCherry no obvious difference in 
CD112-mCherry localisation could be observed between Merlin and MerlinΔUL141 
infections, Figure 4.1. It was therefore concluded that this method was not suitable for high 
throughput screening.  
 
4.2.2. Co-infection of RAd-CD112 mCherry, RAd-UL141 and a RAd 
from the HCMV-RAd-library 
A 96-well plate assay format was sought in order to exploit the potential for a high 
throughput assay with robust readout.  The basis of the assay was co-infection of RAd-
CD112-mCherry with RAd-UL141 plus RAd vectors encoding individual HCMV genes. 
The readout for the assay was primarily a visual one with wells monitored for changes in 
both CD112-mCherry florescent intensity (due to degradation or inhibited transcription) 
and for changes in CD112-mCherry subcellular location (e.g. ER retention). As UL141 
retains CD155 in the ER, a similar effect on CD112 would not have been surprising as 
UL141 is also involved in the down-regulation of CD112 from the cell surface (Figure 
3.5.) Changes in florescence intensity were to be later reconfirmed by spectrophotometry.  
However, it became evident that expression of CD112-mCherry from RAd was unsuitable 
for use with the HFFF-hCAR cell line. As early as 1 day after infection of cells with RAd-
CD112-cherry, the fluorescence intensity of CD112-cherry was oversaturated and it was 
therefore problematic to analyse or image CD112-mCherry expression patterns, Figure 4.2. 
In addition CD112-mCherry showed unexpected localisation, forming intense Intracellular 
foci throughout the cell making imaging and analysis difficult as the image became over 
saturated even at low exposure levels, Figure 4.2. While it was not anticipated that CD112 
would form these intracellular foci, atypical aggregation of fusion proteins has been 
described before (Shaner et al., 2005). In contrast cells infected with CD155-mCherry 
showed expected/typical expression patterns and expression gradually increased 
throughout the course of infection with optimum detection 3 days p.i., Figure 4.2. At this 
time-point CD112-mCherry was so intense that it made visualisation near impossible.  
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Figure 4.1. Magnetofection ensured the co-infection of HCMV and RAd-mCherry. 
HFFF cells were seeded 1x10
6
 / 96well plate. The following day cells were infected with Merlin 
(RCMV1111) or MerlinΔUL141 (RCMV1149). 2 hours post CMV infection cells were 
coinfected with either RAd-CD112-mCherry or RAd-CD155-mCherry using magnetofection. 
CD112 and CD155 expression was monitored by m-Cherry fluorescence. Cells were fixed 
3days p.i. in 2% paraformaldehyde and images taken using florescence microscopy.     
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Figure 4.2. Expression of RAd-CD112-mCherry and RAd-CD155-mCherry in uninfected HFFF-
hCARs  
1 x 10
6
 HFFFF-hCARs in 96 well plate were infected with 5PFU/cell of RAd-CD112-mCherry or RAd-
CD155-mCherry. Day 1, 2 and 3 post infection cells were monitored for mCherry expression by 
florescent microscopy. Images are taken with an exposure of 0.015seconds.  
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It was therefore concluded that this 96-well plate assay format was not suitable for high 
throughput screening. It was also concluded any screening method involving the RAd-
CD112-mCherry was unsuitable due to the intense overexpression and atypical subcellular 
localisation of CD112-mCherry.   
 
4.3. Commencement of large scale screening project 
Flow cytometry had shown to be a reliable method for the detection of cell surface CD112, 
producing robust and highly repeatable results. Flow cytometry was therefore chosen as 
the primary screening method for both the HCMV block deletion library and the RAd-
HCMV-ORF library as this method allowed for a higher throughput than using 
immunoblot. Screening began with infection of HFFF’s with HCMV mutants that 
contained block deletions of non-essential HCMV genes, table 4.1. 
 
Table 4.1. HCMV block deletion library   
RCMV 
designation  
Comment  MOI 
1278 Control RCMV. Containing mutation in RL13 and 
UL128. UL32-GFP tagged, ΔUL16, ΔUL18. N.B. All 
other RCMV block deletion mutants were derived from 
this construct.    
20 
1293 ΔUL2 - UL11  10 
1295 ΔUL22A – UL25  10 
1297 ΔUS12 – US17  20 
1299 Δ US27 – US28  50 
1300 Δ US29 – US34a  15 
1318 ΔUS18-US22 50 
1332 ΔRL1 – RL6R  25 
1333 ΔRL10 – UL1  10 
 
 
  
141 
 
4.3.1. Effect of block deletions in HCMV genome on CD112 expression. 
Recombinant HCMVs (RCMVs) with block deletions of non essential ORFs were 
previously constructed by Dr R Stanton within the laboratory, Figure 4.3/Table 4.1. All 
Block deletion mutants also included deletions in UL16 and UL18, known immunoevasion 
functions.  UL16 inhibits NK cell cytotoxicity though sequestration of ULBP1,2 and 
MICB, while UL18 encodes a MHC class 1 homologue. Both these genes protect Merlin 
infected cells from NK cell cytotoxicity. Deletion of UL16 and UL18 allowed for RCMV 
infected cells to be utilised for NK assays in a separate laboratory project, while the 
presence of UL141 facilitated the usage of HCMV block deletions in screening assays for 
CD112 down-regulation. RCMV block deletions also contained a UL32-GFP fusion which 
allowed infections to be monitored through GFP expression. The RCMV1278 
(MerlinUL32-GFPΔUL16ΔUL18) was the parental strain from which all other block 
deletions were constructed. RCMV1278 down-regulated CD112, CD155 and MHC-1 and 
was used as the control for screening the block deletion mutant library, Figure 4.4.   
RCMV block deletions were screened for a loss of the ability to down regulate the 
expression of CD112 (similar to the effect observed with UL141 deletion, figure 3.5) and 
therefore a loss of function. A positive outcome of this screen would identify a second 
function targeting CD112 and would also significantly narrow down the number of ORFs 
(those within a particular block deletion) for follow-up studies. 
A total of 8 block deletions were initially screened, table 4.1., spanning regions of HCMV 
genes non essential for growth in fibroblasts. Infections were optimised to determine MOIs 
that gave similar levels of GFP expression, as determined by fluorescence microscopy 
detecting UL32-GFP (data not shown). MOIs for each virus can be found in Table 4.1.    
At 3 days p.i. infections were harvested and analysed by two-step cell surface staining via 
flow cytometry and analysed using FlowJo software. A live cell gate was drawn 
determined by comparing forward scatter against side scatter according to laboratory 
protocol. As HCMV block deletions contained GFP tagged UL32, RCMV infected cells 
were gated on by plotting Side scatter of live cells against FL1 (GFP). Gating in this way 
revealed two distinct populations of GFP positive, HCMV infected cells. These were 
classified as GFP low and GFP high populations, Figure 4.4.  
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Figure 4.3. Merlin block deletion mutants. 
Map of HCMV strain Merlin genome with deleted regions marked. The indicated blocks were individually 
deleted to generate a panel of viruses, covering between them 46 HCMV ORFs. All deletions were made 
in the strain Merlin BAC containing mutations in RL13 & UL128. GFP was fused to UL32 to enable 
tracking of virus. To facilitate functional readouts, UL16 and UL18 were also deleted in all mutants - these 
have previously been shown to modulate the NK response. Modified from Dolan et al (2004)  
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Figure 4.4 Baseline RCMV1278 infection for the screening HCMV block deletion library 
HFFF cells were seeded 1x10
6
 in a 25cm
2
 tissue culture flask. The following day cells were infected with 
HCMV1278, control infections for HCMV block deletions. 3 days post infection cells were harvested 
and analysed . A) Infected cells were gated on GFP high cells for analysis. B) light image and GFP 
images of infections were taken to  visually confirm infection. C) HCMV1278 infected cells were gated 
on GFP high population and analysed for cell surface expression of CD112, CD155 and MHC1 shown in 
red, compared to the cell surface expression of CD112, CD155 and MHC1 on uninfected cells, shown in  
black.  
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Cells were infected at MOIs described in table 4.1. The cell surface expression of CD155, 
CD112 and MHC-1 were analysed on live, GFP-high cells. All 8 block deletion mutants 
tested were capable of down-regulating both CD155 and CD112 to as similar degree as 
control HCMV1278 infections, Figure 4.5 and Figure 4.6. As all block deletions were 
capable of down-regulating cell surface CD112 then a second function targeting CD112 is 
likely to lie outside of the genes deleted in block deletion mutants. 
 4.4. Conclusion  
Flow cytometry was considered to be the most effective method for use in large scale 
screening due to its robust and reliable output. A panel off 8 RCMVs containing block 
deletions of non-essential HCMV genes were screened and all were found to down-
regulate cell surface CD112 to as a similar degree as control RCMV1278. If any of the 
deleted genes were essential in CD112 down-regulation there would have been a loss of 
function and CD112 expression levels would not be down-regulated as in RCMV1278 
infection. CD155 and MHC-1 were also all down-regulated from the cell surface as 
expected. The deleted genes, totalling 46 were therefore concluded to have a non-essential 
role in CD112 down-regulation, leaving 121 potential gene candidates for further 
screening using a recombinant Adenovirus library expressing individual HCMV ORFs. 
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Figure 4.5. Screening results for the HCMV block deletion library: RCMV1293, RCMV 1295, 
RCMV1297 and RCMV1298  
HFFF cells were seeded 1x10
6
 in a 25cm
2
 tissue culture flask, one flask per infection.  The following day 
cells were infected with RCMV1278, RCMV1293, RCMV 1295, RCMV1297 and RCMV1298. 3 days 
post infection cells were harvested and analysed for cell surface expression of CD112, CD155 and MHC-
1. Infected cells were analysed on GFP high population determined be side scatter plotted against GFP.  
Cell surface expression of block deletion viruses (red) were compared to those for HCMV1278, the control 
HCMV for the block deletions (blue)  
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Figure 4.6. Screening results for the HCMV block deletion library: RCMV1300, RCMV 1318, 
RCMV1332 and RCMV1333. 
HFFF cells were seeded 1x10
6
 in a 25cm
2
 tissue culture flask, one flask per infection.  The following day 
cells were infected with HCMV1278, HCMV1293, HCMV 1295, HCMV1297 and HCMV1298. 3 days post 
infection cells were harvested and analysed for cell surface expression of CD112, CD155 and MHC-1. 
Infected cells were analysed on GFP high population determined be side scatter plotted against GFP.  Cell 
surface expression of block deletion viruses (red) were compared to those for HCMV1278, the control 
HCMV for the block deletions (blue)  
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5.0. CHARACTERISATION OF THE INTRACELLULAR 
LOCALISATION OF HCMV PROTEINS EXPRESSED FROM RAD 
BY IMMUNOFLUORESCENCE 
 
As part of a long running research theme within the laboratory into the study of HCMV 
gene function; work over the last three years by Dr James Davies and Mr Sepehr Seirafian 
has been centred on the generation of a recombinant Adenovirus library expressing 
individual HCMV strain Merlin ORFs (RAd-HCMV-ORF library). The HCMV genome 
was re-annotated by Dr Andrew Davison, Glasgow University, and ORFs were designated 
as per his most recent annotation (Gatherer et al., 2011). The re-annotation was based on 
deep sequencing of the Merlin genome, transcriptional profiling during productive HCMV 
infection and comparison of the HCMV genome with CCMV to determine likely HCMV 
ORFs (Davison, 2003, Dolan, 2004, Gatherer et al., 2011). This resulted in  170 ORFs 
being designated and all were cloned into RAd vectors using the recombineering technique 
developed by Dr Richard Stanton (Stanton, 2008).  
The RAd-HCMV-ORF library was to be utilised in the screening for HCMV genes 
involved in CD112 down-regulation through co-infection with UL141. As this project was 
the first to use the entire RAd-HCMV-ORF library it was first important to establish 
transgene expression occurred from these vectors. Since each HCMV ORF is V5-tagged, 
anti-V5 immunofluorescent staining (IF) of HFFF-hCAR’s infected with a RAd from the 
RAd-HCMV-ORF library was chosen to both confirm transgene expression and also 
provide qualitative data on the cellular location of each expressed protein.   
The screen was carried out in collaboration with Mr Sepher Seiferian, a fellow PhD 
student in the laboratory who also used the RAd-HCMV-ORF library in a separate project. 
In order to quickly generate data, the decision was taken for Mr Seiferian and I to each 
take half of the RAd-HCMV-ORF library. Mr Seiferian screened from RL1-UL40 and 
UL111A-UL150 and IRS1, figure 4.3, and I screened the remaining RAd-HCMV-ORF’s 
from UL41A-UL105 and all US genes from US1-US34A and TRS1, figure 4.3. The 
transgene expression data for my section, UL41A-UL105, US1-US34A and TRS1, will be 
the subsequent focus of this chapter. Mr Seiferian’s data for RL1-UL40 and UL111A-
UL150 and IRS1 can be found in appendix 1 but will not be analysed in this thesis.  
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5.1. Transgene detection  
Many of the HCMV genes are poorly studied and as a result there are few reagents 
available that allow the detection of individual HCMV protein products. In order to 
facilitate transgene expression studies all transgene ORFs in the RAd-HCMV-ORF library 
were C-terminally tagged with a V5 epitope tag.  The V5 tag is a 14 amino acid sequence, 
GKPIPNPLLGLDST, and was chosen as the epitope is relatively short so should have had 
minimal impact on transgene protein structure and function. There are also high affinity 
reagents available that allow the detection of V5, facilitating further downstream studies.   
HFFF-hCAR cells were infected with a single RAd from the RAd-HCMV-ORF library at 
MOI10 in a glass bottomed 96well plate. At 72hrs p.i. cells were fixed and the V5 tag was 
exploited for immunofluorescent staining of infected cells to test for transgene expression 
using a monoclonal anti-V5 mAb. A secondary α-mouse IgG(FAb’) AlexaFluor- 594 
conjugate (red channel) was used to detect the anti-V5 antibody and staining was observed 
by fluorescent microscopy using a x40 oil objective. RAd1253 is an empty vector control 
containing no transgene but contained the V5 sequence. Staining was carried out on 
uninfected (data not shown) and control RAd-1253 infected HFFF-hCARs as a negative 
staining control to prevent false positive results due to non-specific binding of the anti-V5 
primary or non specific binding of the anti-mouse secondary antibody, figure 5.11. To 
assess cellular location of detected transgenes the nuclear counterstain DAPI (blue 
channel), and phalloidin AlexaFluor-488 that stained actin filaments (green channel), were 
also included.   
Of the UL41A to UL105 and US1-TRS1 region screened, protein expression was 
confirmed and localisation data was obtained for 79 out of 85 transgenes, figures 5.1 – 
5.10.  
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Figure 5.1. Immunofluorescent staining of cells infected with a RAd from the RAd-HCMV-ORF 
library to determine transgene expression and subcellular location: UL41A-UL48 
HFFF-hCARs were seeded at a concentration of 5x10
5
 in a glass bottomed 96-well plate. The following 
day HFFF-hCAR’s were infected with a RAd from the RAd-HCMV-ORF library, as indicated, at MOI10 
for 2hrs in an incubator 37°
C
, 5%CO2 on an oscilating platform at 5 osc.min. After 2hours, media was 
removed and replaced with fresh DMEM-10 and incubated for 3days. After incubation cells were washed 
in PBS, fixed in 2% paraformaldehyde and underwent immunofluorescence staining using Saponin based 
IF-buffer. Antibodies were used as follows: Primary mouse anti-V5 was used 1 in 2,000, phalloining-488 
1 in 50, DAPI 1 in 10,000 and a secondary α-mouse IgG(FAb’) AlexaFluor- 594 conjugate (red channel) 
was used to detect anti-V5, used 1 in 500. Cells were fixed and imaged using fluorescent microscopy 
using a x40 oil objective. Two images are shown for each transgene. The first is individual transgene 
expression as detected with anti-V5 primary (red channel). The second is a merged image consisting 
of transgene expression (red channel), phalloidin-488 (green channel) and DAPI (Blue channel).  
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  Figure 5.2. Immunofluorescent staining of cells infected with a RAd from the RAd-HCMV-ORF 
library to determine transgene expression and subcellular location: UL48A-UL55. 
HFFF-hCARs were seeded at a concentration of 5x10
5
 in a glass bottomed 96-well plate. The following 
day HFFF-hCAR’s were infected with a RAd from the RAd-HCMV-ORF library, as indicated, at MOI10 
for 2hrs in an incubator 37°
C
, 5%CO2 on an oscilating platform at 5 osc.min. After 2hours, media was 
removed and replaced with fresh DMEM-10 and incubated for 3days. After incubation cells were washed 
in PBS, fixed in 2% paraformaldehyde and underwent immunofluorescence staining using Saponin based 
IF-buffer. Antibodies were used as follows: Primary mouse anti-V5 was used 1 in 2,000, phalloining-488 
1 in 50, DAPI 1 in 10,000 and a secondary α-mouse IgG(FAb’) AlexaFluor- 594 conjugate (red channel) 
was used to detect anti-V5, used 1 in 500. Cells were fixed and imaged using fluorescent microscopy 
using a x40 oil objective. Two images are shown for each transgene. The first is individual transgene 
expression as detected with anti-V5 primary (red channel). The second is a merged image consisting 
of transgene expression (red channel), phalloidin-488 (green channel) and DAPI (Blue channel).  
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Figure 5.3. Immunofluorescent staining of cells infected with a RAd from the RAd-HCMV-ORF 
library to determine transgene expression and subcellular location: UL56-UL74. 
HFFF-hCARs were seeded at a concentration of 5x10
5
 in a glass bottomed 96-well plate. The following 
day HFFF-hCAR’s were infected with a RAd from the RAd-HCMV-ORF library, as indicated, at MOI10 
for 2hrs in an incubator 37°
C
, 5%CO2 on an oscilating platform at 5 osc.min. After 2hours, media was 
removed and replaced with fresh DMEM-10 and incubated for 3days. After incubation cells were washed 
in PBS, fixed in 2% paraformaldehyde and underwent immunofluorescence staining using Saponin based 
IF-buffer. Antibodies were used as follows: Primary mouse anti-V5 was used 1 in 2,000, phalloining-488 
1 in 50, DAPI 1 in 10,000 and a secondary α-mouse IgG(FAb’) AlexaFluor- 594 conjugate (red channel) 
was used to detect anti-V5, used 1 in 500. Cells were fixed and imaged using fluorescent microscopy 
using a x40 oil objective. Two images are shown for each transgene. The first is individual transgene 
expression as detected with anti-V5 primary (red channel). The second is a merged image consisting 
of transgene expression (red channel), phalloidin-488 (green channel) and DAPI (Blue channel).  
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  Figure 5.4. Immunofluorescent staining of cells infected with a RAd from the RAd-HCMV-ORF 
library to determine transgene expression and subcellular location: UL75-UL83. 
HFFF-hCARs were seeded at a concentration of 5x10
5
 in a glass bottomed 96-well plate. The following 
day HFFF-hCAR’s were infected with a RAd from the RAd-HCMV-ORF library, as indicated, at MOI10 
for 2hrs in an incubator 37°
C
, 5%CO2 on an oscilating platform at 5 osc.min. After 2hours, media was 
removed and replaced with fresh DMEM-10 and incubated for 3days. After incubation cells were washed 
in PBS, fixed in 2% paraformaldehyde and underwent immunofluorescence staining using Saponin based 
IF-buffer. Antibodies were used as follows: Primary mouse anti-V5 was used 1 in 2,000, phalloining-488 
1 in 50, DAPI 1 in 10,000 and a secondary α-mouse IgG(FAb’) AlexaFluor- 594 conjugate (red channel) 
was used to detect anti-V5, used 1 in 500. Cells were fixed and imaged using fluorescent microscopy 
using a x40 oil objective. Two images are shown for each transgene. The first is individual transgene 
expression as detected with anti-V5 primary (red channel). The second is a merged image consisting 
of transgene expression (red channel), phalloidin-488 (green channel) and DAPI (Blue channel).  
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Figure 5.5. Immunofluorescent staining of cells infected with a RAd from the RAd-HCMV-ORF 
library to determine transgene expression and subcellular location: UL84-UL92. 
HFFF-hCARs were seeded at a concentration of 5x10
5
 in a glass bottomed 96-well plate. The following 
day HFFF-hCAR’s were infected with a RAd from the RAd-HCMV-ORF library, as indicated, at MOI10 
for 2hrs in an incubator 37°
C
, 5%CO2 on an oscilating platform at 5 osc.min. After 2hours, media was 
removed and replaced with fresh DMEM-10 and incubated for 3days. After incubation cells were washed 
in PBS, fixed in 2% paraformaldehyde and underwent immunofluorescence staining using Saponin based 
IF-buffer. Antibodies were used as follows: Primary mouse anti-V5 was used 1 in 2,000, phalloining-488 
1 in 50, DAPI 1 in 10,000 and a secondary α-mouse IgG(FAb’) AlexaFluor- 594 conjugate (red channel) 
was used to detect anti-V5, used 1 in 500. Cells were fixed and imaged using fluorescent microscopy 
using a x40 oil objective. Two images are shown for each transgene. The first is individual transgene 
expression as detected with anti-V5 primary (red channel). The second is a merged image consisting 
of transgene expression (red channel), phalloidin-488 (green channel) and DAPI (Blue channel).  
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 Figure 5.6. Immunofluorescent staining of cells infected with a RAd from the RAd-HCMV-ORF 
library to determine transgene expression and subcellular location: UL93-UL100. 
HFFF-hCARs were seeded at a concentration of 5x10
5
 in a glass bottomed 96-well plate. The following 
day HFFF-hCAR’s were infected with a RAd from the RAd-HCMV-ORF library, as indicated, at MOI10 
for 2hrs in an incubator 37°
C
, 5%CO2 on an oscilating platform at 5 osc.min. After 2hours, media was 
removed and replaced with fresh DMEM-10 and incubated for 3days. After incubation cells were washed 
in PBS, fixed in 2% paraformaldehyde and underwent immunofluorescence staining using Saponin based 
IF-buffer. Antibodies were used as follows: Primary mouse anti-V5 was used 1 in 2,000, phalloining-488 
1 in 50, DAPI 1 in 10,000 and a secondary α-mouse IgG(FAb’) AlexaFluor- 594 conjugate (red channel) 
was used to detect anti-V5, used 1 in 500. Cells were fixed and imaged using fluorescent microscopy 
using a x40 oil objective. Two images are shown for each transgene. The first is individual transgene 
expression as detected with anti-V5 primary (red channel). The second is a merged image consisting 
of transgene expression (red channel), phalloidin-488 (green channel) and DAPI (Blue channel).  
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Figure 5.7. Immunofluorescent staining of cells infected with a RAd from the RAd-HCMV-ORF 
library to determine transgene expression and subcellular location: UL102-UL105 and US2-US7. 
HFFF-hCARs were seeded at a concentration of 5x10
5
 in a glass bottomed 96-well plate. The following 
day HFFF-hCAR’s were infected with a RAd from the RAd-HCMV-ORF library, as indicated, at MOI10 
for 2hrs in an incubator 37°
C
, 5%CO2 on an oscilating platform at 5 osc.min. After 2hours, media was 
removed and replaced with fresh DMEM-10 and incubated for 3days. After incubation cells were washed 
in PBS, fixed in 2% paraformaldehyde and underwent immunofluorescence staining using Saponin based 
IF-buffer. Antibodies were used as follows: Primary mouse anti-V5 was used 1 in 2,000, phalloining-488 
1 in 50, DAPI 1 in 10,000 and a secondary α-mouse IgG(FAb’) AlexaFluor- 594 conjugate (red channel) 
was used to detect anti-V5, used 1 in 500. Cells were fixed and imaged using fluorescent microscopy 
using a x40 oil objective. Two images are shown for each transgene. The first is individual transgene 
expression as detected with anti-V5 primary (red channel). The second is a merged image consisting 
of transgene expression (red channel), phalloidin-488 (green channel) and DAPI (Blue channel).  
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Figure 5.8. Immunofluorescent staining of cells infected with a RAd from the RAd-HCMV-ORF 
library to determine transgene expression and subcellular location: US8-US18. 
HFFF-hCARs were seeded at a concentration of 5x10
5
 in a glass bottomed 96-well plate. The following 
day HFFF-hCAR’s were infected with a RAd from the RAd-HCMV-ORF library, as indicated, at MOI10 
for 2hrs in an incubator 37°
C
, 5%CO2 on an oscilating platform at 5 osc.min. After 2hours, media was 
removed and replaced with fresh DMEM-10 and incubated for 3days. After incubation cells were washed 
in PBS, fixed in 2% paraformaldehyde and underwent immunofluorescence staining using Saponin based 
IF-buffer. Antibodies were used as follows: Primary mouse anti-V5 was used 1 in 2,000, phalloining-488 
1 in 50, DAPI 1 in 10,000 and a secondary α-mouse IgG(FAb’) AlexaFluor- 594 conjugate (red channel) 
was used to detect anti-V5, used 1 in 500. Cells were fixed and imaged using fluorescent microscopy 
using a x40 oil objective. Two images are shown for each transgene. The first is individual transgene 
expression as detected with anti-V5 primary (red channel). The second is a merged image consisting 
of transgene expression (red channel), phalloidin-488 (green channel) and DAPI (Blue channel).  
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Figure 5.9. Immunofluorescent staining of cells infected with a RAd from the RAd-HCMV-ORF 
library to determine transgene expression and subcellular location: US19-US27. 
HFFF-hCARs were seeded at a concentration of 5x10
5
 in a glass bottomed 96-well plate. The following 
day HFFF-hCAR’s were infected with a RAd from the RAd-HCMV-ORF library, as indicated, at MOI10 
for 2hrs in an incubator 37°
C
, 5%CO2 on an oscilating platform at 5 osc.min. After 2hours, media was 
removed and replaced with fresh DMEM-10 and incubated for 3days. After incubation cells were washed 
in PBS, fixed in 2% paraformaldehyde and underwent immunofluorescence staining using Saponin based 
IF-buffer. Antibodies were used as follows: Primary mouse anti-V5 was used 1 in 2,000, phalloining-488 
1 in 50, DAPI 1 in 10,000 and a secondary α-mouse IgG(FAb’) AlexaFluor- 594 conjugate (red channel) 
was used to detect anti-V5, used 1 in 500. Cells were fixed and imaged using fluorescent microscopy 
using a x40 oil objective. Two images are shown for each transgene. The first is individual transgene 
expression as detected with anti-V5 primary (red channel). The second is a merged image consisting 
of transgene expression (red channel), phalloidin-488 (green channel) and DAPI (Blue channel).  
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Figure 5.10. Immunofluorescent staining of cells infected with a RAd from the RAd-HCMV-ORF 
library to determine transgene expression and subcellular location: US28-TRS1 
HFFF-hCARs were seeded at a concentration of 5x10
5
 in a glass bottomed 96-well plate. The following 
day HFFF-hCAR’s were infected with a RAd from the RAd-HCMV-ORF library, as indicated, at MOI10 
for 2hrs in an incubator 37°
C
, 5%CO2 on an oscilating platform at 5 osc.min. After 2hours, media was 
removed and replaced with fresh DMEM-10 and incubated for 3days. After incubation cells were washed 
in PBS, fixed in 2% paraformaldehyde and underwent immunofluorescence staining using Saponin based 
IF-buffer. Antibodies were used as follows: Primary mouse anti-V5 was used 1 in 2,000, phalloining-488 
1 in 50, DAPI 1 in 10,000 and a secondary α-mouse IgG(FAb’) AlexaFluor- 594 conjugate (red channel) 
was used to detect anti-V5, used 1 in 500. Cells were fixed and imaged using fluorescent microscopy 
using a x40 oil objective. Two images are shown for each transgene. The first is individual transgene 
expression as detected with anti-V5 primary (red channel). The second is a merged image consisting 
of transgene expression (red channel), phalloidin-488 (green channel) and DAPI (Blue channel).  
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5.2. Categorisation of localisation 
Proteins were categorised dependant on the type of localisation pattern that they produced. 
Categories were based on the descriptions found in Salsman et al (2008), which was a 
comparable study that looked at the subcellular localisation of HCMV proteins. In this 
study the author expressed multiple proteins from HSV-1, HCMV and EBV and 
categorised transgene localisation based on the expression pattern that they showed.  
In this study there organellar counterstains were not used. Transgene expression that was 
outside the nucleus could not be distinguished between cytoplasm and orgenelles/vesicles 
etc. However, there are two distinct types of expression patterns that were outside the 
nucleus. Salsman et al (2008) referred to these as pan-cytoplasmic and sub-cytoplasmic. 
Although these definitions are not strictly true, as they do not take into account organelles, 
these definitions provided the best way of describing observed expression patterns. It was 
decided that these terms would be used to loosely describe categorisation, with an 
appreciation for their limitations. Therefore the definitions of categories are as follows: 
I. Pan cytoplasmic: Refers to expression that appears throughout the cell, excluding the 
nucleus 
II. Sub-cytoplasmic: Refers to expression that appears enriched in a particular cellular 
location outside of the nucleus which could be cytoplasmic, organellar, vesicular etc. 
III. Pan-nuclear: Refers to diffuse staining throughout the nucleus, as determined by co-
localisation with DAPI nuclear counter stain. 
IV. Punctate-nuclear: Refers to expression that appeared enriched in a particular 
location within the nucleus.  
V. Miscellaneous: Refers to expression that does not fall into any of the above 
categories. This predominantly refered to expression that was both nuclear and 
cytoplasmic. 
VI. Undetectable: Where transgene expression could not be detected, or was below the 
threshold of detection.  
Some proteins had more complex localisation categories and fell into multiple categories 
(e.g. UL54 is both cytoplasmic and nuclear but predominantly showed pan-nuclear 
expression). In this instance the localisation was recorded in the most relevant category.  
Most viral proteins showed cytoplasmic expression with 29 categorised as sub-cytoplasmic 
and 21 as pan-cytoplasmic, figure 5.1. A further 10 transgenes showed pan-nuclear  
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Localisation pattern  Number of proteins showing localisation pattern  
Sub nuclear 5 
Pan nuclear 10 
Sub cytoplasmic  28 
Pan cytoplasmic  21 
Miscellaneous 13 
Undetectable   6 
Figure 5.11. Summary of subcellular locations of HCMV transgene expression detected by 
IF. 
HCMV transgenes were expressed from a RAd in HFFF-CARs. The localisation patterns were 
characterised into five types of subcellular localisation. (A) Summary table indicating the 
localisations of cytomegalovirus proteins expressed in infected HFFF as determined by IF 
detection of the V5 epitope tag. (B) IF images of transgenes representative of the five subcellular 
localisation categories. These include UL42 sub-cytoplasmic, US26, pan-cytoplasmic, UL97 pan-
nuclear, UL49 miscellaneous, and UL57 sub-nuclear.   
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staining and 6 showed punctuate-nuclear staining. 13 were categorised as miscellaneous 
and 9 were undetectable. 
5.3. Comparison of protein localisation to the literature: Differences in 
localisation 
In order to determine whether transgene expression from the RAd-HCMV-ORF library 
correlated with findings of others; a literature search was carried out for all transgenes, 
tables 5.1 – 5.10.  
A total of 43 out of 79 transgenes had localisations previously described in the literature. 
Of the 43, our findings correlated with previous literature descriptions for 29, while 14 had 
partial matches or mismatches. Localisation data could not be found in literature for the 
remaining 36 transgenes. 
The 14 transgenes that had either partial matches (7) or mismatches (7) to the literature 
were reviewed in further detail. 
 
5.3.1. Genes that showed partial matches with descriptions in the 
literature 
There were a total of six proteins that demonstrated partial matches to descriptions 
identified in the current literature. These were UL44, UL48A, UL82, UL8, UL84,  UL86 
and UL98.  
  
UL44 
UL44 is a processivity subunit of DNA polymerase (ICP36) and here showed pan-nuclear 
staining (Ertl and Powell, 1992), Figure 5.1, table 5.1. A literature search showed UL44 to 
be pan-nuclear when expressed in isolation from an expression plasmid, but was shown to 
localise with IE2 in punctuate nuclear staining in HCMV-AD169 infected HFFF cells 
which corresponded to the periphery of viral replication compartments (vRC) (Sourvinos 
et al., 2007).  Phosphonoformic acid is a potent inhibitor of viral DNA synthesis. In 
HCMV AD169 infected fibroblasts, treatment with phosphonoformic acid resulted in 
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dispersal of UL44 throughout the nucleus (pan-nuclear). When phosphonofomric acid was 
washed from the cells, viral DNA synthesis was restored, and the punctuate nuclear 
staining was re-established (Strang et al., 2011).  
Expression UL44 from RAd-HCMV-ORF library was therefore recorded as a partial 
match as these observations indicate that when HCMV DNA replication is inhibited UL44 
formed pan nuclear staining, which correlated with the expression pattern seen during this 
screen.  However, when HCMV is undergoing active viral DNA replication, in the 
presence of IE2, UL44 formed punctuate nuclear staining corresponding to the vRC. 
 
UL48A and UL86 
UL48A and UL86 interact together during capsid assembly (Gibson et al., 1996b, Chee et 
al., 1989). UL48A is referred to as the smallest capsid proteins (SCP) and is located on the 
tips of hexons, while UL86 is referred to as the major capsid protein (MCP). The 
interaction between UL86 and UL48A is dependent on two linear sequences in pUL48A 
(Lai and Britt, 2003). In this study both proteins showed diffuse staining throughout the 
cell excluding the nucleus. Studies using murine mAbs specific for pUL86 or pUL48A in 
human fibroblasts infected for 5 days with HCMV strain AD169 showed expression from 
both proteins was localised to the nucleus where signals from both proteins co-localised 
(Lai and Britt, 2003). When the HCMV capsid proteins were expressed in cells infected 
with a recombinant vaccinia virus expressing individual capsid proteins, both UL86 and 
UL48A localised to the cytoplasm of infected cells. Further studies in transfected Cos7 
cells (an African green monkey fibroblast cell line) showed UL48A was detected in both 
cytoplasmic and nuclear compartments. In contrast UL86 was localised only to the 
cytoplasm in transfected cells. When both plasmids were co-transfected into Cos7 cells 
nearly complete cytoplasmic co-localisation was observed (Lai and Britt, 2003).  The 
nuclear localisation signals of pUL80 (mCP) was required to translocate pUL86 to the 
nucleus (Plafker and Gibson, 1998). It is therefore likely that UL86 and UL48A require an 
interacting protein to translocate to the nucleus.   
Expression of UL48A and UL86 independently from RAd-HCMV-ORF library were 
recorded as partial matches. Both UL48A and UL86 displayed cytoplasmic localisation 
when individually expressed from either a recombinant vaccinia viral vector or plasmid 
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transfected COS7 cells, similar to expression patterns identified in this study, FIgrues 5.1 
and 5.5, tables 5.1 and 5.5.  However, during productive HCMV AD169 infection both 
UL48A and UL86 were found to be expressed in the nucleus.  
  
UL82 
UL82 (pp71) is a transcriptional activator targeted to ND10/PML bodies, known sites of 
DNA replication, where UL82 interacts with hDaxx to regulate IE expression and viral 
replication (Hofmann et al., 2002, Ishov et al., 2002). UL82 is also capable of targeting Rb 
proteins for ubiquitin-independent proteosomal degradation and, along with UL69, is 
capable of imposing a G1/S-like block that deregulates the expression of many cell cycle 
related proteins (Kalejta and Shenk, 2003, Kalejta et al., 2003). In this observation 
expression of UL82 from RAd showed a punctuate-nuclear expression pattern, Figure 5.4, 
table 5.4. A literature review indentified a time course experiment of pUL82 expression 
using polyclonal Ab-UL89 in HCMV strain AD169 infected fibroblasts (Hensel et al., 
1996). At IE stages of infection pUL82 showed punctuate nuclear staining. At 12, 24 and 
72 hrs p.i pUL82 showed cytoplasmic staining (Hensel et al., 1996). Salsman et al (2011) 
showed that expression of UL82 in transfected U2OS human osteosarcoma cells was 
nuclear but following  co-transfection with a plasmid encoding UL35a, UL82 expression 
shifted to the cytoplasm.  
Expression of UL82 from RAd-HCMV-ORF library was therefore recorded as a partial 
match as the punctate nuclear expression pattern observed matched expression patterns 
described in the literature at IE times p.i. but not at E and L times p.i. This is likely due to 
the interaction of UL82 with UL35a during productive HCMV infection.  
 
UL83 
UL83 is known to inhibit the expression of IFN-inducible cellular genes and has been 
shown to be important for efficient induction of transcription from the IE promoter 
(Cristea et al., 2010, Browne and Shenk, 2003). In this observation expression of UL83 
from RAd showed a pan-nuclear expression pattern, Figure 5.4, table 5.4. A literature 
search identified UL83 to form large nuclear aggregates in uninfected Cos7 cells 
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transfected with ppUL83-GFP which possibly formed as a result of dimerisation of pUL83 
(Prichard et al., 2005). Coexpression of ppUL83-GFP and ppUL97-V5 eliminated the 
formation of nuclear ppUL83-GFP aggregates and instead resulted in diffuse nuclear 
staining of ppUL83-GFP (Prichard et al., 2005). Hwang and Kalejta (2009) showed that 
ppUL83 expressed from a RAd showed diffuse nuclear staining, which correlated with 
expression seen in this study, but during HCMV AD169 infection of telomerase 
immortalised HFFF’s formed more punctuate nuclear staining (Hwang and Kalejta, 2009).  
Expression of UL83 from RAd-HCMV-ORF library was therefore recorded as a partial 
match as the pan nuclear expression pattern observed matched expression patterns 
described by Hwang and Kalejta (2009) who also expressed UL83 from RAd. However, 
expression did not match that seen by Prichard et al (2005) or expression patterns seen by 
Hwang and Kalejta (2009) during HCMV AD169 infection.   
 
UL84 
UL84 is required for origin-dependant DNA replication, is a transdominant inhibitor of IE 
transcription and interacts with IE2 in lytically infected cells (Gebert et al., 1997, Sarisky 
and Hayward, 1996). Expression from RAd-HCMV-ORF library showed UL84 formed 
predominantly pan nuclear expression patterns with some cytoplasmic staining, Figure 
5.5., table 5.5. A literature search found UL84  to show pan nuclear expression patterns in 
Cos7 cells transiently transfected with UL84 expression constructs (Xu et al., 2002). In 
UL84-EGFP transfected Cos7 cells co-transfected with all HCMV replication proteins and 
oriLyt,  UL84-EGFP formed punctate nuclear staining in the presence of IE1/IE2 or 
OriLyt, which did not form in the absence of IE1/IE2/OriLyt (Xu et al., 2002). In the 
presence of the HCMV replication proteins and oriLyt, UL84 co-localised with UL44 and 
IE2 in the vRC (Xu et al., 2002).  
Expression of UL84 from RAd-HCMV-ORF library was therefore recorded as a partial 
match as the pan nuclear expression pattern observed matched expression patterns 
described in the absence of IE1/IE2 or OriLyt but not during HCMV infection when those 
proteins are present during viral replication.  
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UL98 
UL98, a deoxyribonuclease, is positionally conserved in gammaherpesvirinae (Sheaffer et 
al., 1997, Davison and Bhella, 2007). UL98 is unusual in that it showed pan-cytoplasmic 
expression and sub-nuclear expression, with only the periphery of nuclei appeared to show 
UL98 expression, Figure 5.6, table 5.6. A literature revealed that in HCMV-AD169 
infected fibroblasts UL98 showed a pan-nuclear expression pattern, although UL98 did 
appear to be slightly enriched towards the periphery of the nucleus (Adamo et al., 2004). 
The authors did not describe any cytoplasmic staining and therefore expression of UL98 
form RAd-HCMV-ORF library was recorded as not a partial match.   
 
5.3.2. Genes that did not match descriptions in the literature 
There were a total of seven proteins that were classified as mismatches when compared to 
expression patterns identified in the current literature. These were UL51, UL52, UL53, 
UL79, UL85, UL87, UL95 and US32.  
 
UL51 
UL51 is an essential HCMV protein that plays a role in DNA packaging and here showed 
pan cytoplasmic expression, Figure 5.2, table 5.2. Glab et al (2009) generated virus 
mutants that allowed for the conditional and reversible disruption of ddFKBP fusion 
proteins regulated by the synthetic ligand shield. The conditional knockdown allowed the 
study of essential herpesvirus proteins such as UL51. UL51 localised to the nucleus in 
cells infected with a modified HCMV strain AD169 (HCMV- ddFKBP-HAUL51) virus 
for conditional UL51 knockdown.    
The expression of UL51 from RAd-HCMV-ORF library was therefore recorded as a 
mismatch.  
 
UL52 
UL52 has a role in DNA packaging and in this study showed pan cytoplasmic expression, 
Figure 5.2., table 5.2. Recombinant HCMV’s encoding N and C terminally HA tagged 
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UL52 were constructed in HCMV strain AD169 (Borst et al., 2008).At day 2p.i. some N-
terminally tagged pUL52HA was localised to the cytoplasm, but a substantial amount was 
evenly distributed throughout the nucleus. From day 3 p.i. onwards, the majority of 
pUL52HA was present in the nucleus. In contrast HCMV containing a C-terminally tagged 
UL52 protein did not support growth of HCMV and did not produce viral progeny when 
the purified BAC was transfected into fibroblasts, indicating that the pUL52 C-terminus 
was crucial for ULl52 function and that a C-terminal tag disrupted this function. In RPE 
cells transfected with both the C- and N-terminally tagged UL52 HCMV-BACs, N-
terminal pUL52HA showed the expected nuclear location of pUL52. While in cells 
transfected with C-terminal pUL52HA, pUL52 was distributed throughout the cells with a 
significant proportion being present in the cytoplasm. The authors concluded that the C 
terminus of pUL52 was crucial for its correct nuclear localisation, which in turn seemed to 
be required for the essential role of UL52 in the HCMV replication cycle.  
The RAd-HCMV-ORF contained C-terminally tagged transgenes. Expression from RAd 
matched the cytoplasmic expression seen by C-terminally tagged UL52 see by Glab et al 
(2009). However, expression differed from the nuclear location of N-terminally tagged 
UL52. The location of N-terminally tagged UL52 is likely to be the correct functional 
location as this construct has no effect on growth, while C-terminally tagged UL52 is 
unable to produce viral progeny. The expression of UL52 from RAd-HCMV-ORF library 
was therefore recorded as a mismatch. 
  
UL53 
UL53, a tegument and nuclear matrix protein that has a role in capsid egress from the 
nucleus (Dal Monte et al., 2002). In this study UL53 showed either pan nuclear or pan 
cytoplasmic staining in different cells infected with RAd expressing UL53, Figure 5.2, 
table 5.2. A literature review showed UL53 to have several expression pattern attributed to 
UL53. In HCMV AD169 infected HELF cells pUL53 showed faint staining dispersed 
throughout the nucleus at 48hrs p.i. (Dal Monte et al., 2002). At 72 hours p.i. the intensity 
of the signal increased as was associated with large cytoplasmic formations thought to 
represent vACs (Dal Monte et al., 2002). In transfected cells, pUL53 is described as being 
predominantly nuclear (Miller et al., 2010, Dal Monte et al., 2002). Coexpresssion of 
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UL50 and UL53 induced to relocalisation of UL53 from the nuclear to the endoplasmic 
reticulum and to the nuclear rim (Miller et al., 2010).  
Expression of UL53 from RAd-HCMV-ORF library was therefore recorded as a 
mismatch. 
 
UL85 
UL85 is known as the minor capsid protein (mCP) and is a component of intercapsomeric 
capsids in triplexes(Baldick and Shenk, 1996). Here UL85 expressed from RAd showed 
predominantly pan cytoplasmic expression, Figure 5.5., table 5.5. A literature search 
described that pUL85 in HCMV-AD169 infected fibroblasts, showed both pan nuclear and 
pan cytoplasmic expression (Adamo et al., 2004). Expression of UL85 from RAd-HCMV-
ORF library was therefore recorded as a mismatch as there was no pan nuclear expression 
of UL85.  
 
UL87 and UL95 
As yet, UL87 and UL95 have no identified function but both have been described as being 
conserved in gammaherpesvirinae. In this study both proteins showed either pan nuclear or 
pan cytoplasmic expression in different cells, Figures 5.5. and 5.6, tables 5.5. and 5.6. A 
literature search showed that fibroblasts infected with a recombinant HCMV TOWNE 
(UL95HA UL87myc), showed punctuate nuclear staining for both proteins (Isomura et al., 
2011). UL95 and UL87 did not appear to co-localise as UL95 foci were distinct from 
UL87 foci and 1 day p.i. (Isomura et al., 2011). However, at 2 and 3 days p.i. both UL95 
and UL87 were recruited into distinct foci where they co-localised (Isomura et al., 2011). 
Both UL95 and UL87 showed co-localisation with UL44 to vRC (Isomura et al., 2011).  
Expression of UL87 and UL95 independently from RAd-HCMV-ORF library were 
recorded as mismatches as both of these proteins did not show punctuate-nuclear staining 
when expressed from RAd.  
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US32 
US32 is a member of the US1 family and contains a duplicated TT virus ORF2 motif. In 
this study US32 showed a pan nuclear expression pattern, Figure 5.10, table 5.10. A 
literature search showed that in transfected 293T cells pUS32 showed punctuate-nuclear 
staining associated with PML bodies, sites of virus replication (Salsman et al., 2008). 
Although nuclear, this does not match expression of US32 from RAd-HCMV-ORF library 
and was recorded as not a match.  
  
5.3.3. Potential causes for difference in localisation described in the 
literature compared to localisation in this study. 
A total of 43 transgenes had localisations described in the literature. Of those 43, 29 had 
localisations that were consistent with results observed in this thesis. The remaining 14 
proteins had expression patterns that differed from those described in the literature. 
Differences in localisation could be due to a number of reasons: 
 
1) The transgene requires other HCMV proteins for correct function/location. 
During HCMV infection, proteins interact to recruit additional proteins to cellular 
locations appropriate for their function. The most notable of these are proteins involved in 
capsid assembly which demonstrate predominantly nuclear location during viral infection, 
corresponding to the site where capsids are assembled. It is therefore possible that a 
negative hit could be achieved when the RAd-HCMV-ORF library is used in a functional 
screen due to the lack of an interacting protein.  
 
2) Time point visualised post infection 
This is particularly important when proteins are looked at in the context of viral infection. 
At IE timepoints p.i. proteins might show one type of expression pattern and a different 
localisation pattern at a later timepoints. This is likely due to other interacting HCMV 
proteins which only become expressed at later timepoints post infection. An example of 
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this is UL82, which is described as showing a punctate nuclear localisation pattern at IE 
p.i. but demonstrates cytoplasmic expression patterns at E and L timepoints p.i.  
 
3) Potential transgene overexpression 
All transgenes in this study are driven from the HCMV MIE promoter, which is one of the 
strongest promoters in mammalian biology. Because of the strength of the MIE promoter it 
is possible that the natural site of protein localisation or its interactions with chaperones 
may get saturated and mis-localisation of the protein may occur. In order to address this 
the experimental protocol could be amended to use reduced viral tires used and reduce 
incubation times and visualise transgene expression earlier than 3 days p.i.. Additionally 
using a weaker promoter might result in a more representative expression pattern for some 
proteins.     
 
4) C-terminal tag prevents correct protein function/location 
In this study both RAd-UL51 and RAd-UL52 showed cytoplasmic expression, but during 
HCMV infection these show a nuclear location. A C terminally tagged UL52 resulted in 
atypical pan cytoplasmic expression as the tag prevented the correct cellular location by 
blocking the nuclear localisation signal. Therefore adding a tag may alter a protein’s 
function and location. To address this problem the transgene could be expressed without a 
tag and an antibody produced to verify its expression and location.  
 
5) Cell line used 
This particular screen was carried out in HFFF-hCARs. However, many different cell 
types have been used throughout the literature to express HCMV genes including human 
fibroblasts, such as HFFF’s, African Green Monkey fibroblasts, such as Cos7 cells, and 
human embryonic kidney cells, such as HEK 293T cells. Proteins could localise to 
different cellular compartments depending on the cell line they are expressed in. If for 
example, a HCMV protein interacts with a cellular protein, that protein might be expressed 
180 
 
differently in different cell type or not at all. Human fibroblasts are permissive to HCMV 
in-vivo and in-vitro and so these provide a physiologically relevant cell line for study.  
 
6) Different tags could results in different locations 
The RAd-HCMV-ORF library uses a V5 tag. Many other tags have been used in the 
literature. For example; myc, FLAG, HA, proteinA and EGFP have all been used. Large 
tags, such as EGFP, could result in atypical location or aggregate formation if 
overexpressed. In order to avoid this possibility untagged protein could be expressed and 
detected with a specific monoclonal antibody.   
 
7) Method of transgene delivery 
The method of transgene delivery varies between studies. Many different methods have 
been used including DNA plasmids, RAd, recombinant HCMVs and recombinant vaccinia 
viruses, which may have an impact on the resultant protein. Ideally transgenes would be 
delivered using multiple vectors to confirm the same expression pattern was observed.  
 
8) Different viral sequences used 
All sequences in the RAd-HCMV-ORF library are derived from the BAC clone of HCMV-
strain Merlin. A variety of other HCMV strains have been used in the literature, with 
HCMV strains AD169 and Towne being the most common. The genomes of HCMV trains 
AD169 and Towne are known to differ significantly to strain Merlin due to the tendency of 
HCMV to acquire genetic mutation over prolonged in-vitro passage. It is possible that 
HCMV strains could have acquired a mutation in a localisation signal which would affect 
localisation. Therefore protein localisation could vary between viral strains.   
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9) Types of detection reagents  
Monoclonal or polyclonal antibodies were used to either detect the protein directly or to 
recognise an epitope tag. Epitope tags could potentially be cleaved from the mature protein 
and consequently the expression pattern would not be indicative of transgene expression. 
Additionally polyclonal antibodies could be non-specific and could be detecting other 
proteins. Monoclonal antibodies raised against the transgene of interest would produce a 
more robust result.  
 
5.4. Undetectable proteins  
The localisation of six viral proteins could not be determined, UL77, US1, US9, US14, 
US17 and US34A. Four of these have previous expression patterns identified in the 
literature, table 5.11. UL77 is described as pan-nuclear and US9 is described as pan-
cytoplasmic (GlaB et al., 2009, Mandic et al., 2009, Huber et al., 2002). US14 is described 
as having granular staining throughout the cytoplasm, while US17 is described as being 
pan-nuclear during HCMV strain AD169 infection (Das et al., 2006).  
There are several possibilities as to why expression could not be determined for these 
proteins. As transgene expression was detected using an antibody against the V5 tag. It is 
possible that with the anti-V5 mAb there was an inability to detect the V5 tag resulting in 
the transgene being undetectable. This could have been due to: 
1) No transgene expression from the vector 
2) Steric hindrance of the V5 tag due to protein structure so the V5 tag is ‘not 
seen’. 
3) Homo- or hetero-dimerisation of the transgene with itself or a cellular protein 
making the V5 tag inaccessible. 
4) Cleavage of the C-terminal V5 tag.  
5) Degradation of the transgene product and the tag before detection.  
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Table 5.11 List of Transgenes that were undetectable by immunofluorescence when expressed from recombinant adenoviral vector  
     
gene Function Location notes Location in literature References 
     
UL77 Role in DNA packaging Undetectable Pan nuclear  
   in cells infected with a modified HCMV strain AD169  virus for conditional UL77 
knockdown. 
Glab et al 2009 
     
US1 US1 family Undetectable None identified N/A 
 Duplicated TT virus 
ORF2motif 
   
     
US9 US6 family Undetectable Pan cytoplasmic  
 Membrane glycoprotein  GFPUS9-Toledo infected HEK293, Hela and HF cells, US9-GFP distributed to both the ER 
and Mitochondria 
Mandic et al 2009 
   In HEC-1A cells infected with Ad vectors expressing US9, US9 was found to colocalise with 
ER markers calnexin and PDI. 
Huber et al 2002 
     
US14 US12 family Undetectable Pan cytoplasmic  
 Puatative membrane 
glycoprotein 
 Uniform granular staining throughout the cytoplasm in AD169 infected HLF cells  
detected using rabbit polyclonal raised against N- and C-terminal fragments of US14 
Das et al 2006 
    
     
US17 US12 family Undetectable Pan nuclear  
 Puatative membrane 
glycoprotein 
 colocalises to infected cells nculei  in AD169 infected HLF cells detected using rabbit 
polyclonal raised against N- and C-terminal fragments of US17 
Das et al 2006 
    
     
US34A Putative membrane 
glycoprotein 
Undetectable None identified N/A 
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Antibodies against these specific ORF products would need to be generated to definitively 
determine whether a protein product is produced from these expression vectors.  
5.5. Conclusion 
The majority of transgenes (79 out of 85) from the RAd-HCMV-ORF library could be 
detected using reagents against the V5 epitope. A literature review allowed expression 
patterns for 43 of these transgenes to be compared to our observed expression patterns. 29 
correlated, while 7 showed partial matches and 7 mismatches when compared to the 
current literature. Differences in expression patterns could be due to a number of reasons, 
with the most notable being differences in the timepoint expression was visualised post 
infections or whether the transgene was expressed in isolation from a vector or expressed 
in the context of viral infection. Some discrepancies would be expected with localisations 
determined in the context of viral infection since interactions with other viral proteins 
could alter location. For such genes it is likely that additional viral genes interact to traffic 
proteins to their alternate cellular location to carry out function. 
The RAd-HCMV-ORF library was concluded to be suitable for the large scale screening 
for HCMV genes involved in the down-regulation of CD112 as most proteins appeared to 
show locations relevant to their function and in agreement with the literature. However, 
these results indicate that the interplay between HCMV genes can affect their subcellular 
localisation and likely their function throughout infection and these should be considered 
in the context of screening for function.  
Finally genes were grouped into categories based on their expression patterns. These 
expression patterns appear to tie in with function and perhaps could be used to narrow 
down functional screening in the future. For example if screening for a protein thought to 
be involved in transcriptional regulation then it would be logical to screen those proteins 
that demonstrated pan- or sub-nuclear expression patterns as a priority over those that 
show pan-cytoplasmic expression patterns.  
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6.0. SCREENING OF THE RECOMBINANT ADENOVIRUS 
LIBRARY FOR CD112 DOWN-REGULATION.  
With the generation of the RAd-HCMV-ORF library and the verification of expression, 
summarised in chapter 5.0., the resource was utilised for the screening of CD112 down-
regulation. Since the expression of UL141 in isolation had no effect on CD112 cell surface 
expression, but was essential for CD112 down-regulation, it was necessary to co-infect 
two RAds to attempt to reproduce the Merlin phenotype. The screening method of choice 
was the co-infection of RAd-UL141 plus a RAd from the RAd-HCMV-ORF-Library. The 
cell surface expression of CD112 was then monitored by Flow cytometry.   
 
6.1 Confirming CD112 down-regulation in HFFF-CAR’s. 
In-vitro, fibroblasts are one of the few cell lines that are permissive for productive HCMV 
infection. As screening the RAd-library of HCMV ORFs would require a large volume of 
cells it was decided that primary fibroblast cell lines were unsuitable due to their finite 
lifespan. Ad5 normally uses the CAR (coxsackie and adenovirus receptor) as a primary 
receptor and an αν integrin as a secondary receptor to gain entry into cells. Whilst human 
fibroblasts are routinely used in HCMV research, they have low levels of cell surface 
CAR. Instead, screening was carried out in the immortalised fibroblast cell line HFFF-
hCAR’s. The HFFF-hCAR cell line was previously generated in-house through the 
retroviral insertion of the telomerase hTERT and the Coxsakie Adenovirus receptor 
(CAR). The telomerase renders this cell line immortalised, while CAR enhances for 
Adenovirus entry. The expression of CAR allows for approximately 10x less Adenovirus 
to provide the equivalent level of infection in primary HFFF’s. The switch from HFFF’s to 
the HFFF-hCAR cell line therefore, allowed lower MOIs to be used and thus conserving 
RAd stocks. It was therefore important to show that cell surface CD112 expression levels 
were down-regulated in HFFF-hCAR’s as well as in primary HFFF’s.  
 
HCMV infections were carried out in HFFF-hCARs and cell surface CD112, CD155 and 
MHC-1 detected by flow cytometry. As expected, during Merlin infection of HFFF-
hCAR’s, CD155, MHC-1 and CD112 were all down-regulated 3 days p.i Figure 6.1.  
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Figure 6.1. Cell surface CD112 is downregulated on HCMV infected HFFF-
hCAR’s  
HFFF-hCARs were infected with HCMV at MOI 10 and the cell surface expression 
of CD112, CD155 and MHC-1 was analysed 3 days p.i. by flow cytometry.   
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MelrinΔUL141 infection resulted in the expected down-regulation of MHC-1 but not 
CD155 nor CD112. This result meant that HFFF-hCARs were suitable for large scale 
screening of the RAd-HCMV-ORF library.    
 
6.2. Screening RAd library by flow cytometry 
Screening of the HCMV block deletion mutants had discounted 46 genes from being 
essential in HCMV down-regulation of CD112, Chapter 4.0. Initial screening of the RAd-
HCMV-ORF library focused on the remaining 124 ORFs. The 46 genes were also 
screened as a low priority, appendix 2.0.   
Screening began with infecting HFFF-hCAR’s with RAd-UL141 plus a RAd from the 
RAd-HCMV-ORF library, and analysing cell surface expression of CD112 by flow 
cytometry. Optimising began with screening with RAds spanning the UL13-UL20 region. 
Initial infections at a MOI of 10 identified CD112 as being down-regulated by several 
HCMV genes (data not shown). However, this was quickly attributed to rounding up of 
cells due to toxicity of RAd over-expression, Figure 6.2a. This was an important 
observation as such screening conditions would provide a false positive result and practical 
steps were required to be taken to reduce the amount of toxicity and therefore false 
positive results. This was achieved in several ways: 
1) If signs of cell rounding occurred, experiments were abandoned and some were 
optimised for reduced cytotoxicity by reducing MOI’s.  
2) Infections were thoroughly washed to remove as many rounded up or dying cells as 
possible. 
3) During analysis strict gating on a live cell population was used to try and limit false 
positive results. 
Toxicity of infections was defined as the rounding up of infected cells which led to their 
detachment from the tissue culture flask so that cells were in suspension, and could have 
been due to a number of reasons. The transgene could have been toxic when expressed in 
HFFF-hCAR’s. There could have been a miscalculation during titration meaning that far 
too much RAd was added to infections (e.g. MOI 100 instead of MOI 10). Or RAd could  
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RAd-HCMV-ORFs that demonstrated signs of toxicity 
RL8A, RL10, RL11, UL2, UL4, UL5, UL15A, 
UL16, UL17, UL19, UL20, UL23, UL26, UL34, 
UL37, UL41A, UL138, US14, US28, US29 
Figure 6. 2. RAd infections that demonstrated signs of toxicity. 
HFFF-hCARs were infected with RAd from the RAd-HCMV-ORF 
library at MOI 10 and analysed 3 days p.i. by phase contrast microscopy 
for signs of toxicity. A) Phase contrast image of  RAd-UL34 + RAd-Ctrl 
infection, which was deemed to be toxic and also RAd-Ctrl infection, 
which was non-toxic B) table of all RAd’s that demonstrated signs of 
toxicity during infection of HFFF-hCAR’s infected  at MOI 10.  
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have picked up E1 region from the packaging cell line, restoring the E1 region to the RAd 
genome resulting in the generation of replication competent virus.  
For the majority of RAd infections, MOI 10 proved to show little or no signs of toxicity. 
However, a total of 20 RAds showed signs of toxicity, Figure 6.2b. Of these, 9 ORFS 
RL8A, RL10, RL11, UL2, UL4, UL5, US14, US28 and US29 are found in regions deleted 
in HCMV block deletion mutants. As these block deletion mutants were still capable of 
down-regulating cell surface CD112, individual HCMV ORF’s in these regions were 
considered to not be essential in CD112 down regulation and no attempts were made to 
optimise infections to avoid toxicity. UL15A, UL16, UL17 and UL19 all showed signs of 
toxicity but a titration of toxicity revealed no signs of toxicity at MOI2 and for these 
infections a reduced MOI was used. Immunofluorescence was undertaken to ensure that 
expression was detectable at these reduced MOI’s. For the remaining 8 ORFs; UL20, 
UL23, UL26, UL34, UL37, UL41A and UL138 reduced MOI’s made no effect on toxicity 
and these viruses could not be used in an assay to analyse their role in CD112 down-
regulation.   
All infections were carried out in HFFF-hCAR’s. All viral infections were controlled for 
total amount of viral load. For example, if RAd-UL141 was used at an MOI10 and RAd-
UL45 was used at MOI10, making a total of MOI20, then empty control RAd-1253 would 
be used at MOI 20.  
Control conditions included; a) mock (uninfected), b) control RAd (RAd-Ctrl) and c) RAd-
UL141 + RAd-Ctrl, Figure 6.3.  The experimental condition consisted of RAd-UL141 + 
RAd-X where RAd-X denotes any ORF in the RAd-HCMV-ORF library and RAd-X + 
RAd-Ctrl to check whether RAd-X had any effect.  
Three days post infection, samples were stained for mIgG (Negative control), CD112 
(experimental test), CD155 (to test for the action of UL141) and finally MHC-1 (a positive 
control for staining, as well as a control for off target down-regulation, Figure 6.4 – 6.35. 
Each RAd-X was analysed a minimum of three times and following figures 6.4-6.35 show 
representative results.    
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Figure 6.3. Control infections for screening RAd-HCMV-ORF library. 
HFFF-hCARs were infected with RAd-Ctrl (MOI 20), RAd-UL141 (MOI10) + 
RAd-Ctrl (MOI10) or mock infected. The cell surface expression of CD112, 
CD155 and MHC-1 was analysed 3 days p.i. by flow cytometry.   
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Figure 6.4. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-β2.7, RAd-UL13, 
RAd-UL14 and RAd-UL15A. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + RAd-
Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene labelled in the figure.  
An exception was RAd-UL15A which was infected at MOI2 due to toxicity seen at higher MOI’s. The cell 
surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by flow cytometry. Infections 
were also monitored by phase contrast microscopy.  
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Figure 6.5. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL16, RAd-
UL17, RAd-UL18 and RAd-UL19. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene labelled in 
the figure.  An exception was RAd-UL15A which was infected at MOI2 due to toxicity seen at higher 
MOI’s. The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by flow 
cytometry. Infections were also monitored by phase contrast microscopy.  
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Figure 6.6. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL20, RAd-
UL21A, RAd-UL26 and RAd-UL27. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted 
in the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by 
flow cytometry.  Infections were also monitored by phase contrast microscopy. Flow cytometry 
histograms were unavailable for RAd-UL20 and RAd-UL26 due to toxicity.  
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Figure 6.7. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL28/29, 
RAd-UL30, RAd-UL30A and RAd-UL31. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted 
in the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by 
flow cytometry.  Infections were also monitored by phase contrast microscopy.  
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Figure 6.8. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL32, RAd-UL33, 
RAd-UL34 and RAd-UL35. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted in 
the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by flow 
cytometry.  Infections were also monitored by phase contrast microscopy. Flow cytometry histograms 
were unavailable for RAd-UL34 due to toxicity.  
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Figure 6.9. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL36, RAd-
UL37, RAd-UL38 and RAd-UL40. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted in 
the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by flow 
cytometry.  Infections were also monitored by phase contrast microscopy. Flow cytometry histograms 
were unavailable for RAd-UL37 due to toxicity.  
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Figure 6.10. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL41A, RAd-
UL42, RAd-UL43 and RAd-UL44. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted in the 
figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by flow 
cytometry.  Infections were also monitored by phase contrast microscopy. Flow cytometry histograms were 
unavailable for RAd-UL41A due to toxicity.  
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Figure 6.11. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL45, RAd-
UL46, RAd-UL47 and RAd-UL48. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted 
in the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by 
flow cytometry.  Infections were also monitored by phase contrast microscopy.  
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Figure 6.12. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL48A, 
RAd-UL49, RAd-UL50 and RAd-UL51. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted 
in the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by 
flow cytometry.  Infections were also monitored by phase contrast microscopy  
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Figure 6.13. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL52, RAd-
UL53, RAd-UL54 and RAd-UL55. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted 
in the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by 
flow cytometry.  Infections were also monitored by phase contrast microscopy.  
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Figure 6.14. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL56, RAd-
UL57, RAd-UL69 and RAd-UL70. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted 
in the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by 
flow cytometry.  Infections were also monitored by phase contrast microscopy.  
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Figure 6.15. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL71, RAd-
UL72, RAd-UL73 and RAd-UL74. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted 
in the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by 
flow cytometry.  Infections were also monitored by phase contrast microscopy.  
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Figure 6.16. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL75, RAd-
UL76, RAd-UL77 and RAd-UL78. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted 
in the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by 
flow cytometry.  Infections were also monitored by phase contrast microscopy.  
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Figure 6.17. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL79, 
RAd-UL80, RAd-UL80.5 and RAd-UL82. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted 
in the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by 
flow cytometry.  Infections were also monitored by phase contrast microscopy.  
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Figure 6.18. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL83, RAd-
UL84, RAd-UL85 and RAd-UL86. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted in 
the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by flow 
cytometry.  Infections were also monitored by phase contrast microscopy.  
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Figure 6.19. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL87, RAd-
UL88, RAd-UL89 and RAd-UL91. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted 
in the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by 
flow cytometry.  Infections were also monitored by phase contrast microscopy.  
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Figure 6.20. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL92, RAd-
UL93, RAd-UL94 and RAd-UL95. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted in 
the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by flow 
cytometry.  Infections were also monitored by phase contrast microscopy.  
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Figure 6.21. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL96, RAd-
UL97, RAd-UL98 and RAd-UL99. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted 
in the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by 
flow cytometry.  Infections were also monitored by phase contrast microscopy.  
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Figure 6.22. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL100, RAd-
UL102, RAd-UL103 and RAd-UL104. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted in 
the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by flow 
cytometry.  Infections were also monitored by phase contrast microscopy.  
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Figure 6.23. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL105, RAd-
UL111A, RAd-UL112 and RAd-UL114. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted in 
the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by flow 
cytometry.  Infections were also monitored by phase contrast microscopy.  
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Figure 6.24. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL115, RAd-
UL116, RAd-UL117 and RAd-UL119. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted in 
the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by flow 
cytometry.  Infections were also monitored by phase contrast microscopy.  
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  Figure 6.25. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL120, 
RAd-UL121, RAd-UL122 and RAd-UL123. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted 
in the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by 
flow cytometry.  Infections were also monitored by phase contrast microscopy.  
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Figure 6.26. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL124, 
RAd-UL128, RAd-UL130 and RAd-UL131A. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted 
in the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by 
flow cytometry.  Infections were also monitored by phase contrast microscopy.  
213 
 
  
Figure 6.27. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL132, 
RAd-UL133, RAd-UL135 and RAd-UL136. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted 
in the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by 
flow cytometry.  Infections were also monitored by phase contrast microscopy.  
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Figure 6.28. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL138, 
RAd-UL139, RAd-UL140 and RAd-UL142. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted 
in the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by 
flow cytometry.  Infections were also monitored by phase contrast microscopy. Flow cytometry 
histograms were unavailable for RAd-UL138 due to toxicity.  
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Figure 6.29. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL144, 
RAd-UL145, RAd-UL146 and RAd-UL147. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted 
in the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by 
flow cytometry.  Infections were also monitored by phase contrast microscopy.  
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Figure 6.30. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL147, 
RAd-UL148, RAd-UL148A and RAd-UL148B. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) 
+ RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene 
denoted in the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 
days p.i. by flow cytometry.  Infections were also monitored by phase contrast microscopy.  
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Figure 6.31. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL148C, 
RAd-UL148D, RAd-UL150 and RAd-IRS1. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) 
+ RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene 
denoted in the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 
days p.i. by flow cytometry.  Infections were also monitored by phase contrast microscopy.  
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Figure 6.32. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-US1, RAd-
US2, RAd-US3 and RAd-US6. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted 
in the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by 
flow cytometry.  Infections were also monitored by phase contrast microscopy.  
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Figure 6.33. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-US7, RAd-
US8, RAd-US9 and RAd-US10. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted 
in the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by 
flow cytometry.  Infections were also monitored by phase contrast microscopy.  
220 
 
 
  
Figure 6.34. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-US11, RAd-
US23, RAd-US24 and RAd-US26. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted 
in the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by 
flow cytometry.  Infections were also monitored by phase contrast microscopy.  
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Figure 6.35. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-TRS1. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + 
RAd-Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted 
in the figure.  The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by 
flow cytometry.  Infections were also monitored by phase contrast microscopy.  
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6.3. RAd-HCMV-ORF library screening results: CD155  
Cell surface CD155 staining of infected cells was used as a positive control for the action 
of UL141, as CD155 is notably down-regulated from the cell surface during RAd-UL141 
infection.  
For the majority of conditions CD155 was down-regulated from the cell surface in 
infections where UL141 was present, namely UL141 + control RAd-1253 and the 
experimental condition of RAd-UL141 and RAd-X. Where UL141 was not present CD155 
remained at similar levels as compared to control RAd-1253. However, there were two 
groups of genes with noticeable exceptions:  
The first group consisted of seven genes that, when co-infected with UL141, showed a 
further decrease in cell surface expression of CD155 than when UL141 was expressed in 
isolation. These were RL12, RL13, UL7, UL16, UL22A, UL43 and UL114. These genes 
had no effect on CD155 expression levels when expressed on with empty RAd control 
(RAd-1253), which was important as it showed that the effect was specific and not a result 
of over-expression of these proteins. This was an interesting observation as it is possible 
that the expressed proteins may interact with UL141 to retain CD155 in the ER. UL16 has 
already been shown to sequester several proteins inside the ER. Alternatively these genes 
could be acting as positive regulators of the MIE promoter, which is used to control 
expression of UL141 in the RAd construct. Most of these genes have no described function 
in the transcriptional regulation. UL114 is a Uracil-DNA glycosylase, and is the only gene 
with described roles in the temporal regulation of DNA replication. UL22A is a secreted 
immunoregualtory RANTES binding decoy receptor. The remaining proteins have as yet 
no assigned function. UL43 is a tegument protein with no current function attached, while 
RL12, RL13 and UL7 are putative membrane glycoproteins and members of the RL11 
family. All of these genes had no affect on CD112 or MHC-1. Further analysis of these 
onservations will now be the subject of an independent project.  
The second group consisted of eight genes that, when co-infected with UL141, did not 
down-regulate CD155 to the same extent as RAd-UL141 + RAd-1253.  These were UL25, 
UL27, UL28/29, UL31, UL33, UL44, UL97 and UL147. It is possibly that these proteins 
could either be directly or indirectly interacting with UL141 to prevent UL141 
sequestering CD155. They could be acting as negative regulators of the MIE promoter, 
preventing UL141 expression and therefore reducing CD155 sequestration. Or there was 
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an titration error altering the ratio of viruses (UL141/X) from 10/10 to, for example, 
10/100 which could mean there was less UL141 in the system. However, functions 
associated with these proteins do not appear to coincide with these hypotheses. Only two 
proteins have functions associated with DNA; UL44 a processivity subunit of DNA 
polymerase and UL97 Serine-threonine protein kinase that has roles in DNA synthesis, 
DNA packaging and nuclear egress.  Another two proteins have assigned function. UL33 
GPCR family and a membrane protein putative chemokine receptor and UL147 is putative 
CXC chemokine. While the remaining genes have no associated function; UL25 is a 
tegument phosphoprotein. UL27 is the locus to maribavir resistance. UL31 is a member of 
the DURP family. All of these genes appeared to have no affect on CD112 or MHC-1.   
 
6.4. RAd-HCMV-ORF library screening results: MHC-1  
There are four HCMV proteins US2, US3, US6 and US11 have all been shown by various 
groups to result in the down-regulation of MHC-1 from the cell surface. As expected these 
four proteins all showed a down-regulation of MHC-1 from the cell surface in RAd 
infections expressing these genes, figure 6.36. No other HCMV gene appeared have any 
effect of the cell surface levels of MHC-1. US3 and US6 resulted in a further down-
regulation than US2 and US11. All had no affect on the cell surface expression of CD155.   
 
6.5. RAd-HCMV-ORF library screening results: US2 appeared to be 
involved in CD112 down-regulation  
Of the entire RAd-HMCV-ORF library there was only one gene that resulted in a further 
down-regulation of CD112 when co-infected with UL141, compared to RAd-UL141 
infection alone, and that was US2, Figure 6.37. Although the shift was small, the result 
was highly reproducible and due to the robust CD112 staining seen in all negative results, 
this shift was deemed to be a positive hit. Both US2 and UL141 worked as expected as cell 
surface CD155 was down-regulated in the presence of UL141 and MHC-1 was down-
regulated in the presence of US2. This confirmed not only that both transgenes were 
expressed, but also that co-infection of two RAd’s could be successfully achieved. RAd-
US2 had no affect on cell surface CD112 when expressed in the absence of RAd-UL141.  
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Figure 6.36. US2, US3, US6 and US11 downregulate MHC-1. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X 
(MOI10) + RAd-Ctrl (MOI10)  or RAd-X (MOI10) + RAd-UL141 (MOI10), where X 
denotes a gene denoted in the figure.  The cell surface expression of MHC-1 was analysed 3 
days p.i. by flow cytometry.   
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Figure 6.37. The coinfection of RAd-US2 and RAd-UL141 resulted in the downregulation of 
CD112.  
HFFF-hCARs were infected with  RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-US2 (MOI10) + 
RAd-Ctrl (MOI10)  or RAd-US2 (MOI10) + RAd-UL141 (MOI10) A) Infections were analysed by 
flow cytometry for the cell surface expression of CD112, CD155 and MHC-1. B) Infections were 
harvested and underwent partial purification using TritonX-114 before being analysed by 
immunoblot for  CD112, CD155, UL141 and actin.  
226 
 
However, CD155 was not down-regulated to the same extent in RAd-UL141+RAd-US2 
infection as compared to RAd-UL141 + RAd-Ctrl.   
Experiments were also harvested and underwent partial purification using TritonX-114 
fractionation. CD155 was found in a lower molecular weight form in all infections that 
contained UL141. During co-infection of US2 and UL141, CD112 appeared to be found at 
a reduced concentration compared to control samples. In particular the upper band of the 
two CD112 bands appeared to be markedly reduced compared to control samples. This 
correlated with observations seen in flow cytometry screening.  
6.6. Conclusion 
The cell surface down-regulation of CD112 by HCMV strain Merlin was confirmed in the 
in HFFF-hCAR cell line. This cell line was then used for the screening of the RAd-
HCMV-ORF library to identify genes involved in CD112 down-regulation by flow 
cytometry. Screening involved the co-infection of UL141 with a RAd from the RAd-
HCMV-ORF library in an attempt to reproduce the Merlin phenotype. Results identified 
US2 to be the only protein that resulted in a further down-regulation of CD112 when co-
infected with UL141. Importantly both RAd-US2 and RAd-UL141 had no affect on 
CD112 when expressed individually, indicating they acted in concert. The shift in CD112 
was small but was highly reproducible.  
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7.0. INVESTIGATION INTO THE US1-11 REGION OF HCMV FOR 
INVOLVEMENT IN CD112 DOWN-REGULATION.   
 
Screening of the RAd-HCMV-ORF library identified US2 as a candidate for involvement 
in the cell surface down-regulation of CD112 during HCMV infection. In order to further 
evaluate whether US2 potentially played a role in CD112 down-regulation during HCMV 
infection, the recombineering technique was used to generate HCMV deletion mutants of 
US2, US11 and US1-11. It was hypothesised that if US2 was involved in CD112 down-
regulation then its deletion would result in a loss of function, similar to HCMVΔUL141, 
chapter 3.0. US11 is highly homologous to US2 and both US2 and US11 target MHC-I for 
proteasome mediated degradation. A US11 deletion was also made as a negative control. 
In addition a deletion virus spanning the US1-11 region was also constructed as an 
additional negative control. 
 
7.1. Generating HCMV deletion mutants using the technique of 
Recombineering  
Dr R Stanton  had previously developed a high efficiency system for the insertion/removal 
of genetic material from a HCMV BAC that eliminated the need for traditional cloning 
steps (Stanton, 2008, Stanton et al., 2010). This system utilised recombination mediated 
genetic engineering (recombineering) and made use of E.coli strain SW102 that contained 
a single copy HCMV BAC. The SW102 strain also contained a defective phage expressing 
lamda red genes, which were transiently induced by heatshock and mediated homologous 
recombination between the BAC vector and an oligonucleotide containing short arms of 
homology.  
In order to generate HCMV deletion mutants two rounds of recombineering were required. 
During the first round, a selection cassette was amplified using 100bp primers. These 
primers contained 20bp that allowed amplification of a selection cassette and 80bp that 
allowed homologous recombination with a desired region of the HCMV genome. If the 
first round of recombineering was successful then the selection cassette was inserted into 
the desired part of the HCMV genome to be removed. A second round of recombineering 
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with a 100bp oligonucleotide, with 50bp designed to flank either side of the genomic 
region to be removed. A successful recombination event removed both the desired 
genomic material and also the selection cassette. Following plating onto selection plates a 
colony was indentified and deletion was confirmed by DNA sequence analysis and, where 
possible, PCR. 
7.2. A HCMVΔUS1-11 mutant did not down-regulate CD112 in infected 
cells.  
Two Merlin BACs were chosen to make HCMV deletions, 1111BAC and 1278BAC. The 
1111BAC encoded the Merlin BAC genome, while 1278BAC encoded a modified BAC 
that contained deletions of UL16 and UL18 and GFP-tagged UL32. The 1278BAC was 
used to construct the HCMV block deletions utilised in chapter 4.0. The RCMVΔUS1-11 
virus was therefore constructed in the 1278BAC background in order to integrate the virus 
into the existing HCMV block deletion library.  
Initially the SacB selection cassette was chosen, as this was routinely used in the 
laboratory. The SacB selection cassette was ~4.5kb and contained, AmpR that conferred 
resistance to ampicillin, SacB that conferred sensitivity to sucrose and LacZ that encoded a 
β-galactosidase that turned blue when galactose is metabolised and allowed for blue/white 
colour selection.  
During the first round of recombineering, the SacB selection cassette was correctly 
inserted into the US1-11 region, as evident by the presence of Blue colonies that contained 
the selection cassette, Figure 7.1A. During the second round of recombination the selection 
cassette was successfully removed. White colonies were picked, grown overnight, 
minipreped and analysed for the correct deletion of US1-11. A BamH1 restriction digest of 
genomic DNA showed that there was no gross genomic alteration compared to the parent 
RCMV1278 genome, Figure 7.1B. The minipreped BAC DNA was also sequenced to 
confirm the removal of the US1-11 region using the in-house CBS sequencing facility. The 
RCMVΔUS1-1 mutant later underwent deep sequencing of the entire genome carried out 
by Dr Andrew Davidson, Glasgow University, who confirmed not only that the US1-11 
region was successfully deleted but that there was no other genetic mutation in the 
RCMVΔUS1-11 genome.  
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Figure 7.1. The construction of  RCMV ΔUS1-11 using the recombineering 
technique and the AmpR/SacB/LacZ selection cassette. 
A) Following the first round of recombineering, bacteria were plated onto selection 
plates. Successful insertion of the AmpR/SacB/LacZ selection cassette into the US1-11 
region resulted in blue colonies. B) Minipred BAC DNA from RCMV1278 and 
RCMVΔUS1-11 colony1 were digested with BAMH1 restriction enzyme and digested 
sample ran on an agarose gel. C) Cells transfected with RCMVΔUS1-11 BAC and 
plaques visualised by fluorescent microscopy. D) HFFF-hTerts infected RCMVΔUS1-11 
, RCMV1278 or uninfected (mock) were harvested 3 days p.i. and samples were 
prepared by tritonX-114 fractionation and the detergent fraction was analysed by 
immunblot for the detection of CD112, CD155, UL141 and Actin. 
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Once sequencing had confirmed the correct deletion, RCMVΔUS1-11 BAC DNA was 
maxipreped and transfected into HFFF-hTert’s. As the parental BAC contained GFP-
tagged UL32, plaques appeared green when visualised with fluorescence microscopy, 
Figure 7.1C. Once plaques were observed, infections were progressed and a viral stock 
generated.  
Following the generation of a HCMVΔUS1-11 stock, HFFF-hTert‘s were infected at 
MOI10 and analysed by immunoblot for the detection of CD112, CD155, UL141 and 
actin, Figure 7.1D. Infected cells were also analysed by flow cytometry for the cell surface 
detection of CD112, CD155, MHC-1, MICA/B and MICB, Figure 7.2. 
Immunoblot detection of CD112 showed that CD112 was clearly detectable in uninfected 
HFFF-hTert’s, while in RCMV1278 (MerlinUL32GFPΔUL16ΔUL18) infected cells, 
CD112 was no longer detectable, Figure 7.1D. In HFFF-hTert’s infected with 
RCMVΔUS1-11, CD112 was readily detectable and was detected at a higher concentration 
than found in uninfected HFFF-hTERt’s.  This indicated that a gene in the US1-11 region 
was essential for HCMV mediated down-regulation of CD112 as its deletion resulted in a 
loss of function.  
CD155 was found in a lower molecular weight form as expected in both RCMV1278 
(Merlin) and RCMVΔUS1-11 compared to uninfected cells. UL141 was also detected in 
HCMV infected but not uninfected cells as expected, Figure 7.1D.  
Flow cytometry data confirmed the observations seen in immunoblot experiments, Figure 
7.2. HFFF-hTert’s were infected with RCMV1278 or RCMVΔUS1-11 and three days p.i. 
the cell surface expression of mIgG, CD112, CD155, MHC-1, MICA/B and MICB were 
analysed on the GFP high population, as per protocol developed for screening HCMV 
block deletions, chapter 4.0.  
The cell surface expression of CD112 was down-regulated in RCMV1278 infected cells 
compared to uninfected HFFF-hTert’s, Figure 7.2. This confirmed the observation that the 
US1-11 region was essential for HCMV mediated down-regulation of CD112 and deletion 
of US1-11 resulted in a loss of function.  
MHC-1 was down-regulated in RCMV1278 infected cells but was not down-regulated in 
RCMVΔUS1-11 infected cells, Figure 7.2. This was as expected as all four HCMV genes 
involved in MHC-1 down-regulation (US2, US3, US6 and US11) were deleted in this  
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Figure 7.2. RCMV ΔUS1-11 does not downregulate CD112 or MHC-1. 
1 x 10
6
 HFFF-hTert’s were infected with MOI of 10 of RCMV1278 (blue), 
RCMVΔUS1-11 (RCMV1528) (Red) or mock infected (black). 3 days p.i. Cells were 
harvested and analysed for the cell surface detection of CD112, CD155, MHC-1, 
MicA/B and MicB by flow cytometry.   
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RCMV mutant. The cell surface staining of MHC-1 therefore served as an additional 
control confirming the successful deletion of the US1-11 region.  
During HCMV infection, the HCMV gene UL16 successfully sequesters several proteins, 
including MicB, in infected cells thus preventing their cell surface expression. As 
RCMV1278 and RCMVΔUS1-11 both contained UL16 deletions, then the MicB ligand 
would not be retained. The cell surface expression of MicB was analysed using antibodies 
that either recognised both MicA and MicB (MicA/B) or just MicB. Infection with either 
RCMV1278 or RCMVΔUS1-11 resulted in the up-regulation of MicB at the infected cells 
surface, compared to uninfected HFFF-hTert’s, Figure 7.2.This observation served as an 
additional staining control confirming the functional deletion of UL16.   
CD155 was down-regulated in both RCMV1278 and RCMVΔUS1-11 infected cells due to 
the presence of UL141 in these viruses. 
 
7.3. Recombineering using the GALK selection cassette generated 
HCMVΔUS11 but not HCMVΔUS2.  
Primers designed to create US2 and US11 deletions, successfully amplified the SacB 
selection cassette (data not shown). However, the first round of recombineering was 
unsuccessful and the SacB selection cassette was not inserted into US2 or US11. Another 
selection cassette was chosen that allowed for more stringent selection.  
The E.coli galactose operon consists of four genes, GalE, GalT, GalK and GalM, that are 
necessary for the growth and the metabolism of galactose, when galactose is the only 
carbon source. The GalK product, galactokinase, catalyses the first step in the galactose 
degradation. The galactokinase also catalyses the phosphorylation of a glactose analog, 2-
deoxygalactose-1-phosphate (DOG). The product of this reaction cannot be further 
metabolised, leading to a toxic build up. Thus both positive and negative selection is 
conferred by GalK, which is absent in the E.coli SW102 strain.   
The GalK selection cassette was successfully amplified and inserted into US2 and US11 as 
evident by white colonies (data not shown). White colonies were picked and spread onto 
MacConkey Agar plates, where colonies that contained the GalK cassette fermented 
galactose present in the agar plates and appeared pink, Figure 7.3A. A functional GalK  
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Figure 7.3. The construction of  RCMV ΔUS11 using the recombineering technique and the 
GalK selection cassette. 
A) Following the first round of recombineering, bacteria were plated onto selection plates. A white 
colony was then streaked onto MacConkey indicator plates to test for Functional GalK. B) Following 
the second round of recombineering,recovered bacteria were plated onto DOG plates. C) Minipred 
BAC DNA from RCMV1111 and  two colonies representing RCMVΔUS11 and two colonies 
representing RCMVΔUS2 were digested with BAMH1 restriction enzyme and digested sample ran on 
an agarose gel. D) PCR reaction was carried out on minipreped BAC DNA from 4 colonies 
representing RCMVΔUS11 and 4 colonies representing RCMVΔUS2 and RCMV1111 as a control. 
PCR reactions were run on a 0.7% agarose gel. E) Cells transfected with RCMVΔUS11 BAC and 
plaques visualised by phase contrast microscopy.   
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was also confirmed by negative selection, where pink colonies were streaked onto DOG 
plates and did not grow (data not shown). The GalK selection cassette was then removed 
during the second round of recombineering, as evident by white colonies, Figure7.3B.  
Colonies were picked and sequenced to confirm the correct deletion. A BamH1 restriction 
digest of two colonies of RCMVΔUS11 and two colonies of RCMVΔUS2 purified BAC 
showed that there were no gross genomic alterations, Figure7.3C. A PCR reaction of US11 
showed that US11 had been successfully deleted in 4 colonies, Figure 7.3D. A PCR 
product of ~1042bp was expected if US11 was present and a PCR product of ~ 300bp if 
US11 was successfully deleted. A band of approximately 1kb was amplified from control 
RCMV1111BAC, a PCR product near the 250bp marker band was amplified from all 4 
colonies, corresponding to the deletion of US11. A PCR reaction of US2 also showed that 
US2 had been successfully deleted in 4 colonies, Figure 7.3D. A PCR product of ~ 870bp 
was expected if US2 was present and ~147bp if US2 had been successfully deleted. A 
band in between the 750bp and 1kb marker was amplified from control RCMV1111 BAC 
DNA, a PCR product of less than 250bp was amplified from all 4 colonies, corresponding 
to the deletion of US2.  Once sequencing confirmed a successful deletion, a colony was 
picked, BAC DNA maxipreped, transfected into HFFF-hTert’s and observed for the 
development of HCMV plaques. After approximately 3weeks post transfection, the 
RCMVΔUS11 successfully generated plaques, Figure 7.3E, and a RCMVΔUS11 stock 
was generated. HFFF-hTert’s transfected with RCMVΔUS2 BAC DNA did not produce 
plaques and a virus stock could not be generated.  
Following the generation of a RCMVΔUS11 stock, HFFF-hTert’s were infected with 
RCMV1111 (Merlin) and RCMVΔUS11 and three days p.i. the cell surface expression of 
mIgG, CD112, CD155 and MHC-1, were analysed by flow cytometry, Figure 7.4.  
CD155 was down-regulated from the cell surface in both RCMV1111 (Merlin) and 
RCMVΔUS1-11 infections due to the presence of UL141. The cell surface of MHC-1 was 
also down-regulated to a similar degree by both RCMV111 and RCMVΔUS1-11. It 
appeared that the deletion of US11 had no effect on the ability of HCMVΔUS1-11 to 
downregulate MHC-1 from the cell surface of infected cells at 3 days p.i. 
CD112 was down-regulated on both RCMV1111 (Merlin) infected cells and also 
RCMVΔUS11 infected cells. As there was no loss of function, and CD112 was still 
successfully down-regulated during RCMVΔUS11 infection, it was concluded that US11  
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Figure 7.4. RCMV ΔUS11 is still capable of downregulating CD112.  
1 x 10
6
 HFFF-hTert’s were infected with MOI of 10 of RCMV1111 (blue), 
RCMVΔUS11 (RCMV1579) (Red) or mock infected (black). 3 days p.i. Cells were 
harvested and analysed for the cell surface detection of CD112, CD155, MHC-1, 
MicA/B and MicB by flow cytometry.   
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did not play an essential role in the down-regulation of CD112 during HCMV infection 
and could be eliminated from future studies.   
   
7.4. Recombineering using the Strep selection cassette did not generate 
HCMVΔUS2.             
Although PCR and sequencing confirmed US2 had been deleted using the GalK selection 
system, Figure 7.3D, and a BAMH1 digest indicated that there were no gross genomic 
alterations, Figure 7.3C. A successful HCMVΔUS2 virus could not be generated.  A third 
selection system was therefore tried. The rpsL-Neo-LacZ system takes advantage of the 
fact that the S12 ribosomal protein is the target of streptomycin. Most commonly used 
E.coli strains, including SW102, carry a mutation in the rpsL gene that confers 
streptomycin resistance. If the wild type rpsL gene is introduced then the strain will 
become streptomycin sensitive. The bacterial neomycin-kanamycin phosphotransferase, 
type II enzyme is encoded by the Neo gene and conferred resistance to kanamycin.  When 
the rpsL-Neo-LacZ cassette is inserted colonies will be sensitive to streptomycin and 
resistant to Kanamycin. When the rpsL-Neo-LacZ cassette is lost, colonies will be resistant 
to streptomycin but sensitive to kanamycin. The presence of LacZ in the selection cassette 
allowed for blue/white screening of colonies.  
The rpsL-Neo-LacZ selection cassette was successfully amplified (data not shown) and 
successfully inserted into US2 during the first round of recombineering, as evident by blue 
colonies, Figure 7.5A.The selection cassette was successfully removed during the second 
round of recombineering as evident by white colonies, Figure 7.5B. Colonies were picked, 
minipred and BAC DNA analysed for the correct deletion of US2.  
A PCR reaction of US2 showed that US2 had been successfully deleted in 3/4 colonies, 
Figure 7.5D. A PCR product of ~897bp was expected is US2 was present and ~ 147bp if 
US2 was successfully deleted. A PCR product amplified from control RCMV1111 BAC 
DNA produced a product in between the 750bp and 1kb marker. A PCR product amplified 
from BAC DNA from 6/7 colonies, colony 1 and colonies 3-7, produced a product just less 
than the 250bp marker which corresponded to the deletion of US2. Colony 2 did not 
produce the expected PCR product and was eliminated from future work. Sequencing 
confirmed the successful  
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Figure 7.5. RCMV ΔUS2 could not be generated using the recombineering technique and the RpsL-
Neo-LacZ selection cassette. 
A) Following the first round of recombineering, bacteria were plated onto kanamycin selection plates. B) 
A blue colony from the first round of recombineering underwent a second round and once recovered was 
plated onto Streptomycin selection plates. C) Minipred BAC DNA from RCMV1111 and  RCMVΔUS 
colony 1 were digested with BAMH1 restriction enzyme and digested sample ran on an agarose gel. D) 
PCR reaction was carried out on minipreped BAC DNA from 7 colonies representing RCMVΔUS2  
following second round of recombination and plating onto streptomycin plates. RCMV1111 was used as  
a control. PCR reactions were ran on 0.5% agarose gel.    
 
238 
 
deletion of US2 (date not shown). A BAMH1 digest of colony 1 showed that there were no 
gross genomic alterations in the BAC DNA compared to RCMV1111, Figure7.5C.   
Once sequencing confirmed a successful deletion, BAC DNA was maxipreped, transfected 
into HFFF-hTert’s and observed for the development of HCMV plaques. However, HFFF-
hTert’s transfected with RCMVΔUS2 BAC DNA failed to produce plaques and a virus 
stock could not be generated. 
 
7.5. Co-infection of RCMVΔUS1-11 with RAd expressing one of the US1-
11 genes did not rescue the Merlin phenotype of CD112 down-regulation. 
The Merlin phenotype of CD112 down-regulation could be rescued by co-infection of 
Merlin ΔUL141 with RAd-UL141, chapter 3.0, Figure 3.5. A similar result was expected 
when RMCVΔUS1-11 was co-infected with a RAd expressing one of the US1-11 ORFs.  
Results are shown for US2, US3, US6 and US11, Figure 7.6. MHC-1 was down-regulated 
in all RAd infections (black line), compared to uninfected cells (purple line). However, 
when co-infected with RCMVΔUS1-11, MHC-1 is no longer efficiently down-regulated in 
cells infected with RAd-US2, RAd-US3, RAd-US6 or RAd-US11 (red line). As expected 
there was no down-regulation in cells infected with MerlinΔUS1-11 (blue line). The fact 
that MHC-1 is not down-regulated in the presence of one of these proteins perhaps 
explains why HCMV has 4 proteins targeting MHC-1 using different mechanisms. Or it is 
possible that co-infection of RAd and HCMV did not occur.   
CD155 was down-regulated in all HCMV infections due to the presence of UL141. The 
Merlin phenotype of CD112 down-regulation could not be restored by co-infection of 
MerlinΔUS1-11 with any of the US1-11 RAd’s. The cell surface expression of CD112 was 
equivalent between MerlinΔUS1-11 and MerlinΔUS1-11 + RAd-X, Figure 7.6.   
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Figure 7.6. Coinfection of RAd with RCMVΔUS1-11 did not rescue the Merlin 
phenotype.  
1 x 10
6
 HFFF-hTert’s were seeded into a 25cm2 tissue culture flask and the 
following day infected with MOI of 10 of RCMV and/or MOI10 RAd. Infections 
consisted of RAd-X (black), where X denoted the RAd expressing genes labelled in 
the figure. RCMV1528 (RCMVΔUS1-11) (blue), RCMVΔUS1-11  + RAd-X (Red) 
or mock infected (purple). 3 days p.i. Cells were harvested and analysed for the cell 
surface detection of CD112, CD155 and MHC-1 by flow cytometry.   
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7.6. Infecting with multiple RAd’s in the US1-11 region did not 
reproduce the Merlin phenotype. 
The rescue function experiment whereby RCMVΔUS1-11 was co-infected with RAd 
expressing one of the US1-11 genes failed to reproduce the HCMV phenotype of CD112 
down-regulation. It was hypothesised that more than one gene in the US1-11 region might 
be involved in this process.  Triple RAd infections of UL141 + US2 + one of RAdUS1-11, 
denoted RAd-X in the figure legend, were carried out but there was no further down-
regulation of CD112, compared to UL141 + US2 infection, Figure 7.7. CD155 was down-
regulated as expected in all infections containing UL141, Figure 7.8. MHC-1 was also 
down-regulated in all conditions where US2 was present as expected, Figure 7.9. For those 
genes known to be involved in MHC-1 down-regulation (US3, US6 and US11) there was a 
further down-regulation of MHC-1 when co-infected with UL141 and US2 proving that 
three RAd’s could be successfully co-infected into HFFF-hCAR’s 
 
7.7. CD112 was down-regulated in RAd-UL141 infected HELA-US2 cells, 
but not -UL141 infected Hela-US11.   
The cell surface expression of CD112 was down-regulated in RAd-UL141 + RAd-US2 
infected HFFF-hCAR’s. To confirm this observation the cell surface expression of CD112 
was analysed on a stable Hela cell lines expressing either US2 or US11, which were 
infected with RAd-UL141. A titration using a RAd-GFP identified an MOI100 was 
required to provide 100% infection, while infection at MOI200+ proved to be toxic to 
HELA cells, which resulted in cells becoming detached from the tissue culture flask (data 
not shown).  
Hela cell lines were infected with RAd-Ctrl, RAd-UL14 or RAd-UL141 and 3 days p.i. the 
cell surface of mIgG, CD112, CD155 and MHC-1 was analysed by flow cytometry.  UL14 
was chosen as a control as UL14 and UL141 form the UL14 family, but importantly, RAd-
UL14 had shown no effect on cell surface expression of CD112 during screening of the 
RAd-HCMV-ORF library, chapter 6.0. In Hela and Hela-US11 cells there was no effect on 
cell surface expression levels of CD112 when infected with RAd-Ctrl or RAd-UL14, 
Figure 7.10. There was a slight shift down in cell surface expression level of CD112 in  
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Figure 7.7. Flow cytometry detection of CD112 in HFFF-CARs infected with three RAds: US2, 
UL141 and one RAd covering the US1-11 region 
1 x 10
6
 HFFF-hTert’s were seeded into a 25cm2 tissue culture flask and the following day infected 
with RAd with a total MOI 15. Control conditions were RAd-UL141 (MOI5) + RAd-Ctrl (MOI10) 
(black), RAd-US2 (MOI5) + RAd-Ctrl (MOI10) (Red) and RAd-UL141 (MOI5) + RAd-US2 (MOI5) 
+ RAd-Ctrl (MOI5) (Blue). Experimental condition consisted of RAd-UL141 (MOI5) + RAd-US2 
(MOI5) + RAd- X (MOI5) (Green), where X denoted a RAd expressing one of the HCMV US1-11 
ORFs as denoted in the figure. 3 days p.i. Cells were harvested and analysed for the cell surface 
detection of CD112 by flow cytometry. 
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Figure 7.8. Flow cytometry detection of CD155 in HFFF-CARs infected with three RAds: 
US2, UL141 and one RAd covering the US1-11 region 
1 x 10
6
 HFFF-hTert’s were seeded into a 25cm2 tissue culture flask and the following day infected 
with RAd with a total MOI 15. Control conditions were RAd-UL141 (MOI5) + RAd-Ctrl (MOI10) 
(black), RAd-US2 (MOI5) + RAd-Ctrl (MOI10) (Red) and RAd-UL141 (MOI5) + RAd-US2 
(MOI5) + RAd-Ctrl (MOI5) (Blue). Experimental condition consisted of RAd-UL141 (MOI5) + 
RAd-US2 (MOI5) + RAd- X (MOI5) (Green), where X denoted a RAd expressing one of the 
HCMV US1-11 ORFs as denoted in the figure. 3 days p.i. Cells were harvested and analysed for 
the cell surface detection of CD155 by flow cytometry.  
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  Figure 7.9. Flow cytometry detection of MHC-1 in HFFF-CARs infected with three RAds: US2, 
UL141 and one RAd covering the US1-11 region 
1 x 10
6
 HFFF-hTert’s were seeded into a 25cm2 tissue culture flask and the following day infected with 
RAd with a total MOI 15. Control conditions were RAd-UL141 (MOI5) + RAd-Ctrl (MOI10) (black), 
RAd-US2 (MOI5) + RAd-Ctrl (MOI10) (Red) and RAd-UL141 (MOI5) + RAd-US2 (MOI5) + RAd-
Ctrl (MOI5) (Blue). Experimental condition consisted of RAd-UL141 (MOI5) + RAd-US2 (MOI5) + 
RAd- X (MOI5) (Green), where X denoted a RAd expressing one of the HCMV US1-11 ORFs as 
denoted in the figure. 3 days p.i. Cells were harvested and analysed for the cell surface detection of 
MHC-1 by flow cytometry.  
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Figure 7.10. CD112 is downregulated in RAd-UL141 infected Hela-US2 cells.  
2 x 10
6
 Hela, HelaUS11 of Hela-US2 cells were seeded into a 25cm
2
 tissue culture flask and the 
following day infected with RAd-UL14 (Blue), RAd-UL141 (Red) on Rad-Ctrl (black) at 
MOI100. 3 days p.i. Cells were harvested and analysed for the cell surface detection of CD112, 
CD155 and MHC-1 by flow cytometry.  
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Hela-US11 cell lines infected with UL141, but not in Hela cells. Previous data, Figure 6.34 
and Figure 7.4., had already discounted US11 from being involved in CD112 cell surface 
down-regulation. Therefore this small shift was classified as background. In Hela-US2 
cells infected with UL141, CD112 was notably down regulated from the cell surface of 
infected cells. This result confirmed previous observations that the co-expression of US2 
and UL141 resulted in a down-regulation of cell surface CD112.  
The cell surface expression of CD155 was equivalent in all three cell lines and CD155 was 
down-regulated in cells infected with RAd-UL141 but not RAd-UL14 or RAd-Ctrl.   
The cell surface expression of MHC-1 was down regulated in HELA-US2 and HELA-
US11 cell lines compared to HELA cells. MHC-1 was not affected in Hela cells infected 
with RAd-UL141 or RAd-UL14. MHC-1 was up-regulated in the Hela-US2 cell line when 
infected with RAd-UL14, but not RAd-UL141 or RAd-Ctrl. MHC-1 was up-regulated in 
Hela-US11 cells infected with either RAd-UL141 or RAd-UL14.   
 
7.8. CD112 is degraded via the proteasome.  
Results from screening RAd-HCMV-ORF library resulted in the identification of US2 as 
potentially being involved in HCMV mediated down-regulation of CD112. US2 is already 
known to be involved in MHC-I degradation via the proteasome. To determine whether 
CD112 was degraded via the proteasome HCMV infected HFFF-hTert’s were treated with 
proteasome inhibitor MG132 overnight before harvesting at 72hours p.i. Harvested 
infections were processed by tritonX-114 fractionation and visualised by immunoblot, 
Figure 7.11. 
CD112 could be detected in uninfected but not RCMV1111 (Merlin) infected cells. In 
RCMV1111 (Merlin) infections treated with proteasome inhibitor MG132, CD112 
detection was partially restored. Restoration of CD112 appeared to be in a concentration 
dependant manner with a higher proteasome inhibitor concentration resulting in a larger 
amount of CD112 being detected. The proteasome inhibitor appeared to have no affect on 
CD112 in uninfected HFFF-hTert’s.  
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Figure 7.11. Proteasome inhibitors prevent the degradation of CD112 in HCMV 
infection of HFFF’s. 
HFFF were infected (MOI20) for 48 h with RCMV1111 (Merlin) or mock-infected, then 
treated for 12 h with proteasome inhibitors MG132 as indicated and analysed by 
immunoblot using antibodies to: CD112, CD155, UL141 and actin.   
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CD155 was found in a lower molecular weight form in RCMV1111 (Merlin) infected cells 
compared to uninfected cells. UL141 was clearly detectable in RCMV1111 (Merlin) 
infected cells but not in uninfected cells. The proteasome inhibitor appeared to have no 
affect on CD155 of UL141 uninfected or RCMV1111 infected HFFF-hTert’s.    
 
7.9 Conclusion  
Using the recombineering technique RCMVΔUS1-11 and RCMVΔUS11 mutants were 
generated. A RCMVΔUS2 mutant could not be generated, despite utilising three different 
selection cassettes. The US2 gene was clearly deleted using both GalK and RpsL-Neo-
LacZ selection cassettes as evident by both correct PCR products and sequencing results. 
However, a viral stock of RCMVΔUS2could not be generated when transfected into 
HFFF-hTerts, and no plaques were formed. The successful generation of a RCMVΔUS1-
11 mutant showed that US2 is not an essential gene, as US2 was absent in this construct. It 
was hypothesised that the oligonucleotide used in the second round of recombineering, to 
simultaneously remove the selection cassette and delete US2, might also be causing 
genomic alteration elsewhere in the genome rendering the virus unviable. Sequencing of 
the entire BAC would reveal if this was the case, while new primers would need to be 
designed if recombineering were to be retried.  
Deletions of US1-11 in RCMVΔUS1-11 resulted in loss of function and CD112 was 
unable to be down-regulated, identifying a gene in the US1-11 region to be involved in the 
down-regulation of CD112. US11 was unlikely to be essential in CD112 down-regulation 
as a US11 deletion mutant, RCMVΔUS11, retained the ability to down-regulate the cell 
surface expression of CD112.  Additionally, infection of Hela –US11 with RAd-UL141 
showed no notable CD112 down-regulation. However, CD112 was down-regulated in a 
Hela-US2 cell line infected with RAd-UL141.  
Preventing proteasome degradation during HCMV infection by treating with proteasome 
inhibitors restored the ability to detect CD112 expression by western blot. US2 is known 
to degrade MHC-1 via the proteasome, and while this data does not prove the involvement 
of US2 in this process it adds weight to the hypothesis that US2 is involved.  
248 
 
It therefore appears that US2 and UL141 cooperatively act to degrade CD112 via the 
proteasome to prevent CD112 cell surface expression.  
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8.0. DISCUSSION   
CD112 is involved in a variety of functions including cell adhesion, contact inhibition and 
NK-cell activation. Specifically, CD112 signals via CD226 (DNAM-1) activating receptor 
to modulate NK-cell cytotoxicity. Since the CD226-activating ligand, CD155, was down-
regulated from the cell surface during HCMV infection (Tomasec, 2005) it was important 
to address whether CD112 was also down-regulated from the cell surface during 
productive HCMV infection. 
Prior to commencement of this project, preliminary screening of the cell surface proteome 
of HCMV-infected cells performed in this laboratory identified that CD112 was down-
regulated compared to uninfected cells. This initial observation was confirmed and the 
deletion of UL141 from the HCMV genome was able to restore CD112 cell surface 
expression in HCMVΔUL141-infected cells, as demonstrated in Chapter 3.0. The 
expression of UL141 on its own had no effect on CD112 cell surface expression (Tomasec 
et al 2005 and chapter 3.0.). Since UL141 appeared necessary but not sufficient to 
modulate CD112 expression, this thesis focused on a hypothesis whereby UL141 was 
acting in a conjunction with another HCMV protein. Two complementary approaches were 
initially projected to identify HCMV genes essential in CD112 down-regulation:  
The first approach was to screen a library of HCMV block deletion mutants for a loss of 
the ability to down-regulate CD112, which anticipated that a second HCMV gene acting 
with UL141 played an essential role in CD112 down-regulation and its deletion would 
restore CD112 cell surface expression. If a result scored then this approach would identify 
a block of genes potentially involved in CD112 down-regulation, narrowing down 
potential gene candidates for future studies. This approach was the focus of chapter 4.0 
The second approach was the screening of a library of RAd vectors encoding individual 
HCMV ORFs by co-infecting with RAd-UL141 for a gain of the ability to down-regulate 
CD112. This approach anticipated that a combination of two specific HCMV genes would 
be sufficient for this effect. This approach would specifically identify a second essential 
HCMV gene and was the focus of chapter 6.0.  
Both approaches were predicted to independently identify gene(s) involved in CD112 
down-regulation. By employing two complementary approaches, the probability of a 
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successful outcome was increased along with confidence in the result if both approaches 
delivered the same result.  
Screening of a library of a HCMV-block deletion mutants did not identify any potential 
candidates. Results from chapter 4.0 showed that all RCMVs down-regulated the cell 
surface expression of CD112 to a similar degree as Merlin infected cells. As a result, the 
46 genes deleted in these mutants were screened as a low priority in further analysis. The 
remaining genes were screened using a RAd-HCMV-ORF library, chapter 6.0. The 
HCMV genes were screened both individually and also in conjunction with UL141. The 
co-infection of RAd-UL141 and RAd-US2 resulted in a single, clear, positive hit in the 
final screening process. Although the shift in cell surface down-regulation in 
RAdUL141/US2 infected cells was not of the same magnitude as during HCMV infection 
it was robust and highly reproducible. A down-regulation of CD112 was also seen 
immunoblots where RAd-UL141 and RAd-US2 were co-infected but not in RAd-UL141 
or RAd-US2 infected HFFF-hCAR’s, chapter 6.0. A Hela-US2 cell line that stably 
expressed US2 also down-regulated CD112 when infected with RAd-UL141, but not RAd-
UL14 or RAd-Ctrl, chapter 7.0. However, the possibility still exists that more than 2 
HCMV genes and/or an additional HCMV-upregulated cellular function is required to 
realise full CD112 down-regulation seen in productive HCMV infection.  
In order to further these observations, HCMV mutants with deletions in US2, US11 or 
US1-11 were constructed. Despite multiple attempts, using three different recombineering 
strategies with selection cassettes (AmpR/SacB/LacZ, GalK and RpsL/Neo/LacZ) a 
HCMVΔUS2 mutant could not be generated. However RCMVΔUS11 and RCMVΔUS1-
11 mutants were successfully constructed, chapter 7.0. 
Deletions in the US1-11 region in RCMVΔUS1-11 resulted in a loss of function and 
CD112 was unable to be fully down-regulated from the cell surface of RCMVΔUS1-11 
infected cells. This phenotype indicated that a gene in the US1-11 region was essential for 
the down-regulation of cell surface CD112. A RCMVΔUS11 was successfully generated 
and crucially was still capable of down-regulating the cell surface expression of CD112 
during productive infection, Figure 7.4. RAd-US11 also scores negatively in the screening 
of the RAd-HCMV-ORF library when co-infected with RAd-UL141, Figure 6.34. As a 
consequence, US11 was excluded as a candidate for involvement in CD112 down-
regulation.  
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The addition of proteasome inhibitors to HCMV infections resulted in the partial recovery 
of CD112 in a concentration dependant manner, chapter 7.0. This result suggested some 
obvious routes for further investigation. It is well documented that both US2 and US11 
degrade MHC class I via the proteasome. Provided that CD112 and MHC-I are degraded 
via the same mechanism then the knockdown of essential proteins known to be involved in 
MHC-I degradation pathways could be investigated. Protein disulphide isomerise (PDI) is 
involved and is essential in US2 mediated MHC-I down-regulation during HCMV 
infection (Lee et al., 2010). Derlin-1 is an ER membrane protein essential in US11 
dependant degradation of MHC-1 during HCMV infection (Lilley and Ploegh, 2004). 
Therefore, through RNA interference, siRNAs could be used to knock down PDI and 
Derlin-1 to see if these pathways are involved in the degradation of CD112.  
It is worth noting that UL141 is involved in the down-regulation of both CD155 via ER 
sequestration and CD112 through proteasome mediate degradation. Why CD155 is 
retained, while CD112 is degraded remains unanswered to date. One possibility is that 
sequestered CD155 still has some signalling ability which is preferential for HCMV. The 
fact that Ul141 both sequesters and is involved in targeted degradation suggests that 
UL141 is a multifunctional protein. Indeed, UL141 has also recently been reported to be 
involved in the down-regulation of TRAILR1 and TRAILR2 (Smith et al., Under 
submission ). The fact that both DNAM-1 activating ligands are removed from the surface 
of infected cells again demonstrates the importance of this activating receptor in the 
context of NK cytotoxicity during HCMV infection. However these experiments become 
complicated when looked at in the context of HCMV infection as using a HCMVΔUL141 
deletion virus would affect CD155, CD112, TRAILR1 and TRAILR2. While expressing 
UL141 in isolation from RAd-UL141 would affect CD155, TRAILR1 and TRAILR2 but 
not CD112. Due to the effect of UL141 on a range of NK cell activating ligands it will be 
essential to dissect these functions apart in order to study the importance of CD112 down-
regulation in functional NK assays. Functional domain mapping using a series of UL141 
deletions and modifications might identify domains/residues that are essential for one, or 
multiple UL141 functions and is something to be considered if this work is to be taken 
further. 
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8.1. Use of RAd-HCMV-ORF library in screening for HCMV function.  
This project was the first to utilise the entire RAd-HCMV-ORF library to screen for 
function. The RAd-HCMV-ORF library clearly provided an extremely powerful tool for 
the screening of HCMV gene function as results were highly repeatable and robust. During 
optimisation it was important to take practical steps to reduce signs of toxicity, chapter 
6.0., to reduce false positive hits. Some toxic genes fell into regions deleted in the RCMV 
block deletion mutants. As all RCMV block deletions were capable of down-regulating 
CD112, it was unlikely that these genes played an essential role in CD112 down-
regulation. For the remaining genes that demonstrated signs of toxicity, results were 
excluded from analysis due to the likelihood of a false positive result. However, potentially 
one of these genes could be play a role in CD112 down-regulation. HCMV deletions 
would need to be generated to definitively discount these genes from having any 
involvement in CD112 down-regulation.  
Immunofluorescent detection of the RAd-HCMV-ORF- library showed that the majority 
of HMCV proteins were a) detectable and b) found in their expected cellular location when 
compared to the observations of others. However, there were examples of proteins that 
were in disagreement with the literature and were not expressed in the expected location. 
For example, in this study UL86 was found to be expressed in the cytoplasm but in the 
literature UL86 was described as being present in the vRC in the nucleus during HCMV 
infection, due to the NLS of UL80 (Plafker and Gibson, 1998). It was therefore possible 
that some genes expressed from RAd vector require a localisation signal from another 
interacting protein in order to locate to the correct cellular compartment to carry out 
function. There are many other reasons hypothesised as to why transgenes may not found 
in the correct location summarised in chapter 5.0. 
Transgene detection could not be achieved for all RAd constructs. A handful of genes were 
found to be undetectable by immunofluorescence. As reagents used in this study were 
raised against the V5 tag, then it could be an inability of V5 detection rather than a lack of 
transgene expression. Indeed, while transgene detection proves expression, the lack of 
transgene detection does not necessarily preclude expression. In order to definitively prove 
whether transgenes are expressed from RAd vectors, antibodies would have to be raised 
against these specific proteins.  
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A further consideration is that the RAd-HCMV-ORF-library uses only one ORF sequence. 
However, these ORFs may, or may not, be alternatively spliced during HCMV infection to 
produce a different protein. Altered transcriptional profile during HCMV is evident from 
E, IE and L gene expression and there is evidence that some genes are alternatively spliced 
during HCMV infection. This is true for IE1 and IE2, which are differentially spliced 
variants from the MIE locus along with IE1p38, IE2p55 and IE2p18 (Kerry et al., 1995).  
These differentially spliced products are expressed at different timepoints throughout 
infection, or only in a particular cell type. Alternative splicing during HCMV infection 
could result in the production of a protein, which would not be picked up using the RAd-
HCMV-ORF library.   
8.2. Building further screening tools  
Due to the complexity of HCMV infection perhaps the next stage in building tools for 
screening for HCMV function would be to create a library of HCMV single gene deletions, 
similar to the HCMV block deletion library. Deletions of UL141 and US1-11 in viruses 
HCMVΔUL141 and HCMVΔUS1-11 respectively, resulted in a loss of function. These 
viruses were unable to down-regulate cell surface CD112 during infection. To further this 
study, individual gene deletions in US1, US2, US3, US6, US7, US8, US9 and US10 would 
need to be generated to identify the specific gene in the US1-11 region involved in CD112 
down-regulation (US11 has already been discounted, chapter 7.0).  
Some genes in HCMV are essential for growth/replication and cannot be deleted. For 
essential genes, conditional knockouts could be created. By fusing a destabilising domain 
of the FK506-binding protein to essential cytomegalovirus proteins, Glab et al (2009) 
generated virus mutants that allowed for the conditional and reversible disruption of fusion 
proteins regulated by the synthetic ligand shield. This method allowed the study of 
essential herpesvirus proteins. A HCMV-UL51-ddFKBP mutant was constructed that 
encoded fusions of ddFKBP to the N terminus of UL51, along with an influenza viral 
haemagglutinin derived epitope (HA), inserted at an ectopic genomic location ΔUL1-10 of 
BAC-cloned AD169. In the absence of shield-1 the fusion proteins were knocked down 
but in the presence of shield-1, pUL51 showed a nuclear location (GlaB et al., 2009). This 
methodology could be employed to create a library of HMCV mutants with conditional 
knockdown of essential genes.  
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8.3. Potential future work: CD112 in NK and DC cell interaction 
Work in this thesis has involved HCMV infection of fibroblasts. However, there are other 
cell types permissive to HCMV infection. Cells of the myeloid lineage are considered to be 
sites of HCMV latency, and differentiation of myeloid progenitors to dendritic cells may 
reactivate HCMV (Sinclair, 2008). Indeed, dendritic cells are also capable of being 
infected with HCMV. Monocyte-derived DC (moDCs) appeared susceptible to in-vitro 
infection and HCMV infection of moDCs by endothelial cell adapted strains, resulted in 
inhibited cell surface expression of MHC I and II, costimulatory molecules and chemokine 
receptors (CCR1 and CCR5) (Riegler et al., 2000, Kessler et al., 2008, Moutaftsi et al., 
2002, Varani et al., 2005). In addition, a second DC subtype, plasmacytoid DCs (pDCs), 
which are found in secondary lymphoid tissue are also permissive to HMCV infection 
(Schneider et al., 2008, Varani et al., 2007). 
Dendritic cells may cross talk with NK cells and reciprocally regulate their functions both 
in inflamed peripheral tissues and in secondary lymphoid compartments (Zitvogel, 2002). 
Myeloid DCs can induce NK cell functions and activated NK cells may alternatively kill 
immature DCs or promote their maturation. Different receptor-ligand interactions and 
cytokine secretion characterise this cross talk (Degli-Esposti and Smyth, 2005). These 
interactions allow NK cells to discriminate between iDCs (that typically underexpress 
HLA class I molecules) and mDCs that, after Ag uptake, up-regulate HLA class I 
expression (Della Chiesa et al., 2003). The process by which NK cells eliminate iDCs has 
been shown to initiate with the engagement of NKp30 and DNAM-1 activating receptors 
with their cognate ligands (Pende et al., 2006). In particular, during the maturation process, 
CD112 expression was up-regulated on iDCs, as compared with monocytes, and reached 
maximal surface density on mDCs, whereas up-regulation of CD155 was confined to 
mDCs (Pende et al., 2006). Blocking of NKp30 or DNAM-1 by specific mAbs inhibited 
NK mediated killing of both iDCs and mDCs (Pende et al., 2006). I therefore hypothesise 
that a reduction of the ligands for these receptors (such as down-regulation of CD155 and 
CD112 in HCMV infection) would also inhibit NK mediated killing of DCs during the 
maturation process, in particular DCs with low MHC class I expression due to HCMV 
infection.  
The DNAM-1 ligands have been shown to play a role in the NK cell mediated ‘quality 
control’ of DC maturation, a process whereby the most-fitting DC’s, characterised by high 
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expression of HLA class I molecules and of costimulatory ligands, are optimised for the 
ability to prime T-cells, polarising T-cells into the relevant subset required for the 
particular immune response (Della Chiesa et al., 2005, Moretta, 2005, Pende et al., 2006). 
One subset of circulating CD4
+
 T-cells are CD4
+
 CD25
+
 Foxp3
+
 regulatory T-cells (Treg) 
which have suppressive properties (Sakaguchi, 2000, Shevach, 2000).  Human Treg cells 
have been identified and characterised in peripheral blood and the thymus (Baecher-Allan 
et al., 2001, Jonuleit et al., 2001, Stephens et al., 2001). Treg  cells can also be induced in 
the periphery after antigen activation and are termed adaptive Treg (Bluestone and Abbas, 
2003). These adaptive Treg cells can be induced in-vitro by cytokine priming and co-
culture with iDCs (Jonuleit et al., 2000, Yamagiwa et al., 2001). In addition to suppressing 
auto- and alloreactive T-cells maintaining self-tolerance, Treg cells can also suppress 
immune responses to human tumours and to bacterial and acute viral infections in animal 
models (Belkaid et al., 2002, Suvas et al., 2003, Woo et al., 2002). It is therefore 
hypothesised that HCMV infection of DC’s results in the down-regulation of DNAM-1 
activatory ligands, in particular CD112, allowing inefficient, virally infected DCs which 
possess low HLA class I surface expression to mature, or alter lineage commitment to a 
more tolerant DC phenotype. These DCs are also implicated in T-cell polarisation and 
induce tolerance through the presentation of antigen with inadequate costimulation and 
cytokine production for effector T-cell activation (Sotomayor et al., 2001). The result 
would hypothetically be the tolerisation of the human immune response to HCMV antigen, 
in a similar way to tolerisation of the immune system to self antigen. Therefore HCMV 
proteins could effectively be recognised as ‘self’ and therefore would not induce a potent 
enough immune response capable of clearing the infection. This mimics the theory behind 
TolDC therapy, whereby an immune suppressive environment is sought to suppress 
immune response to self antigen. Injection of ex-vivo modified TolDCs has proven to be 
beneficial in models of autoimmune disease, including collagen-induced arthritis, diabetes 
and experimental autoimmune encephalo-myelitis (Popov et al., 2006, Chorny et al., 2005, 
Adorini, 2003). In addition, DC’s that express low MHC-1 have been indicated in 
tolerisation of antigen in therapeutic cancer vaccines, limiting the potency of an antigen-
specific T-cell response (Fiore et al., 2005, Camporeale et al., 2003).  This could have an 
important implication for HCMV vaccine research, which has thus far failed to deliver a 
vaccine that is capable of preventing infection, or treatments that are capable of clearing 
infection. Such questions remain to be answered and provide many avenues for future 
research into HCMV down-regulation of DNAM-1 ligands. 
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8.4. Conclusion  
The HCMV UL141 protein was identified as having an essential role in HCMV mediated 
down-regulation of CD112 during HCMV infection. However, UL141 was unable to 
down-regulate the cell surface expression of RAd-UL141 infected cells.  Since UL141 
appeared necessary but not sufficient to modulate CD112 expression, this thesis focused 
on a hypothesis whereby UL141 was acting in a conjunction with another HCMV protein. 
Screening strategies were implemented and this project was the first to utilise the entire 
RAd-HCMV-ORF library to screen for function. The RAd-HCMV-ORF library clearly 
provided an extremely powerful tool for the screening of HCMV gene function as results 
were highly repeatable and robust. The co-infection of RAd-UL141 and RAd-US2 resulted 
in a single, clear, positive hit in the final screening process. Although the shift in cell 
surface down-regulation in RAdUL141/US2 infected cells was not of the same magnitude 
as during HCMV infection it was robust and highly reproducible. A down-regulation of 
CD112 was also seen immunoblots where RAd-UL141 and RAd-US2 were co-infected but 
not in RAd-UL141 or RAd-US2 singly infected HFFF-hCAR’s, while a Hela-US2 cell line 
that stably expressed US2 also down-regulated CD112 when infected with RAd-UL141. 
US2 is known to target MHC-1 for proteasome mediated degradation. The addition of 
proteasome inhibitors was able to partially restore CD112 expression in HCMV infected 
cells. It therefore appeared that US2 and UL141 act to degrade CD112 via the proteasome 
during HCMV infection. This may have the potential to prevent DNAM-1:CD112 
interaction between HCMV infected targets and effector cells of the immune system.  
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10.0 APPENDIX I 
 
Immunofluorescent detection of RL1-UL40 and UL111A-UL150 and IRS, carried out by 
Mr Sepehr Seiferian. 
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Appendix.I.A. Immunofluorescent staining of cells infected with a RAd from the RAd-HCMV-ORF 
library to determine transgene expression and subcellular location: RL1-UL1. 
HFFF-hCARs were seeded at a concentration of 5x10
5
 in a glass bottomed 96-well plate. The following 
day HFFF-hCAR’s were infected with a RAd from the RAd-HCMV-ORF library, as indicated, at MOI10 
for 2hrs in an incubator 37°
C
, 5%CO2 on an oscilating platform at 5 osc.min. After 2hours, media was 
removed and replaced with fresh DMEM-10 and incubated for 3days. After incubation cells were washed 
in PBS, fixed in 2% paraformaldehyde and underwent immunofluorescence staining using Saponin based 
IF-buffer. Antibodies were used as follows: Primary mouse anti-V5 was used 1 in 2,000, phalloining-488 
1 in 50, DAPI 1 in 10,000 and a secondary α-mouse IgG(FAb’) AlexaFluor- 594 conjugate (red channel) 
was used to detect anti-V5, used 1 in 500. Cells were fixed and imaged using fluorescent microscopy 
using a x40 oil objective. Two images are shown for each transgene. The first is individual transgene 
expression as detected with anti-V5 primary (red channel). The second is a merged image consisting of 
transgene expression (red channel), phalloidin-488 (green channel) and DAPI (Blue channel).  
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Appendix.I.B. Immunofluorescent staining of cells infected with a RAd from the RAd-HCMV-ORF 
library to determine transgene expression and subcellular location: UL2-UL11. 
HFFF-hCARs were seeded at a concentration of 5x10
5
 in a glass bottomed 96-well plate. The following 
day HFFF-hCAR’s were infected with a RAd from the RAd-HCMV-ORF library, as indicated, at MOI10 
for 2hrs in an incubator 37°
C
, 5%CO2 on an oscilating platform at 5 osc.min. After 2hours, media was 
removed and replaced with fresh DMEM-10 and incubated for 3days. After incubation cells were washed 
in PBS, fixed in 2% paraformaldehyde and underwent immunofluorescence staining using Saponin based 
IF-buffer. Antibodies were used as follows: Primary mouse anti-V5 was used 1 in 2,000, phalloining-488 
1 in 50, DAPI 1 in 10,000 and a secondary α-mouse IgG(FAb’) AlexaFluor- 594 conjugate (red channel) 
was used to detect anti-V5, used 1 in 500. Cells were fixed and imaged using fluorescent microscopy 
using a x40 oil objective. Two images are shown for each transgene. The first is individual transgene 
expression as detected with anti-V5 primary (red channel). The second is a merged image consisting of 
transgene expression (red channel), phalloidin-488 (green channel) and DAPI (Blue channel).  
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Appendix.I.C. Immunofluorescent staining of cells infected with a RAd from the RAd-HCMV-ORF 
library to determine transgene expression and subcellular location: UL13-UL21A. 
HFFF-hCARs were seeded at a concentration of 5x10
5
 in a glass bottomed 96-well plate. The following 
day HFFF-hCAR’s were infected with a RAd from the RAd-HCMV-ORF library, as indicated, at MOI10 
for 2hrs in an incubator 37°
C
, 5%CO2 on an oscilating platform at 5 osc.min. After 2hours, media was 
removed and replaced with fresh DMEM-10 and incubated for 3days. After incubation cells were washed 
in PBS, fixed in 2% paraformaldehyde and underwent immunofluorescence staining using Saponin based 
IF-buffer. Antibodies were used as follows: Primary mouse anti-V5 was used 1 in 2,000, phalloining-488 
1 in 50, DAPI 1 in 10,000 and a secondary α-mouse IgG(FAb’) AlexaFluor- 594 conjugate (red channel) 
was used to detect anti-V5, used 1 in 500. Cells were fixed and imaged using fluorescent microscopy 
using a x40 oil objective. Two images are shown for each transgene. The first is individual transgene 
expression as detected with anti-V5 primary (red channel). The second is a merged image consisting of 
transgene expression (red channel), phalloidin-488 (green channel) and DAPI (Blue channel).  
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Appendix.I.D. Immunofluorescent staining of cells infected with a RAd from the RAd-HCMV-ORF 
library to determine transgene expression and subcellular location: UL22A-UL30. 
HFFF-hCARs were seeded at a concentration of 5x10
5
 in a glass bottomed 96-well plate. The following 
day HFFF-hCAR’s were infected with a RAd from the RAd-HCMV-ORF library, as indicated, at MOI10 
for 2hrs in an incubator 37°
C
, 5%CO2 on an oscilating platform at 5 osc.min. After 2hours, media was 
removed and replaced with fresh DMEM-10 and incubated for 3days. After incubation cells were washed 
in PBS, fixed in 2% paraformaldehyde and underwent immunofluorescence staining using Saponin based 
IF-buffer. Antibodies were used as follows: Primary mouse anti-V5 was used 1 in 2,000, phalloining-488 
1 in 50, DAPI 1 in 10,000 and a secondary α-mouse IgG(FAb’) AlexaFluor- 594 conjugate (red channel) 
was used to detect anti-V5, used 1 in 500. Cells were fixed and imaged using fluorescent microscopy 
using a x40 oil objective. Two images are shown for each transgene. The first is individual transgene 
expression as detected with anti-V5 primary (red channel). The second is a merged image consisting of 
transgene expression (red channel), phalloidin-488 (green channel) and DAPI (Blue channel).  
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Appendix.I.E. Immunofluorescent staining of cells infected with a RAd from the RAd-HCMV-ORF 
library to determine transgene expression and subcellular location: UL31-UL38. 
HFFF-hCARs were seeded at a concentration of 5x10
5
 in a glass bottomed 96-well plate. The following 
day HFFF-hCAR’s were infected with a RAd from the RAd-HCMV-ORF library, as indicated, at MOI10 
for 2hrs in an incubator 37°
C
, 5%CO2 on an oscilating platform at 5 osc.min. After 2hours, media was 
removed and replaced with fresh DMEM-10 and incubated for 3days. After incubation cells were washed 
in PBS, fixed in 2% paraformaldehyde and underwent immunofluorescence staining using Saponin based 
IF-buffer. Antibodies were used as follows: Primary mouse anti-V5 was used 1 in 2,000, phalloining-488 
1 in 50, DAPI 1 in 10,000 and a secondary α-mouse IgG(FAb’) AlexaFluor- 594 conjugate (red channel) 
was used to detect anti-V5, used 1 in 500. Cells were fixed and imaged using fluorescent microscopy 
using a x40 oil objective. Two images are shown for each transgene. The first is individual transgene 
expression as detected with anti-V5 primary (red channel). The second is a merged image consisting of 
transgene expression (red channel), phalloidin-488 (green channel) and DAPI (Blue channel).  
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Appendix.I.F. Immunofluorescent staining of cells infected with a RAd from the RAd-HCMV-ORF 
library to determine transgene expression and subcellular location: UL40-UL120. 
HFFF-hCARs were seeded at a concentration of 5x10
5
 in a glass bottomed 96-well plate. The following 
day HFFF-hCAR’s were infected with a RAd from the RAd-HCMV-ORF library, as indicated, at MOI10 
for 2hrs in an incubator 37°
C
, 5%CO2 on an oscilating platform at 5 osc.min. After 2hours, media was 
removed and replaced with fresh DMEM-10 and incubated for 3days. After incubation cells were washed 
in PBS, fixed in 2% paraformaldehyde and underwent immunofluorescence staining using Saponin based 
IF-buffer. Antibodies were used as follows: Primary mouse anti-V5 was used 1 in 2,000, phalloining-488 
1 in 50, DAPI 1 in 10,000 and a secondary α-mouse IgG(FAb’) AlexaFluor- 594 conjugate (red channel) 
was used to detect anti-V5, used 1 in 500. Cells were fixed and imaged using fluorescent microscopy 
using a x40 oil objective. Two images are shown for each transgene. The first is individual transgene 
expression as detected with anti-V5 primary (red channel). The second is a merged image consisting of 
transgene expression (red channel), phalloidin-488 (green channel) and DAPI (Blue channel).  
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Appendix.I.G. Immunofluorescent staining of cells infected with a RAd from the RAd-HCMV-
ORF library to determine transgene expression and subcellular location: UL121-UL136. 
HFFF-hCARs were seeded at a concentration of 5x10
5
 in a glass bottomed 96-well plate. The following 
day HFFF-hCAR’s were infected with a RAd from the RAd-HCMV-ORF library, as indicated, at MOI10 
for 2hrs in an incubator 37°
C
, 5%CO2 on an oscilating platform at 5 osc.min. After 2hours, media was 
removed and replaced with fresh DMEM-10 and incubated for 3days. After incubation cells were washed 
in PBS, fixed in 2% paraformaldehyde and underwent immunofluorescence staining using Saponin based 
IF-buffer. Antibodies were used as follows: Primary mouse anti-V5 was used 1 in 2,000, phalloining-488 
1 in 50, DAPI 1 in 10,000 and a secondary α-mouse IgG(FAb’) AlexaFluor- 594 conjugate (red channel) 
was used to detect anti-V5, used 1 in 500. Cells were fixed and imaged using fluorescent microscopy 
using a x40 oil objective. Two images are shown for each transgene. The first is individual transgene 
expression as detected with anti-V5 primary (red channel). The second is a merged image consisting of 
transgene expression (red channel), phalloidin-488 (green channel) and DAPI (Blue channel).  
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Appendix.I.H. Immunofluorescent staining of cells infected with a RAd from the RAd-HCMV-
ORF library to determine transgene expression and subcellular location: UL138-UL148. 
HFFF-hCARs were seeded at a concentration of 5x10
5
 in a glass bottomed 96-well plate. The following 
day HFFF-hCAR’s were infected with a RAd from the RAd-HCMV-ORF library, as indicated, at MOI10 
for 2hrs in an incubator 37°
C
, 5%CO2 on an oscilating platform at 5 osc.min. After 2hours, media was 
removed and replaced with fresh DMEM-10 and incubated for 3days. After incubation cells were washed 
in PBS, fixed in 2% paraformaldehyde and underwent immunofluorescence staining using Saponin based 
IF-buffer. Antibodies were used as follows: Primary mouse anti-V5 was used 1 in 2,000, phalloining-488 
1 in 50, DAPI 1 in 10,000 and a secondary α-mouse IgG(FAb’) AlexaFluor- 594 conjugate (red channel) 
was used to detect anti-V5, used 1 in 500. Cells were fixed and imaged using fluorescent microscopy 
using a x40 oil objective. Two images are shown for each transgene. The first is individual transgene 
expression as detected with anti-V5 primary (red channel). The second is a merged image consisting of 
transgene expression (red channel), phalloidin-488 (green channel) and DAPI (Blue channel).  
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Appendix.I.I. Immunofluorescent staining of cells infected with a RAd from the RAd-HCMV-ORF 
library to determine transgene expression and subcellular location: UL148A-IRS1. 
HFFF-hCARs were seeded at a concentration of 5x10
5
 in a glass bottomed 96-well plate. The following 
day HFFF-hCAR’s were infected with a RAd from the RAd-HCMV-ORF library, as indicated, at MOI10 
for 2hrs in an incubator 37°
C
, 5%CO2 on an oscilating platform at 5 osc.min. After 2hours, media was 
removed and replaced with fresh DMEM-10 and incubated for 3days. After incubation cells were washed 
in PBS, fixed in 2% paraformaldehyde and underwent immunofluorescence staining using Saponin based 
IF-buffer. Antibodies were used as follows: Primary mouse anti-V5 was used 1 in 2,000, phalloining-488 
1 in 50, DAPI 1 in 10,000 and a secondary α-mouse IgG(FAb’) AlexaFluor- 594 conjugate (red channel) 
was used to detect anti-V5, used 1 in 500. Cells were fixed and imaged using fluorescent microscopy 
using a x40 oil objective. Two images are shown for each transgene. The first is individual transgene 
expression as detected with anti-V5 primary (red channel). The second is a merged image consisting of 
transgene expression (red channel), phalloidin-488 (green channel) and DAPI (Blue channel).  
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11.0 APPENDIX II 
 
Screening RAd-HCMV-ORF library for CD112 down-regulation: Genes covered by 
RCMV block deletion mutants  
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Appendix II.A. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-RL1, RAd-
RL5A, RAd-RL6 and RAd-RL8A. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + RAd-
Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted in the figure.  
The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by flow cytometry.  
Infections were also monitored by phase contrast microscopy. Flow cytometry histograms were unavailable 
for RAd-RL8A due to toxicity. 
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Appendix II.B. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-RL9A, RAd-
RL10, RAd-RL11 and RAd-RL12. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + RAd-
Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted in the figure.  
The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by flow cytometry.  
Infections were also monitored by phase contrast microscopy. Flow cytometry histograms were unavailable 
for RAd-RL8A due to toxicity. 
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Appendix II.C. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-RL13, RAd-
UL1, RAd-UL2 and RAd-UL4. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + RAd-
Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted in the figure.  
The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by flow cytometry.  
Infections were also monitored by phase contrast microscopy. Flow cytometry histograms were unavailable 
for RAd-RL8A due to toxicity. 
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Appendix II.D. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL5, RAd-
UL6, RAd-UL7 and RAd-UL7/8. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + RAd-
Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted in the figure.  
The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by flow cytometry.  
Infections were also monitored by phase contrast microscopy. Flow cytometry histograms were unavailable 
for RAd-RL8A due to toxicity. 
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Appendix II.E. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL8, RAd-
UL9, RAd-UL10 and RAd-UL11. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + RAd-
Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted in the figure.  
The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by flow cytometry.  
Infections were also monitored by phase contrast microscopy. Flow cytometry histograms were unavailable 
for RAd-RL8A due to toxicity. 
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Appendix II.F. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-UL22A, RAd-
UL23, RAd-UL24 and RAd-UL25. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + RAd-
Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted in the figure.  
The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by flow cytometry.  
Infections were also monitored by phase contrast microscopy. Flow cytometry histograms were unavailable 
for RAd-RL8A due to toxicity. 
 
307 
 
  
Appendix II.G. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-US12, RAd-
US13, RAd-US14 and RAd-US15. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + RAd-
Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted in the figure.  
The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by flow cytometry.  
Infections were also monitored by phase contrast microscopy. Flow cytometry histograms were unavailable 
for RAd-RL8A due to toxicity. 
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Appendix II.H. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-US16, RAd-
US17, RAd-US18 and RAd-US19. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + RAd-
Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted in the figure.  
The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by flow cytometry.  
Infections were also monitored by phase contrast microscopy. Flow cytometry histograms were unavailable 
for RAd-RL8A due to toxicity. 
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Appendix II.I. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-US20, RAd-
US21, RAd-US22 and RAd-US27. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + RAd-
Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted in the figure.  
The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by flow cytometry.  
Infections were also monitored by phase contrast microscopy. Flow cytometry histograms were unavailable 
for RAd-RL8A due to toxicity. 
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Appendix II.J. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-US28, RAd-
US29, RAd-US30 and RAd-US31. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + RAd-
Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted in the figure.  
The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by flow cytometry.  
Infections were also monitored by phase contrast microscopy. Flow cytometry histograms were unavailable 
for RAd-RL8A due to toxicity. 
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Appendix II.K.. Screening RAd-HCMV-ORF library for CD112 downregulation: RAd-US32, RAd-
US34, RAd-US34A. 
HFFF-hCARs were infected with RAd-UL141 (MOI10) + RAd-Ctrl (MOI10), RAd-X (MOI10) + RAd-
Ctrl (MOI10) or RAd-X (MOI10) + RAd-UL141 (MOI10), where X denotes a gene denoted in the figure.  
The cell surface expression of CD112, CD155 and MHC-1 was analysed 3 days p.i. by flow cytometry.  
Infections were also monitored by phase contrast microscopy. Flow cytometry histograms were unavailable 
for RAd-RL8A due to toxicity. 
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